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Antibiotic stewardship was recently defined as “a coherent set of actions which promote using 
antimicrobials responsibly” in an era of increasing antibiotic resistance and few antibiotics in 
the development pipeline.1 The intensive care unit (ICU) is a key consumer of antibiotics in the 
hospital. As the antibiotic decision-making process is complicated by diagnostic uncertainty and 
potential involvement of multidrug-resistant (MDR) pathogens, the ICU constitutes an important 
target for antibiotic stewardship programs (ASP). 
Detailed monitoring of antibiotic prescription, infection diagnosis and antibiotic resistance 
patterns is essential to identify meaningful stewardship intervention targets and to assess the 
impact of a stewardship action following its implementation. Computerization of the patient ICU 
record and introduction of computerized physician order entry (CPOE) created new possibilities 
to support this surveillance process. A software program with the acronym COSARA: ‘Computer-
based Surveillance and Alerting of nosocomial infections, Antimicrobial Resistance and 
Antibiotic consumption in the ICU’ was developed by a consortium of the Ghent University 
Hospital ICU department and the Department of Information Technology of the Faculty of 
Engineering of Ghent University. COSARA serves as a data visualization dashboard on infection 
management for the individual ICU patient and has been available on every personal computer 
dedicated to patient care since 2010. As such, COSARA facilitates linking of antimicrobial 
prescription data, microbiology data and clinical information of each individual ICU patient 
during the daily workflow of the ICU physician, which results in the building up of a large 
longitudinal relational database on infection. 
In a first stage of this PhD project we evaluated the validity of COSARA as a surveillance tool and 
assessed the practical feasibility of continued infection registration. Surveillance through 
COSARA was compared with paper-based surveillance (PBS) based on Centers for Disease 
Control and Prevention (CDC) criteria for three infection types: bloodstream infections, 
respiratory tract infections and urinary tract infections. Good agreement between both 
surveillance methods was recorded. In addition, surveillance through COSARA required less 
than one-third of the time spent on PBS. 
In a second stage of this research project we aimed to acquire more insight in our local antibiotic 
prescription practices and microbiological resistance patterns based on in-depth analyses of the 
datasets that were constructed through the use of COSARA. 
On the one hand, we performed a descriptive analysis of a dataset covering four years of 




revealed that the antibiotic burden is high in our ICU. However, only half of the overall antibiotic 
consumption is used to treat infections that were classified as highly probable. As such, we were 
able to identify meaningful areas for improvement of our prescribing patterns. 
On the other hand, we evaluated the potential impact of 3 highly recommended ASP 
interventions in our ICU. Firstly, we assessed the potential of a treatment guideline for empirical 
antibiotic prescription in hospital-acquired pneumonia (HAP) based on local ecology data and 
the added value of incorporating surveillance culture (SC) results in such an algorithm. We 
found no difference in appropriate antibiotic coverage rates between the antibiotic treatment 
that was actually prescribed by physicians in our ICU and the treatment proposed by the 
algorithms. Addition of SC results in the guidelines, however, resulted in a significant reduction 
of the use of broad-spectrum agents. 
Secondly, we analyzed the frequency and determinants of de-escalation (i.e. reduction of the 
antibiotic spectrum) of empirical anti-pseudomonal beta-lactam antibiotics and its effect on 
patient outcome. Our results showed that de-escalation was performed in one-quarter of the 
prescriptions. In multivariate analysis, de-escalation was solely associated with the 
identification of etiologic pathogens. Surprisingly, the duration of the antibiotic course in the ICU 
was significantly longer in the de-escalated prescriptions compared to prescriptions that were 
not altered during the treatment course. In addition, the emergence of antibiotic-resistant 
bacteria after exposure to anti-pseudomonal beta-lactam antibiotics was not lower following de-
escalation. 
Thirdly, we calculated the potential saving in antibiotic consumption for three antibiotic classes 
(glycopeptides, oxazolidinones and carbapenems), by a systematic assessment of the ongoing 
need of an antibiotic treatment 48-72 h following its initiation. One third of carbapenem 
consumption was classified as potentially unjustified by previously defined criteria, compared to 
only 13% of glycopeptide/oxazolidinone use. 
In conclusion, by using COSARA, we were able to construct a dynamic longitudinal dataset on 
infection in our ICU. Over the last few years, we acquired detailed insight in local antibiotic 
prescription practices and antibiotic resistance patterns, which is of inestimable value in the 
further expansion of an ASP. Continuous merging of antimicrobial prescription data, 
microbiology data and clinical information of each ICU patient, represents the strength our 
surveillance strategy. COSARA enables integration of this process in the daily workflow of the 
ICU physician and as such, allows for sustained prospective surveillance. However, we have to 
acknowledge that the persistent commitment of dedicated physicians remains vital for its 
chances of success.




De resistentie van bacteriën voor antibiotica is de laatste decennia aanzienlijk toegenomen. De 
ontwikkeling van nieuwe antibiotica is evenwel gestagneerd en dwingt gezondheidswerkers tot 
verdere acties. ‘Antibiotic stewardship’ wordt gedefinieerd als “een samenhangend geheel van 
interventies die als doel hebben het verantwoord gebruik van antimicrobiële middelen te 
bevorderen”.1 De dienst Intensieve Zorg (IZ) is verantwoordelijk voor een aanzienlijk aandeel in 
het antibioticumverbruik in het ziekenhuis. De complexe diagnostiek in deze patiëntenpopulatie 
en de mogelijke betrokkenheid van multidrug-resistente (MDR) kiemen bemoeilijkt de 
beslissing rond het al dan niet starten van antibiotica bij kritiek zieke patiënten en de correcte 
keuze hierbij. IZ-afdelingen vormen dan ook een belangrijke doelgroep voor ‘Antibiotic 
stewardship’-programma’s (ASP). 
Een continue en gedetailleerde monitoring van het antibioticumvoorschrift, de infecties en de 
antibioticumresistentie kan de identificatie van potentiële interventies en de evaluatie van de 
impact hiervan na implementatie bevorderen. De invoering van het elektronisch 
patiëntendossier en het elektronisch medicatievoorschrift op IZ heeft dit documentatieproces 
duidelijk beïnvloed over de voorbije jaren. De dienst IZ van het Universitair Ziekenhuis Gent 
ontwikkelde in samenwerking met de vakgroep Informatietechnologie van de faculteit 
Ingenieurs-wetenschappen van de Universiteit Gent een elektronisch registratieprogramma met 
de naam COSARA: ‘Computer-based Surveillance and Alerting of nosocomial infections, 
Antimicrobial Resistance and Antibiotic consumption in the ICU’. Deze software integreert alle 
infectie-gerelateerde informatie en presenteert deze aan de gebruiker onder de vorm van een 
continue, visuele samenvatting en is sinds 2010 beschikbaar op iedere IZ computer. COSARA 
faciliteert het maken van connecties tussen antibioticumdata, microbiologiegegevens en 
klinische informatie van een individuele IZ patiënt en laat toe dat dit proces geïntegreerd wordt 
in de dagelijkse klinische zorg van de IZ arts. Deze gecombineerde gegevens worden opgeslagen 
in een gedetailleerde, longitudinale database. 
In het eerste deel van deze thesis evalueerden we de validiteit van COSARA als monitoring 
systeem en gingen we na in hoeverre deze registratiemethode haalbaar was over langere 
tijdsperiodes. Voor drie geselecteerde infectietypes (bloedstroominfecties, luchtweginfecties en 
urineweginfecties) werd een vergelijking gemaakt tussen de documentatie met behulp van 
COSARA en de ‘klassieke’ monitoring, waarbij een zorgverstrekker schriftelijk de infecties 
registreert op basis van de Centers for Disease Control and Prevention (CDC) criteria. We 




COSARA nam echter slechts een derde van de tijd die nodig was voor de ‘klassieke’ registratie in 
beslag. 
Het tweede deel van ons onderzoek was gericht op het verkrijgen van meer inzicht in ons lokaal 
antibioticumvoorschriftgedrag en onze lokale antibioticumresistentiepatronen, gebaseerd op 
diepgaande analyses van de datasets die werden opgebouwd met behulp van COSARA. 
Enerzijds wilden we een globaal overzicht verkrijgen van ons antibioticumgebruik op basis van 
een beschrijvende analyse van een dataset die de gecollecteerde gegevens bevat van alle IZ 
patiënten over een periode van 4 jaar. Deze evaluatie toonde aan dat het antibioticumverbruik 
hoog is in onze IZ en dat slechts de helft van het totale verbruik aangewend wordt voor de 
behandeling van infecties met een hoge graad van zekerheid. Dit liet ons toe om deelgebieden te 
identificeren die in aanmerking komen voor ASP interventies. 
Anderzijds analyseerden we de potentiële impact in onze IZ van drie sterk aanbevolen ASP 
interventies. Als eerste evalueerden we de meerwaarde van een richtlijn, ontwikkeld op basis 
van lokale antibioticumresistentiecijfers, voor de empirische behandeling van een pneumonie 
ontstaan in het ziekenhuis. Daarnaast gingen we de toegevoegde waarde na van het 
incorporeren van de resultaten van routine surveillantie culturen (SC) in een dergelijk 
algoritme. Er werd geen verschil genoteerd in de adequaatheid van de antibiotische behandeling 
die in realiteit toegediend werd aan de patiënt en deze die aangeraden werd door de 
bovenstaande richtlijnen. Het inbouwen van de resultaten van de SC resulteerde echter wel in 
een significante reductie in het gebruik van breedspectrumantibiotica. 
Een tweede analyse was gericht op antibiotische deëscalatie, een stewardship-strategie die zich 
toespitst op het vernauwen van het antibiotisch spectrum. We gingen na hoe vaak een empirisch 
beta-lactam antibioticumvoorschrift met activiteit voor Pseudomonas gedeëscaleerd werd in 
onze IZ, wat de determinanten voor deëscalatie waren en wat de impact hiervan was op de 
evolutie van onze patiënten. Onze resultaten toonden aan dat deëscalatie werd uitgevoerd in een 
vierde van de voorgeschreven behandelingen en dat dit in multivariaat analyse enkel 
geassocieerd was met de identificatie van de ziekteverwekkende kiem. Een opmerkelijke 
bevinding was dat de duur van de antibioticumkuur op IZ significant langer was indien werd 
gedeëscaleerd. Deëscalatie ging niet gepaard met een afname van het aantal verworven 
resistente kiemen. 
Ten derde, trachtten we te berekenen in welke mate we het verbruik van drie 
antibioticumklassen (glycopeptiden, oxazolidinone en carbapenems) zouden kunnen beperken 
door op systematische wijze na te gaan of deze therapie nog steeds aangewezen is 48 tot 72 uur 
na de start van een behandeling. We konden concluderen dat volgens een set van eerder 
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gedefinieerde criteria, 33% van het carbapenem-verbruik potentieel ongerechtvaardigd was in 
vergelijking met amper 13% van het glycopeptiden/oxazolidinone-verbruik. 
We kunnen besluiten dat het gebruik van COSARA ons in staat heeft gesteld een dynamische en 
longitudinale dataset op te bouwen rond infecties op IZ. Over het verloop van de voorbije jaren 
hebben we meer inzicht verkregen in ons lokaal antibioticumvoorschriftgedrag en onze lokale 
antibioticumresistentie, wat van onschatbare waarde is in de uitbouw van een ASP. Het 
basisprincipe en de sterkte van onze monitoringsstrategie bestaat uit het longitudinaal 
combineren van antibioticumdata, microbiologiegegevens en klinische informatie voor iedere IZ 
patiënt. Met behulp van COSARA is het mogelijk om dit proces te integreren in de dagelijkse 
klinische praktijk van de IZ arts, waardoor deze registratie kan aangehouden worden over 






























“Information is the lifeblood of medicine and health information technology is destined 









A. INFECTION AND ANTIBIOTICS IN CRITICAL ILLNESS 
Critical illness caused by infection, either acquired in the community or associated with 
healthcare settings, is one of the most common reasons for intensive care unit (ICU) admission.2 
In addition, ICU patients are prone to develop new infections for multiple reasons: e.g. the 
presence of invasive catheters, the need for invasive ventilation, a post-operative, weakened 
and/or immunosuppressed status.3-5 A large multicenter point prevalence study collecting data 
in 75 different countries showed that an infection was present in 51% of the patients admitted 
to the ICU and that 71% of the patients received an antibiotic treatment on the day of study.2 
Smaller-scale studies performed over longer periods of time reported comparably high rates of 
infection and antibiotic use, although these figures varied between different types of ICUs and 
subsets of patients.6-9 
The outcome of an infected patient is positively affected by the administration of adequate 
antibiotic therapy covering all causative pathogens early in the course of the infection.10-13 In the 
case of the ICU patient, this can be quite challenging. First of all, multiple non-infectious 
conditions frequently occurring in ICU patients can mimic an infection in its early stage and 
complicate the diagnostic process. Some examples are: fever in the patient with an intracerebral 
bleeding, elevated C-reactive protein (CRP) indicating inflammation in the absence of infection 
in case of acute pancreatitis, the development of an acute respiratory distress syndrome (ARDS) 
secondary to trauma or inhalation and hemodynamic instability resulting from post-operative 
bleeding. In addition, the selection of an appropriate empirical(1) treatment strategy is hampered 
by increasing antimicrobial resistance rates.14, 15 This is especially the case for the present-day, 
complex ICU patient with underlying chronic illness or protracted hospitalization stay. Prior 
antibiotic use, hospital readmission and acute renal replacement therapy are only some of the 
factors that are considered to be a risk for the involvement of multidrug-resistant (MDR) 
pathogens.16-18 The aforementioned difficulties have enforced the authors of the ‘Surviving 
Sepsis Campaign’ (SSC) guidelines, which are international instructions for the management of 
sepsis and septic shock, to advocate timely administration of broad-spectrum, often 
combination,  antibiotic therapy to cover all likely pathogens. It is recommended to tailor the 
empirical antibiotic scheme to the individual patient’s comorbidities, prior known colonization 
status and antibiotic courses, current clinical status and to local epidemiology.18 As soon as 
                                                          
1 Empirical antibiotic treatment is defined as a treatment initiated in the absence of microbiological 




microbiology results are available and/or the clinical course of the patient becomes clear, 
physicians are encouraged to narrow the spectrum of this empirical treatment whenever 
possible. 
In summary, making adequate antibiotic treatment decisions for the critically ill patient is not 
straightforward. Detailed, timely and easy accessible patient and infection related information is 
required to guide the ICU physician in his/her antibiotic decision-making process. 
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B. ANTIBIOTIC STEWARDSHIP AND THE ICU 
Since the discovery of the first antibiotic agent, benzylpenicillin in 1928 by Sir Alexander 
Fleming, antibiotics have proven to be live-saving and indispensable in an ICU environment.19 
Unfortunately, the liberal deployment of antibiotics was closely followed by the emergence of 
resistant bacterial strains.20 Once very potent antibiotic agents are no longer considered to be a 
safe empirical treatment option, due to concerns about the possible involvement of MDR 
pathogens. At the present time, it is a well-known fact that antibiotic exposure promotes the 
emergence of antibiotic resistance.21-24 Bearing this in mind, it is quite troublesome to realize 
that 30 to 60% of antibiotic prescriptions in the ICU are superfluous or inappropriate.23 
In 1996, McGowan and Gerding made a plea for the optimization of antibiotic consumption to 
refrain the growing problem of antibiotic resistance. In their statement the term ‘antimicrobial 
stewardship’ was introduced.25 Over the past 20 years this concept has been refined. In a 
consensus statement from the Infectious Diseases Society of America (IDSA), the Society for 
Healthcare Epidemiology of America (SHEA), and the Pediatric Infectious Diseases Society 
(PIDS), antimicrobial stewardship is currently defined as “coordinated interventions designed to 
improve and measure the appropriate use of antibiotic agents by promoting the selection of the 
optimal antibiotic drug regimen including dosing, duration of therapy and route of 
administration”.26 The ultimate goal of these interventions is finding the right balance between: 
a) ensuring a good clinical outcome for the present patient and b) minimizing adverse effects 
related to antibiotic use i.e. antibiotic toxicity, selection of MDR and increasing costs for the 
present as well as the future patient and society.27 The need for a well-designed antimicrobial 
stewardship program (ASP) is increasingly being recognized and has even been incorporated in 
the National Action Plan for Combating Antibiotic-Resistant Bacteria published by the White 
House in 2015.28 
Guidelines for the implementation of these ASP in hospital settings are issued and updated 
regularly.29 It has been stressed that the selection of stewardship actions must be carried out in 
a judicious manner to ensure maximum efficiency of actions in the current setting of limited 
healthcare personnel and financial resources. Figure 1 displays the crucial steps in the 
implementation process of a stewardship intervention. 
Over the last few years, a growing body of evidence demonstrating the positive effects of ASP 
became available.30-32 Unfortunately, large-scale studies performed over longer periods in time 
are scarce and issues about sustainability and generalizability of these effects cannot be 






Figure 1: Implementation process of a stewardship intervention 
°Quality indicators are defined as measures to assess a particular structure, process or outcome.33, 34 
*Monitoring is defined as surveillance or tracking of antibiotic utilization, antimicrobial resistance 
patterns and infection rates.
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C. ELECTRONIC SURVEILLANCE SYSTEMS 
Monitoring is considered to be a core element of hospital ASP.35, 36 Prior to the implementation 
of the electronic health record (EHR), dedicated personnel was trained and deployed to perform 
surveillance manually. It is evident that this approach is prone to human error. In addition, the 
surveillance process is complicated by the fact that conventional definitions used for manual 
chart review often include subjective criteria, leading to surveillance personnel inter-observer 
variability in sensitivity and specificity.37-39 As traditional manual surveillance is time and 
resource consuming it is most often performed for a limited period in time and/or focused on 
specific types of infections, pathogens or patient populations.40 Some major drawbacks are 
linked to this restricted surveillance strategy. Surveillance within narrow time frames for 
instance hampers the correct evaluation of stewardship actions, as effects can be directly related 
to the intervention or just reflect a seasonal trend.41 
The computerization of administrative, microbiology, pharmacy and clinical data and the 
introduction of computerized physician order entry (CPOE) created new possibilities to support 
surveillance. In recent years, reports on a wide and very diverse range of electronic surveillance 
systems (ESS) have been published.37, 38, 42-46 The majority of these systems are locally developed 
in-house ESS instead of commercially supplied software packages.37 Consequently, an in-hospital 
validation of these systems is imperative. Considerable variation in sensitivity and specificity 
exists between different ESS. Performance depends on the source data that are being used and 
on the type of infection under study. 
Experience has been gained with the use of many different types of data to support surveillance. 
Until now, administrative coding data (ACD) are probably the most frequently used data source 
as this information is already collected for other purposes such as coding and billing.47 
Unfortunately, ESS uniquely based on ACD have proven to be largely inaccurate, mainly because 
surveillance is not the primary objective of this registry and its validity depends largely on the 
precision of the information that is provided by the physician.38, 45, 48 The importance of 
combining information from several data sources is increasingly recognized.37, 46 Results from 
microbiology, biochemistry and antimicrobial prescription reports are quite easy to retrieve. 
The main challenge consists of picking up nuanced clinical diagnostic information from EHRs. 
Clinical data however have shown to outperform ACD.49 In this respect, major progress has been 
made in the application of natural language processing tools to convert unstructured electronic 
patients charts to structured information, but additional research is needed to allow routine 




Until now, the majority of the ESS still focuses on selected types of infections. Most attention is 
devoted to infections that serve as a hospital quality indicator and/or are used for benchmarking 
e.g. central line-associated bloodstream infection (CLABSI), surgical site infection (SSI) and 
ventilator-associated pneumonia (VAP).38 Consistently high sensitivity figures are reported in 
studies targeting bloodstream infections (BSI). ESS targeting infections, such as pneumonia, for 
which a diagnostic ‘gold standard’ is unavailable or depending on subjective diagnostic criteria 
perform substantially worse.37 
ESS can be fully automated or require a certain amount of manual input. Some of the semi-
automated systems use algorithms to detect potentially interesting cases that subsequently need 
detailed manual assessment.50 Others depend on the (mandatory) input of clinical patient 
information by healthcare professionals.51, 52 Fully and semi-automated systems each have their 
own advantages and drawbacks. Fully automated surveillance has evolved significantly over the 
last years, driven by an increasing demand for benchmarking and public reporting of infection 
rates and antibiotic consumption figures. Infections for which a set of clear, objective and 
electronically easy accessible diagnostic criteria is available e.g. a CLABSI, are an ideal target for 
fully automated ESS. Semi-automated systems on the other hand offer the possibility to capture 
more complex clinical info and steps of the diagnostic reasoning process which is often required 
to make the correct diagnosis of a complicated intra-abdominal infection or VAP. 
Different strategies may underlie the case finding process of an ESS. The most frequently applied 
and best studied approach is the use of a computerized rule-based decision tree algorithm. As a 
rule, this strategy offers a dichotomous answer: infection is present or not. Complex infections 
are more difficult to capture by these static algorithms.53 An alternative approach based on 
multivariable regression modelling was examined for CLABSIs, SSI and drain-related 
meningitis.54 This method relies on the construction of a model which weighs individual 
predictors from multiple data sources to generate a prediction of the presence of an infection. As 
such, manual chart review can be limited to those patients that are identified as having a high 
probability of infection. Sensitivity and specificity of the model can be altered by selection of 
different probability cut-offs. Further research on the application of this technique is mandatory. 
A myriad of other strategies, such as machine learning techniques, are under investigation and 
the number of reports on this subject is growing steadily.55-58 
Most ESS use traditional diagnostic criteria to construct their case finding strategy. The 
increasing demand for inter-hospital comparison initiated some changes in the field of 
surveillance over the last few years.38 For instance, to bypass the problem of interrater 
variability in the traditional diagnostics of VAP, a new definition using exclusively electronically 
available data has been created.59-63 This new concept of ventilator-associated events (VAE) is 
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accepted by the Centers for Disease Control and Prevention - National Healthcare Safety 
Network (CDC-NHSN).64 Multiple reports with conflicting results on the reliability and 
usefulness of this ‘synthetic’ definition have been published in recent years.65-67 
In conclusion, implementation of an ESS has shown to be feasible, provide accurate results and 
save time. However, we still have a long way to go before manual surveillance will be fully 
replaced by its electronic counterparts. Some important prerequisites to promote the chances of 
a successful implementation of an ESS need to be addressed. These components are summarized 
in table 1.37, 38, 44, 68 
 
1. Involvement of healthcare practitioners* in the design 
2. Standardization of data collection 
3. Incorporation of surveillance in daily workflow 
4. Timely reporting of results to healthcare practitioners 
5. General applicability - transferability to other hospitals 
 
Table 1: Prerequisites for successful implementation of an electronic surveillance system 






























“The most profound technologies are those that disappear. They weave themselves into 









The most severely ill patients are monitored and treated in the ICU. Complex and/or urgent, but 
nonetheless well-balanced and accurate actions are often imperative. Information technology 
(IT) is considered to be an efficient tool supporting daily clinical decisions in the data-rich 
critical care environment.69-71 The implementation process of an Intensive Care Information 
System (ICIS) was initiated in May 2003 in the ICU of the Ghent University Hospital. From that 
moment on large amounts of patient monitoring and observational data are being collected and 
stored at the point of care, supplemented by data derived from multiple bedside medical devices. 
In addition, this specialized ICU software allows CPOE and computerized medication 
administration recording. As such, an overabundance of digital information became readily 
available which created new challenges and opportunities. 
 
A. DESIGN OF A DATA VISUALIZATION DASHBOARD ON INFECTION 
As more patient related information is currently offered in an electronic format, physicians can 
rely on a more comprehensive and complete set of data when making treatment decisions. 
However, the process of mental data aggregation is often a time-consuming cognitive challenge 
as, depending on the specific clinical question that is being addressed, the required info is 
scattered across multiple data sources. Clinical dashboards are increasingly being adopted as 
means to assist physicians in specific task oriented data integration. The dashboard principle 
originated in the management sector and was subsequently introduced in healthcare.72, 73 This 
visualization tool supports easy access to timely and relevant clinical information in a concise, 
visually attractive and user-friendly format.74 Although this field of research is still in his infancy, 
a growing number of reports supporting the use of clinical dashboards has been published.73, 75-
79 
Considering the central and complex role of infection management in ICU patients, the option to 
design a data visualization dashboard on infection management was explored in our ICU. The 
first brainstorming sessions between ICU healthcare workers and software engineers from the 
Department of Information Technology (INTEC) of the Faculty of Engineering of Ghent 
University, took place in 2005. The project was named COSARA: ‘Computer-based Surveillance 
and Alerting of nosocomial infections, Antimicrobial Resistance and Antibiotic consumption in 
the ICU’. Financial support from the Institute for the Promotion of Innovation through Science 




multiple multidisciplinary meetings and resulted in the implementation of the software in 2009. 
COSARA received a thorough makeover in 2011 and was converted from a desktop program to a 
web application. Shortly thereafter, this COSARA 2.0 version was implemented in Antwerp 
University Hospital. In doing so, it was demonstrated that the software could be made 
compatible with various ICIS, laboratory and X-ray systems. The next important step was taken 
in 2014 with the introduction of COSARA in the pediatric ICU of Ghent University Hospital. 
Compared to the adult population, infections in critically ill children are more often viral of 
nature and anti-viral therapy is not always required. As the identification of an infection by 
COSARA is triggered by the initiation of antibiotic treatment (see below), some adjustments to 
the software were needed to capture information regarding these viral infections in the 
pediatric population correctly. The latest version of COSARA was launched in 2016. The COSARA 
2.5 version was created to run on mobile devices to promote its use during ward rounds. Figure 
2 shows in more detail the COSARA design and implementation timeline.
 
Figure 2: COSARA design and implementation timeline 
ICU: intensive care unit; ICIS: intensive care information system 
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The cornerstone of the COSARA software is a central infection dashboard view which is built up 
around a timeline (figure 3). Infection related patient data from distributed stand-alone vendor 
specific systems (ICIS, laboratory reports and X-ray images) are merged through the software, 
aiming to minimize navigation. Real-time synchronization with the individual systems ensures 
the presentation of up-to-date information. Time-graphs at the top of the page show the 
evolution of selected clinical (e.g. fever) and laboratory (e.g. leukocytosis, CRP) variables and 
indicators of severity-of-illness (e.g. the arterial oxygen tension (PaO2)/ fractional inspired 
oxygen (FiO2) ratio, sequential organ failure assessment score (SOFA)). For every antibiotic 
prescription that is entered via CPOE, a horizontal bar is created that runs just above the 
timeline and lengthens upon duration of the prescription. This bar is accompanied by a second 
bar running in parallel below the timeline and describing the indication for this antibiotic 
(introduced manually and structured: see below). More detailed information on prescription 
and infection are revealed on the base of the screen by hovering over the bars. All positive 
microbial culture results and matching susceptibility patterns are automatically indicated above 
the timeline using small symbols, whereas selected microbiological isolates that are linked to an 
infection are displayed underneath the timeline. Additional tabs within the selected case file 
present identical information in an alternative format (e.g. microbiology, antibiotic-infection 
combinations) (figure 4 and 5) or supplementary data (e.g. catheter information, consecutive 
chest X-rays) (figure 6). 
As such, a more holistic perspective on a complex history in a patient with a long ICU stay 
involving multiple infectious episodes and antibiotic treatments, is presented to the physician. A 
valuable insight into difficult patient files may facilitate the decision-making process during 
ward rounds and interdisciplinary staff meetings with microbiologists and infectious diseases 
specialists. In addition, the graphically attractive overview assists shift reports and teaching 





Figure 3: COSARA central infection dashboard view 













Figure 5: COSARA antibiotic-infection combinations linked to microbiology data










B. REAL-TIME MAPPING OF THE ANTIBIOTIC DECISION-MAKING PROCESS 
The antibiotic treatment decision-making process is often influenced by multiple factors. As a 
rule this information is not or incompletely recorded in the patient’s file, which complicates 
retrospective reconstruction of this process. The ambition to capture the physician’s motivation 
at the time of a new antibiotic prescription was incorporated in the basic structure of the 
COSARA software and makes it unique in its kind. The infection bar in the overview is fed by 
data from a short questionnaire that ‘pops up’ in real-time after each electronic antibiotic 
prescription and inquires the prescriber about indication, likely focus and severity of infection 
and the presence of microbiological data guiding the antibiotic choice. This survey is self-
explanatory and requires only a limited time investment (less than one minute) (figure 7). The 
resulting preliminary infection bar can be altered manually during the course of the infection 
when more data concerning the origin and clinical evolution of the infection become available. 
Additionally, more details on the infection focus can be added and stored as structured data 
(figure 8).













Figure 7 b: COSARA pop-up questionnaire










C. CONSTRUCTION OF A RELATIONAL DATABASE ON INFECTION 
As outlined in the previous paragraphs, COSARA integrates patient and infection related data 
from different electronic sources. The data visualization dashboard promotes information 
management and enables manual linking of microbiology data to antibiotic-infection 
combinations. Microbial pathogens may be designated as causative pathogens, or as non-
causative pathogens influencing antibiotic prescription (e.g. nasal carriage of methicillin-
resistant Staphylococcus aureus promoting glycopeptide prescription in suspected pneumonia 
with negative sputum cultures). Merging of antibiotic, clinical diagnostic and microbiology data 
can be performed during clinical workflow or at any later stage. To ensure high quality data, the 
COSARA dashboard of every individual patient admitted to the ICU is reviewed and completed 
following ICU discharge by designated users. 
The continuous data merging results in the built-up of a large relational database. This data 
warehouse can be consulted for multiple purposes e.g. clinical research, management, 
surveillance and education. A distinct module in the software allows real-time assessment of a 
vast array of predefined analyses by physicians. Until now, assistance of an IT specialist is 
required to extract the raw data. The architecture of the database, however, permits physicians 
to execute comprehensive and complex analyses autonomously by linking of these extracted 
data. 
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3 STUDY OUTLINE 
A. USE OF A COMPUTER-ASSISTED REGISTRATION PROGRAM TO FACILITATE 
SURVEILLANCE IN THE ICU 
Documentation of infections is a crucial step in the implementation process of an ASP (figure 
1).35, 36 COSARA is designed to facilitate prospective collection of infection related information as 
structured data. Assessment of the validity of COSARA as an infection surveillance tool and the 
feasibility to perform registration in a continuous way was deemed essential. In a first study, 
traditional manual paper-based surveillance (PBS) was compared with computer-assisted 
surveillance (CAS) by means of COSARA for ICU-acquired respiratory tract, urinary tract and 
bloodstream infections during a four-month period (November 1st 2011 –February 29th 2012). A 
formal checklist based on CDC-NHSN criteria to document infection was used by PBS, whereas 
CAS assigned diagnoses based on a clinical estimation of the probability of infection by the 
physician. Overall agreement between both surveillance methods was measured. Conflicting 
results were reviewed by an independent panel of physicians. Additionally, the time investment 





B. INVESTIGATION OF ANTIBIOTIC PRESCRIPTION AND ANTIBIOTIC RESISTANCE IN 
THE ICU TO SUPPORT THE DESIGN OF AN ASP 
The collection of high quality surveillance data primarily serves a higher purpose, in particular, 
the design of an ASP and ultimately the improvement of bedside clinical care. Data acquisition 
for the following studies was performed through the use of COSARA. 
 
3.B.1 A complete and multifaceted overview of antibiotic use and infection diagnosis in 
the ICU 
As mentioned previously, comprehensive longitudinal data on antimicrobial management in the 
ICU are currently lacking. Details on prescription indications are often insufficiently captured as 
this process is considered too time and resource consuming. To the best of our knowledge, the 
basic principle of COSARA (which is the continuous prospective merging of antibiotic, clinical 
and microbiology data) has not been applied elsewhere. This approach has resulted in the 
prospective building up of an extensive database since the implementation of COSARA. A 
descriptive analysis of a dataset covering four years of surveillance thus enables a unique 
presentation on global antibiotic utilization, infection epidemiology and microbiology in our ICU. 
As such, we tried to get a bird’s eye view of our local antibiotic prescribing practices. We aimed 
to provide a starting point for the design of an ASP based on an evaluation of the infection 
probability (high/moderate/low) that was assigned to all therapeutic prescriptions. 
 
3.B.2 Empirical antibiotic prescription in hospital-acquired pneumonia and the added 
value of the use of surveillance cultures 
Hospital-acquired pneumonia (HAP) is defined as pneumonia occurring 48 h or more after 
hospital admission. VAP is a subgroup of HAP, developing in mechanically ventilated patients 48 
h or more following endotracheal intubation.80 HAP is considered as one of the most important 
hospital-acquired infections in terms of prevalence, morbidity, mortality and use of resources.81, 
82 HAP is a major driver for antibiotic consumption in the ICU and as such also an important 
stewardship target. Up until now microbiology turnaround time for respiratory samples is 48 h, 
subsequently the initial antibiotic treatment choice is as a rule empirical.82 To ensure early 
appropriate therapy, the use of broad-spectrum antibiotic therapy is advocated in international 
guidelines.17 It is recommended to adjust this antibiotic regimen to local antibiotic resistance 
data. In addition, treatment selection should be guided by the patient’s severity of illness and 
risk for involvement of MDR pathogens. Surveillance cultures (SC), which are cultures taken at 
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ICU admission and further at regular intervals during ICU stay, contribute to a better knowledge 
of the patient’s colonization status.83 The use of these SC to improve empirical antibiotic choice 
and restrict superfluous broad-spectrum agents has extensively been studied over the last years, 
but remains a matter of debate.84-89 
In Ghent University Hospital ICU, the selection of an empirical HAP treatment is not guided by 
formal algorithms. By retrospective evaluation of all HAP episodes in the period from July 1st 
2009 to October 31st 2012 we assessed the potential impact of the implementation of a 
treatment algorithm on appropriateness and spectrum of the proposed treatment strategy. Two 
different algorithms were constructed. A local ecology-based algorithm (LEBA) takes previously 
recorded local resistance patterns into account combined with patient related characteristics e.g. 
severity of illness and clinical risk factors for MDR colonization. A surveillance culture-based 
algorithm (SCBA) assessed the added value of the incorporation of information from 
systematically collected SC to guide empirical antibiotic choice. 
 
3.B.3 Local antibiotic de-escalation practices and impact on the emergence of antibiotic 
resistance 
Over the last decades, de-escalation has been a widely recommended and commonly applied 
stewardship strategy.90, 91 Empirical broad-spectrum combination therapy, initiated to cover all 
potential causative pathogens, is streamlined as soon as more information on infection 
probability, clinical course and causative microbiology becomes available. De-escalation is still 
not well-defined. It may consist of replacement of broad-spectrum drugs by more narrow-
spectrum agents, stopping one or more components of a combination therapy, limitation of 
treatment duration or discontinuation of all antimicrobial agents in the absence of an 
infection.92-94 A reduction in overall broad-spectrum antibiotic consumption and MDR 
emergence is pursued. Intuitively, de-escalation is a very attractive stewardship action 
harmonizing early appropriate therapy with restriction of the unfavorable effects of 
antimicrobial treatments. Unfortunately, large-scale, high quality data supporting a positive 
clinical and ecological outcome are lacking.93, 95, 96 
To gain more insight into our local de-escalation practices we analyzed all beta-lactam antibiotic 
courses of at least 48 h duration that were prescribed as first line treatment for an infection 
between January 1st 2013 and December 31st 2014. Frequency and determinants for de-
escalation (and escalation) of therapy were assessed. Subsequently, we evaluated the effect of 
de-escalation on patient outcome. We focused on the emergence of antibiotic resistance 




availability of routine SC in our ICU population combined with our COSARA dataset, offered the 
opportunity to assess: 
 
- The emergence of resistance to the initially prescribed beta-lactam antibiotic 
- The emergence of MDR pathogens 
 
3.B.4 Facilitation of internal stewardship decision-making: identification of potentially 
unjustified prolonged antibiotic treatment courses 
The systematic assessment of the ongoing need of an antibiotic treatment 48-72 h following its 
initiation is considered a core action of ASP. A drill-through-to-detail analysis on the 
aforementioned dataset covering four years of surveillance (section 3.B.1) was performed to 
illustrate the potential of our surveillance method to make an estimate of the effect of such a 
stewardship intervention. Three ‘last resort’ antibiotic classes for which a prudent use is 
recommended (carbapenems, glycopeptides and oxazolidinones) were assessed. We identified 
prescriptions of these three antibiotic classes which were sustained more than 3 days of therapy 
without clear clinical or microbiological justification. We calculated the potential saving in 
antibiotic consumption by an antibiotic time out for each of these antibiotic agents. 
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An electronic decision support program was developed within the intensive care unit (ICU) that 
provides an overview of all infection-related patient data, and allows ICU physicians to add 
clinical information during patient rounds, resulting in prospective compilation of a database. 
Aim: 
To assess the validity of computer-assisted surveillance (CAS) of ICU-acquired infection 
performed by analysis of this database. 
Methods: 
CAS was compared with prospective paper-based surveillance (PBS) for ICU-acquired 
respiratory tract infection (RTI), bloodstream infection (BSI) and urinary tract infection (UTI) 
over four months at a 36-bed medical and surgical ICU. An independent panel reviewed the data 
in the case of discrepancy between CAS and PBS. 
Findings: 
PBS identified 89 ICU-acquired infections (13 BSI, 18 UTI, 58 RTI) and CAS identified 90 ICU-
acquired infections (14 BSI, 17 UTI, 59 RTI) in 876 ICU admissions. There was agreement 
between CAS and PBS on 13 BSI (100 %), 14 UTI (77.8 %) and 42 RTI (72.4 %). Overall, there 
was agreement on 69 infections (77.5%), resulting in a kappa score of 0.74. Discrepancy 
between PBS and CAS was the result of capture error in 11 and 14 infections, respectively. 
Interobserver disagreement on probability (13 RTI) and focus (two RTI, one UTI) occurred for 
16 episodes. The time required to collect information using CAS is less than 30% of the time 
required when using PBS. 
Conclusion: 
CAS for ICU-acquired infection by analysis of a database built through daily workflow is a 
feasible surveillance method and has good agreement with PBS. Discrepancy between CAS and 
PBS is largely due to interobserver variability. 




Intensive care unit (ICU)-acquired infection is a frequent complication in patients admitted to 
the ICU,97, 98 and is associated with adverse outcomes.99, 100 Although the incidence of ICU-
acquired infection varies according to the patient case-mix, it is, to some extent, a preventable 
complication. Surveillance of various types of infection has been advocated as a means to 
measure hospital quality, and serves as an instrument to guide and evaluate the infection control 
policy.101 However, conventional surveillance requires time-consuming extraction of data from 
dispersed information sources by dedicated and trained personnel. The cost and workload 
associated with conventional surveillance is a major barrier to its continuous implementation; 
as such, surveillance is generally performed erratically or for limited time periods. In a joint 
project with the Department of Information Technology of Ghent University, the authors 
designed and implemented a software application for electronic decision support in infectious 
diseases at the ICU [Computer-based Surveillance and Alerting of infections, Antimicrobial 
Resistance and Antibiotic consumption in the ICU (COSARA)]. COSARA has been fully 
operational since 2010 at the study ICU, where it assists the attending ICU physician in acquiring 
oversight of various data related to infection diagnosis and treatment. The program facilitates 
the compilation of an extensive data warehouse on antibiotic use and infection in the ICU, which 
can be consulted for various purposes.102 It was hypothesized that analysis of the COSARA data 
warehouse would facilitate surveillance of ICU-acquired infection, and the list of infections 
resulting from conventional prospective paper-based surveillance (PBS) was compared with the 
list of infections retrieved from COSARA [computer-assisted surveillance (CAS)]. For the 
purpose of this study, surveillance was restricted to ICU-acquired respiratory tract infection 
(RTI), urinary tract infection (UTI) and bloodstream infection (BSI). 
 
4.A.3 Materials and methods 
The study was conducted at the 14-bed medical ICU (MICU) and the 22-bed surgical ICU (SICU) 
of Ghent University Hospital (1050 beds). The MICU and SICU are completely computerized, and 
COSARA software has been available on every personal computer dedicated to patient care since 
2010. With COSARA, all infection-related data from the various electronic patient records are 
integrated and presented to the treating ICU physician by means of a continuously updated 
clinical dashboard. This includes a graphical display of current and past antibiotic treatments as 
a timeline, and provides direct links to a real-time copy of the various source records. The 
graphical interface allows episodes of antibiotic treatment to be labelled according to a 
predefined list of indications and diagnoses, and linked with microbiological culture results. 




questionnaire that pops up at the time of electronic prescription; and a definitive label can be 
assigned after review of all relevant data. This can be done during clinical patient rounds, 
interdisciplinary staff meetings or at any given time. All data are stored in a data warehouse. 
The study was approved by the institutional ethics committee. Only patients aged 16 years or 
more were included. All patients and relatives were informed about the surveillance through a 




The results from CAS were compared with those from PBS over a four-month study period (1st 
November 2011-29th February 2012). It was estimated that four months of surveillance would 
allow the inclusion of 100 infections, based upon average observed incidence rates at the study 
ICU [RTI (N=15/1000 ICU-days), UTI (N=5/1000 ICU-days) and BSI (N=5/1000 ICU-days)] 
found by previous surveillance in collaboration with the national Scientific Institute of Public 
Health. An infection was defined as ICU-acquired if it occurred 48 h or more after admission to 
the ICU. Infections diagnosed at re-admission of a patient who was discharged from the ICU less 
than 48 h previously were also considered to be ICU-acquired. Only the first infectious episode 
was included for patients who developed consecutive infections during the same ICU stay. 
Results of CAS and PBS were compared with a reference set to determine sensitivity and 
specificity (see below). The time required for data collection using both surveillance systems 
was recorded per week. 
Paper-based surveillance 
One of the investigators (GD) screened all ICU patients for the presence of ICU-acquired infection 
three times per week. GD was blinded to the COSARA graphical display, but had access to all 
electronic source data and was allowed to contact the treating physician for more information if 
necessary. The starting point for detection of a potential case of BSI, UTI or RTI was the presence 
of a pathogenic micro-organism in a blood, urinary or respiratory culture, respectively. In 
addition, the patient’s electronic medical record was screened to detect episodes of clinically 
suspected RTI treated with antibiotics in the absence of microbiological documentation to 
ensure completeness of the dataset. PBS used formal checklists that were developed based on 
Centers for Disease Control and Prevention-National Healthcare Safety Network (CDC-NHSN) 
criteria,103 and modified to make them applicable to the ICU patients as described below. 
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A BSI was defined as the presence of a pathogen (excluding common skin contaminants) in at 
least one blood culture. The presence of common skin contaminants in at least two blood 
cultures drawn on separate occasions, together with fever, chills or hypotension, and judged to 
require antimicrobial treatment by the ICU physician was defined as ICU-acquired BSI. 
Urinary cultures were performed quantitatively three times per week on a regular basis as part 
of the surveillance program. Symptoms of suprapubic tenderness or dysuria were not 
considered for UTI as these are difficult to assess in ICU patients.104 UTI was defined as episodes 
of sepsis, pyuria (>25 white blood cells/mm3), a positive urinary culture [growth of a 
uropathogen ≥ 105 colony-forming units (cfu)/mL], and judged to require antibiotic therapy by 
the treating physician. All episodes with a positive urinary culture that did not fulfill all of the 
criteria were considered as asymptomatic bacteriuria and were not retained. Episodes of UTI 
with the same pathogen growing in urinary and blood cultures were classified as UTI. 
Clinical and radiological criteria for RTI conform with CDC-NHSN definitions.103 CDC-NHSN 
diagnosis of microbiologically confirmed pneumonia relies on invasive sampling such as 
bronchoalveolar lavage (BAL) or protected specimen brushing. However, in the study hospital, 
microbiological analysis of respiratory samples routinely consists of semi-quantitative culture of 
blind end tracheal aspirate (ETA) in the ventilated patient or sputum in the non-intubated 
patient. For logistical reasons, BAL is not performed systematically in patients with a clinical 
suspicion of pneumonia, similar to current practice in the majority of ICUs.105 It has been shown 
previously that quantitative and semi-quantitative culture results of BAL and ETA were 
concordant in a cohort of patients with suspected ventilator-associated pneumonia (VAP). 
Positive and negative predictive values of a semi-quantitative score of 1+ growth of a pathogen 
in ETA to identify the same pathogen in at least 104 cfu/mL in BAL were 81% and 87%, 
respectively.106 Consequently, microbiologically confirmed pneumonia was defined as 1+ growth 
or more of a potential pathogen in ETA in the case of VAP, or in a purulent sputum sample of 
good quality (defined as less than three squamous epithelial cells per low power field) in the 
case of hospital-acquired pneumonia. Episodes of pneumonia complicated with BSI were 
classified as RTI. 
Computer-assisted surveillance 
Labelling of antibiotic indications and infections in the clinical dashboard was undertaken as 
part of daily routine clinical work and reflected the clinical opinion of the treating physician. The 
clinical dashboard was completed and supervised by two investigators [LDB (SICU) and PD 
(MICU)] during clinical rounds and interdisciplinary staff meetings. While the PBS checklist was 




entered by consensus and using the same clinical, radiological and microbiological criteria as in 
the PBS. RTI was considered to be highly probable in the case of presence of a new or worsening 
infiltrate on chest X-ray, together with clinical signs of sepsis and new respiratory symptoms 
(increased sputum, increased purulence of sputum, worsening oxygenation), and a semi-
quantitative score of 1+ growth or more of a pathogen in a good-quality respiratory sample. RTI 
was considered to be moderately probable in the case of all previous criteria but in the absence 
of respiratory pathogens or growth below the threshold of 1+. UTI was considered to be 
moderately probable in the case of pyuria and sepsis, other foci of infection being unlikely, and 
the presence of a urinary pathogen in ≥ 105 cfu/mL. Highly probable UTI required isolation of 
the same pathogen in blood and urinary cultures. BSI was defined by the same criteria as in PBS; 
episodes with coagulase-negative staphylococci alone were considered to be moderately 
probable, and episodes with pathogenic bacteria were considered to be highly probable. By 
querying the COSARA data warehouse, all episodes from the study period that were labelled as 
RTI, BSI or UTI with high or moderate probability and a start date beyond 48 h of ICU admission 
were retrieved as ICU-acquired infection. 
Reference set 
All episodes of ICU-acquired infection that had discordant results on CAS and PBS were 
reviewed independently by a senior microbiologist/infection control practitioner (ILR) and a 
senior ICU physician (JD), using the PBS criteria as described previously. Reasons for 
disagreement between CAS and PBS were discussed. Episodes with concordant results and those 
retained after independent review comprised the reference set. 
 
Statistical analysis 
All data are presented as absolute numbers with or without percentages. All statistical analyses 
were performed using Statistical Package for the Social Sciences Version 21 (SPSS Inc., Chicago, 
IL, USA). Kappa measures of agreement were calculated. As universally accepted guidelines do 
not exist, the guidelines of Fleiss were adopted (kappa ≥0.75, excellent agreement; kappa >0.4 










Comparison of CAS and PBS 
PBS identified 89 ICU-acquired infections and CAS identified 90 ICU-acquired infections in 876 
ICU admissions. The results are shown in Table 2. Overall, CAS agreed with PBS on 69 infections 
(77.5%), resulting in kappa = 0.74. Agreement was lower for RTI (kappa = 0.70) than for BSI 
(kappa = 0.96) and UTI (kappa = 0.80). 
 
Table 2: ICU-acquired infections identified by paper-based surveillance (PBS) and computer-
assisted surveillance (CAS) 
Type of infection Cases identified by PBS Cases identified by CAS 
Proportion of infections 
identified by PBS, which 










UTI 18 17 14/18 (77.8%) 
RTI 58 59 42/58 (72.4%) 
All infections 89 90 69/89 (77.5%) 
BSI= bloodstream infection, RTI= respiratory tract infection, UTI= urinary tract infection 
 
Comparison of CAS and PBS with the reference set 
The reference set comprised 99 ICU-acquired infections: 14 BSI, 65 RTI and 20 UTI, 
corresponding to a cumulative incidence of 1.6 cases per 100 ICU admissions for BSI, 7.4 cases 
per 100 ICU admissions for RTI and 2.3 cases per 100 ICU admissions for UTI. Overall sensitivity 
and specificity were 89% and 100%, respectively, for PBS, and 81% and 99%, respectively, for 




Table 3: Test characteristics of paper-based surveillance (PBS) and computer-assisted surveillance 
(CAS) as compared to the reference set 
Type of ICU-acquired infection Sensitivity,% Specificity, % 
BSI - PBS 93 100 
BSI - CAS 100 100 
RTI - PBS 88 99.9 
RTI - CAS 77 99 
UTI - PBS 90 100 
UTI - CAS 80 99.9 
BSI= bloodstream infection, RTI= respiratory tract infection, UTI=urinary tract infection 
 
PBS was more prone to human error than CAS (11 vs 4). However, more technical problems 
were encountered with CAS, including failure to store antibiotic episodes (N = 5) and query 
errors (N = 5). However, for the greater part, discordant results between conventional PBS and 
CAS were the consequence of interobserver variability. Reasons for disagreement between the 
two surveillance methods are shown in Table 4. 
 
Assessment of time expenditure 
Manual PBS data collection required a mean time investment of approximately 7 h/week. The 
average time spent, in total, by the supervisors in charge of updating the COSARA graphical 
platform was 2 h/week.
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Table 4: Reasons for discrepancy between paper-based surveillance (PBS) and computer-assisted 
surveillance (CAS) 
 False negative episodes False positive episodes 
 PBS CAS PBS CAS 










1 RTI, 2 UTI  
wrong labelling in  
clinical dashboard 
 
5 RTI: not stored 
in data-warehouse 
 
1 RTI, 1 UTI: not 
retrieved by query 
- 
 
1 RTI: wrong 
labelling  in 
clinical dashboard 
 





- 6 RTI: PBS criteria 
met, classified as 
low probability by 
CAS 
 
2 RTI, 1 UTI: PBS 
criteria met, 
assigned to other 
infection focus by 
CAS 
1 RTI: PBS criteria 
not met when 
reassessed 





infection by CAS 





Good agreement was found between CAS for ICU-acquired infection conducted through analysis 
of the COSARA data warehouse and conventional, prospective PBS. CAS and PBS methods 
concurred with an overall kappa score of 0.74 for RTI, BSI and UTI. 
The approach used in this study is one of the various forms of CAS that have been developed 
thanks to the advanced computerization of medical data, in order to facilitate the time-
consuming process of PBS. Distinction can be made between fully or partially automated tools, 
depending on whether they replace or assist healthcare personnel in the act of surveillance. 
Fully automated tools rely on computer programmes retrospectively combing through 
microbiological data, administrative records, pharmacy data or a combination of these to 
capture key indicators of infection. While screening diagnostic codes is the most simple and 
straightforward electronic method of identifying infection, it has been shown to be largely 
inaccurate.109-111 To improve sensitivity and specificity, more complex algorithms have been 
developed that combine different sets of data or sieve through the captured episodes with 
additional filters.43, 112 In contrast, CAS, as performed in this study, can be classified as partially 
automated as it requires a substantial input of interpretative information. With COSARA, the 
automated collection of infection-related data from various electronic sources in a single data 
warehouse is complemented by prospective manual insertion of medical diagnoses as 
structured data. Partially automated methods are based upon the assumption that the 
comparison of parameters and data against predefined sets of criteria by a computer 
programme may support but not fully replace the complex human reasoning involved in making 
a diagnosis such as that of an infection.113 This has been corroborated by the results of a study by 
Steinmann et al.,114 where ward physicians not only had to fill in clinical parameters on a daily 
basis to feed a programme for electronic infection registration, but were also invited to give a 
personal opinion on the presence or absence of infection. The fully automated registration 
resulting from comparison of these clinical parameters with predefined criteria for VAP showed 
relatively poor agreement with the physician’s evaluation for pneumonia, as reflected by a kappa 
score of 0.49. This was essentially due to low specificity of the automated system, and illustrates 
that automated identification of infection based upon raw clinical data may lead to over-
diagnosis, unless reviewed by ICU physicians or infection control practitioners.114 
Case finding is a critical step within partially automated methods that determines sensitivity of 
the surveillance method. With COSARA, a treatment-based selective surveillance approach was 
used, with potential cases identified by the presence of an electronic antibiotic prescription. 
Consequently, infections for which no antibiotic therapy was initiated were not recorded. It is 
postulated that the number of these is very low under the assumption that a diagnosis of 
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clinically relevant infection very likely implies antimicrobial therapy in the absence of do-not-
resuscitate codes. Specificity of treatment-based case selection depends on the efforts made to 
distinguish between likely infection and prolonged empirical antimicrobial therapy for non-
infectious conditions. In this application, all antibiotic prescriptions were re-assessed and linked 
with microbiological culture results, and received a final classification by ICU physicians 
involved in daily care. In a study comparing different methods of CAS, a method selecting cases 
upon antibiotic prescription had sensitivity of 82% and specificity of 67%; filtering these cases 
for the presence of a positive microbiological culture result increased specificity to 87%.115 
The validity of CAS programmes is usually assessed by comparison with traditional PBS. 
However, as illustrated by other analyses and the present study, it is clear that PBS is not ‘set in 
stone’, as it is subject to screening failure and interobserver variability.60, 116-118 In order to 
enable a less biased calculation of the test characteristics of both CAS and PBS in the absence of a 
true gold standard test, a reference set serving as a surrogate gold standard was constructed. 
Cases on which both surveillance methods agreed were not re-evaluated by the independent 
panel; this is a limitation of this approach, as this could have influenced sensitivity and 
specificity analyses. However, it is believed that the number of episodes of ICU-acquired 
infection missed by both methods, and the number of false-positive registrations of ICU-acquired 
infection by both methods, are fairly low. Interobserver variability was found to account for 
most of the discrepancy between the two methods. This was most pronounced for RTI; a finding 
which is in accordance with the literature and can be explained by the inaccurate diagnosis of 
RTI in critically ill patients, involving many subjective components and non-specific clinical, 
radiological and biochemical signs.60 This insight has led the CDC to modify the 2008 NHSN 
definitions, proposing a novel algorithm based on more objective criteria and amenable for 
automatic processing; however, these new criteria need further validation.62 Interobserver 
variability may have been increased by the design of the study, as the PBS investigator used a 
more rigid checklist whereas the CAS investigators applied clinical judgement. The CAS 
investigators were deliberately asked to use clinical appreciation to stay as close as possible to 
routine clinical work. Application of the CDC-NHSN criteria may allow better comparison 
between centres, but at the expense of producing results that deviate from what is perceived or 
present in reality. 
With increasing public awareness of healthcare-associated infection as an adverse event related 
to healthcare delivery, the pressure to provide continuous surveillance data is growing stronger. 
In addition, as increasing antibiotic resistance requires more judicious use of currently available 
antibiotics, managing antibiotic prescription within the ICU has become a priority. CAS as 




Regular queries of the data warehouse may enable the identification of outbreaks, observation of 
trends in antibiotic consumption, and evaluation of the effect of targeted interventions. 
Depending on local hospital organization and staffing, supervision of the COSARA graphical 
platform and ultimate labelling of infections can be performed by any professional engaged in 
infection control. In COSARA, the presentation of all clinical, microbiological and radiological 
data on a single platform facilitates the use of different criteria, including the CDC-NHSN criteria 
for labelling the infectious episodes, depending on the purpose of the surveillance. Stricter use of 
criteria is preferable for benchmarking or comparison between ICUs, while less stringent 
surveillance that reflects clinical practice more closely serves best to analyse antibiotic use or 
evaluate the effect of interventions. 
Drawbacks of COSARA include the aforementioned omission of infections for which no 
antibiotics are prescribed, and a reliance on healthcare workers to complete diagnostic labels, 
which may lead to human errors such as incomplete recording or mislabelling. Finally, as this 
was a single-centre study, it is possible that the good performance of CAS by COSARA is linked to 
the characteristics of the particular clinical patient information system in use. However, the 
authors are currently deploying COSARA in another tertiary hospital ICU that uses a different 
clinical information system. 
In summary, CAS for ICU-acquired infection by analysis of the COSARA data warehouse has good 
agreement with PBS, and required less than one-third of the time spent on PBS. Conventional 
surveillance is usually restricted to a limited number of infections over a short period of time 
due to workload and time restraints. Data collection using COSARA is integrated in the clinical 
workflow, closely linked to decision support, and can be pursued on a prospective continuous 
basis without much additional effort. 
 




This research project was funded by the IWT (Institute for the Promotion of Innovation through 
Science and Technology in Flanders) (Project IWT-TBM COSARA: IWT project number 060517).
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B. A COMPLETE AND MULTIFACETED OVERVIEW OF ANTIBIOTIC USE AND INFECTION 
DIAGNOSIS IN THE INTENSIVE CARE UNIT: RESULTS FROM A PROSPECTIVE FOUR-
YEAR REGISTRATION 
 
Liesbet De Bus, Bram Gadeyne, Johan Steen, Jerina Boelens, Geert Claeys, Dominique Benoit, Jan 









The implementation of antibiotic stewardship programs requires detailed information on 
overall antibiotic use, prescription indication and ecology. However, longitudinal data of this 
kind are scarce. Computerization of the patient chart has offered the potential to collect 
complete data of high resolution. To gain insight in our global antibiotic use, we aimed to explore 




We studied all adult patients admitted to Ghent University Hospital ICU between January 1st 
2013 until December 31st 2016. Antibiotic prescription data were prospectively merged with 
clinical diagnostic (e.g. infection focus, severity, probability at start) and microbiology data by 
ICU physicians during daily workflow through a dedicated software program. Appreciation of 




During the study period, 8763 patients were admitted with an overall antibiotic consumption of 
1232 days of therapy (DOT)/1000 patient days. Of all DOT, 52.7% was used to treat infections 
with high probability; whereas prophylactic treatment accounted for 25%. Infections were 
microbiologically confirmed in 56% (3496/6206) of cases. Bacterial infections were mainly 
respiratory and abdominal (49% and 19% respectively). Of the total DOT used for respiratory 
infection, 42% was for moderate to low probability infections, whereas for abdominal infection, 
this was only 15%. 
 
Conclusions: 
We were able to construct a longitudinal, multifaceted dataset on global antibiotic use and 
infection diagnosis. Categorization of prescriptions by infection probability may guide 
construction and monitoring of future stewardship actions. 




Antibiotics are among the most often prescribed drugs in an intensive care unit (ICU).2, 6 
Whereas the positive impact of timely and appropriate antimicrobial therapy on outcome in 
severe bacterial infection is beyond discussion, the strong association between antibiotic 
exposure and the emergence of antibiotic-resistant bacteria mandates rationalization of 
antibiotic prescription. The concept of ‘antibiotic stewardship’ refers to policies and 
interventions to optimize antibiotic therapy and restrict unnecessary use.1, 3, 23, 26, 27, 119, 120 The 
latter comprises avoiding antibiotic prescription for non-infectious disease, limiting use of 
broad-spectrum drugs when a narrower antimicrobial spectrum suffices and shortening 
duration of therapy when prolonged antibiotic courses do not provide benefit.29, 35, 121 
Surveillance of antibiotic prescription is a first essential step to measure antibiotic expenditure, 
to document physician’s incentives to prescribe antibiotics and to identify areas of potential 
overuse or misuse which could then be a target for antimicrobial stewardship interventions.27, 28, 
122, 123 In general, surveillance metrics are derived from antibiotic prescription data (pharmacy-
based), microbiology results (laboratory-based) or diagnostic codes (administration-based) or a 
combination thereof. However, surveillance is not the primary purpose of these sources of 
information: they mostly have poor matching of antibiotic prescription with the corresponding 
clinical and microbiological data. This limits their ability to represent the complex nature of the 
antibiotic treatment decision-making process and thus their practical usefulness.38, 45, 48 
Prospective surveillance on the ICU floor is more precise and informative but since it is 
demanding in time and resources, it is usually only applied for relatively short periods of time or 
for a limited scope of prescription, e.g. for certain classes of reserved antibiotics.52 The 
computerization of the patient ICU chart has offered the potential to record healthcare processes 
as complete data of high resolution in a way that minimally interferes with the healthcare-
deliverer’s workflow.102 
In this manuscript, we present a complete and in-depth analysis of global antibiotic prescription 
and infection diagnosis in a university hospital ICU over a four-year period. These data were 
collected with the help of a locally developed software program which has been designed to link 
pharmaceutical, clinical and microbiological data together with diagnostic interpretation while 
performing daily bedside clinical work. As such, we tried to get a bird’s eye view of our local 
antibiotic prescribing practices, which can then serve as a starting point for the future 





4.B.3 Materials and methods 
Setting 
This study was conducted from January 1st 2013 until December 31st 2016 at the medical (14 
beds) and surgical (22 beds) ICU of Ghent University Hospital (1054 beds). The Ghent University 
Hospital Ethics Committee approved the study (registration number B670201628197) and 
waived informed consent based on the non-interventional nature of this study. Only patients 
aged 16 years or older were included. 
An Intensive Care Information System (Centricity Critical Care, GE Health Care) integrating 
computerized physician order entry for medication prescriptions, computerized medication 
administration recording and clinical patient monitoring data is available bedside since 2003. 
Patients are managed in a closed ICU model and all antibiotic prescriptions are at the discretion 
of the attending senior ICU physician, without the use of stringent protocols or antibiotic 
restrictions. Empirical antibiotic choices are guided by systematically collected surveillance 
cultures whenever available. Turnaround time for microbial identification and antimicrobial 
susceptibility is 24-48 h for blood cultures and 48 h for other cultures. Direct microscopic 
examination is performed on all diagnostic respiratory and per-operative samples. Pathogen 
identification is routinely performed by matrix-assisted laser desorption ionization time-of-
flight mass spectrometry (MALDI-TOF MS). All microbiology results are reported electronically. 
Interdisciplinary staff meetings with medical microbiologists reviewing all antibiotic 
prescriptions take place once weekly in the medical ICU and three times weekly in the surgical 
ICU; these staffs also include the presence of infectious diseases specialists in the surgical ICU. In 
addition, daily advice and follow-up by these specialties is possible on a demand basis for 
individual cases. Treatment duration and opportunities for antibiotic de-escalation are 
evaluated daily by the attending ICU physician and during the interdisciplinary discussions. 
A software program with the acronym COSARA (Computer-based Surveillance and Alerting of 
infections, antimicrobial Resistance and Antibiotic consumption in the ICU) was developed by a 
consortium of the Ghent University Hospital ICU department and the Department of Information 
Technology (INTEC) of the Faculty of Engineering of Ghent University.102 The project was funded 
by the Flemish government. The goal of COSARA is to support the ICU physician in the daily 
workflow by automatically integrating all relevant infection-related data (clinical parameters, 
antibiotic prescription, laboratory variables including microbiology and chest X-ray images) 
from different data sources and presenting these as a graphic overview. The antibiotic 
prescription is graphically presented as a horizontal bar, running along a timeline and 
lengthening upon duration of this prescription (antibiotic bar). This bar is accompanied by a 
second bar running in parallel and describing the indication for this antibiotic (infection bar). 
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The infection bar is created in a two-step fashion. A preliminary version is fed by data from a 
short questionnaire that ‘pops up’ in real-time after any antibiotic prescription and inquires the 
prescriber about indication, likely focus, severity and probability of infection and presence of 
microbiological data guiding the antibiotic choice. This preliminary bar can be altered manually 
when more data concerning the origin and clinical evolution of the infection become available. 
Multiple antibiotic prescriptions can thus be linked with the same infection bar; in addition, the 
same antibiotic bar can be linked with multiple infection bars (e.g. antibiotic prescribed for 
simultaneous intra-abdominal and respiratory infection). For each infectious episode, focus, 
severity and probability of infection is selected from a drop-down menu. Probability is classified 
as low, moderate or high, as described previously,124 using clinical, radiological and 
microbiological criteria. An infection was defined as ICU-acquired if it occurred 48 h or more 
after admission to the ICU. The coupled antibiotic-infection bars can be linked to microbiological 
culture results; microbial pathogens may be designated as causative pathogens, or as non-
causative pathogens influencing antibiotic prescription (e.g. nasal carriage of methicillin-
resistant Staphylococcus aureus promoting glycopeptide prescription in suspected pneumonia 
with negative sputum cultures). For this study, all preliminary infection bars were reviewed, 
completed or modified if necessary by the investigators LDB and PD after consultation of the 
treating ICU physician or the patient charts. 
Antimicrobial days of therapy (DOT) per admission and per patient days is recommended as 
utilization metric by the STEWARDS panel and others.122, 123, 125 In agreement with the 
recommendations of the Centers for Disease Control and Prevention - National Healthcare Safety 
Network (CDC-NHSN), DOT is defined as the number of days with systemic administration of at 
least one dose of an antimicrobial agent as recorded by COSARA.35 
 
Statistics 
Categorical variables were expressed as frequencies (percentages), continuous variables were 
described as median values with the interquartile range (IQR; 25–75th percentile). Statistical 










A total of 10743 ICU admissions were recorded in 8763 patients resulting in a total of 47403 
patient days from January 1st 2013 until December 31st 2016. ICU and hospital mortality was 
10.7% (n=936) and 15% (n=1314) respectively. Median APACHE II score at admission was 18 
(IQR 13-25). Mechanical ventilation was provided in 3958 admissions (36.8%) with a median 
duration of 2 days (IQR 1-6), resulting in 20897 ventilation days. Vasopressor therapy was 
administered in 3639 admissions (33.9%) with a median duration of 2 days (IQR 2-4). 
Methicillin resistance was present in 23% of the Staphylococcus aureus isolates in our ICU 
population. Vancomycin resistance was present in 1.9% of the Enterococcus species isolates. 
Extended spectrum beta-lactamase production (ESBL) was present in 33% of 
Enterobacteriaceae isolates, whereas carbapenemase production was present in 1.2%. 
Patients were exposed to at least one antibiotic class in 66% of ICU admissions. An infection was 
present within the first 48 h of ICU admission in 35% (3804/10743) of admissions. An ICU-
acquired infection was diagnosed in 23% (1096/4851) of admissions with an ICU length of stay 
of more than 48 h. Detailed information on antibiotic exposure and infection diagnosis per ICU 
episode is provided in table 5. 
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Table 5: Antibiotic exposure and infection diagnosis per ICU episode 
 LOS ICU <48h (n=5892) LOS ICU ≥ 48h (n=4851) 
Antibiotic exposure (%)   
n antibiotic classes    
0 classes 2892 (49%) 800 (16%) 
1 class 2309 (39%) 1489 (31%) 
2 classes 519 (9%) 1050 (22%) 
3 classes 127 (2%) 655 (14%) 
> 3 classes 45 (1%) 857 (18%) 
Carbapenem exposure    
2013-2016 142 (2%) 679 (14%) 
2013 34/1439 (2%) 200/1149 (17%) 
2014 54/1519 (4%) 169/1228 (14%) 
2015 20/1447 (1%) 148/1265 (12%) 
2016 34/1487 (2%) 162/1209 (13%) 
Fluoroquinolone exposure   
2013-2016 205 (3%) 997 (21%) 
2013 52/1439 (4%) 261/1149 (23%) 
2014 48/1519 (3%) 270/1228 (22%) 
2015 57/1447 (4%) 218/1265 (17%) 
2016 48/1487 (3%) 248/1209 (21%) 
Glycopeptides exposure   
2013-2016 141 (2%) 551 (11%) 
2013 37/1439 (3%) 136/1149 (12%) 
2014 40/1519 (3%) 150/1228 (12%) 
2015 38/1447 (3%) 139/1265 (11%) 
2016 26/1487 (2%) 126/1209 (10%) 
Linezolid exposure   
2013-2016 37 (1%) 292 (6%) 
2013 12/1439 (1%) 66/1149 (6%) 
2014 12/1519 (1%) 76/1228 (6%) 
2015 5/1447 (0.3%) 67/1265 (5%) 
2016 8/1487 (0.5%) 83/1209 (7%) 
Infection diagnosis (%)   
Infection within the first 48h of ICU admission 1182 (20%) 2622 (54%) 
ICU-acquired infection (≥ 48h)   
1 infection - 706 (15%) 
2 infections - 239 (5%) 
> 2 infections - 151 (3%) 





A total number of 10731 treatment courses (infection bars) was recorded during the study 
period. Respectively 4525 (42.2%) and 6206 (57.8%) of these courses were prescribed for 
prophylaxis or for infection. Fungal infections represented 8% (520/6206) of the infectious 
episodes. Infections were microbiologically confirmed in 56% (3169/5686) and 63% (327/520) 
of bacterial and fungal infections, respectively. Infections were ICU-acquired in 28% of cases 
(1767/6206). The focus of the bacterial infections was predominantly respiratory and 
abdominal (respectively, 49% and 19%). Infection probability was classified as high, moderate 
or low in respectively 50%, 34% and 16% of the respiratory infections compared to respectively 
76%, 16% and 8% of the abdominal infections. Only 19% of the respiratory infections were 
classified as ventilator-associated. A total of 345 ventilator-associated pneumonia (VAP) and 
182 ventilator-associated tracheobronchitis (VAT) were diagnosed, resulting in VAP and VAT 
incidences of 16.5/1000 ventilation days and 8.7/1000 ventilation days, respectively. The 
median treatment duration of VAP and VAT episodes on the ICU was respectively, 7 days [IQR 5-
9] and 6 days [IQR 4-7]. See figure 9 for more details on bacterial and fungal infection focus. See 
table 6 for more detailed information on the duration of therapy per focus of infection. 
 
Antimicrobial utilization 
A total of 14908 antibiotic courses (antibiotic bars) were administered, resulting in 58413 DOT 
(1232 DOT/1000 patient days). Detailed utilization analysis per antibiotic agent and infection 
probability is presented in table 7a. Utilization analysis per antibiotic agent over the study years 
2013-2016 is presented in table 7b. Anti-pseudomonal penicillins combined with a beta-
lactamase inhibitor, non-anti-pseudomonal penicillins combined with a beta-lactamase inhibitor 
and fluoroquinolones were the most frequently consumed antibiotic classes (respectively, 218 
DOT/1000 patient days, 172 DOT/1000 patient days and 114 DOT/1000 patient days), azoles 
were the predominantly used antifungal class (162 DOT/1000 patient days). 
Only 36% of the total antifungal DOT was used to treat infections with a high probability, 
whereas this figure was 56% of the total DOT in the case of antibacterial agents. First generation 
cephalosporins, folate pathway inhibitors and monobactams were predominantly used in the 
prophylactic setting. However, even 32% of the total DOT of non-antipseudomonal penicillins 
combined with a beta-lactamase inhibitor were prescribed prophylactically. Indications for 
prophylactic therapy in the non-antipseudomonal penicillins combined with a beta-lactamase 
inhibitor group were mainly aspiration (30%), severe trauma (30%), perioperative prophylaxis 
(20%) and variceal bleeding (6%). 
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Respectively, 36% and 21% of the total antibacterial DOT was used to treat respiratory and 
abdominal infections. Of the total amount of DOT used to treat bacterial respiratory infections, 
42% was used to treat infections with a moderate and low probability, compared to 15% of the 
DOT used for bacterial abdominal infections. 
 
Microbiology 
Enterobacteriaceae were the predominant bacterial species that were designated as causative 
pathogens in both respiratory and abdominal infections (respectively, 39% and 46% of all 
pathogens linked to these groups of infections). Amoxicillin/clavulanic acid resistance and 
cefuroxime resistance was present in 48% and 39%, respectively. Enterococci were the second 
most prevalent pathogens that were linked as causative in the abdominal infections and 
ampicillin resistance was present in 44% of the isolates (figure 10). 
 
Table 6: Duration of therapy per focus of infection 
Focus of infection All antibiotic courses Antibiotic course completed on 
ICU 












Respiratory infection 2779 5 [3-7] 1389 6 [4-9] 
Community-acquired pneumonia 281 4 [2-6] 123 6 [3.5-8] 
Aspiration pneumonia 554 5 [3-8] 293 7 [5-9] 
Hospital-acquired pneumonia 668 5 [3-7] 279 6 [4-8] 
Healthcare-associated pneumonia 224 4 [2-6] 81 6 [4-8] 
Tracheobronchitis (not ventilated) 174 4 [2-6] 83 5 [3-7] 
Ventilation-associated pneumonia 345 7 [5-9] 264 7 [5-10] 
Tracheobronchitis (ventilated) 182 6 [4-7] 134 6 [4-8] 
     
Abdominal infection 1094 4 [2-8] 329 8 [4-14] 
Intra-abdominal collection – abcedation 201 6 [3-12] 54 14.5 [7-20] 
Localized secondary peritonitis 155 4 [2-9] 37 10 [7-15] 
Diffuse secondary peritonitis 137 5 [3-10] 40 11.5 [7-18] 
     
Uro-genital infection 418 3 [2-4] 158 3 [1-6] 
     
Skin & soft tissue infection 317 4 [2-7] 82 7 [3-11] 
     
Catheter related infection 147 4 [2-7] 66 5 [3-9] 
     
Neutropenic fever 145 4 [2-7] 42 8 [3-9] 




Figure 9: a) Focus of bacterial infections (n=5686)
 
Infection probability was classified as low, moderate or high in respectively 14%, 27% 
and 59% of the bacterial infections. 
 
 
Figure 9: b) Focus of fungal infections (n=520)
 
Infection probability was classified as low, moderate or high in respectively 12%, 17% 
and 71% of the fungal infections. 
° presence of yeast in a normally sterile body site combined with clinical signs of 
infection 
* fungal infection considered clinically likely by treating physician in the absence of 
yeast in a normally sterile body site 
^ mucocutaneous candidiasis, candidiasis of the genitourinary tract, extra-pulmonary 
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Figure 9: c) Bacterial respiratory infection (n=2779)
 
° bacterial pneumonia following macroaspiration 
* tracheobronchitis criteria include: fever, purulent tracheobronchial secretions, 
isolation of a respiratory pathogen of a good quality lower respiratory tract sample, no 
radiographic signs of new pneumonia 


































































Table 7a: Antimicrobial utilization per antimicrobial class and per infection probability 
 DOT (%) DOT/1000 
patient 
days 
DOT (% of total DOT/antibiotic class) 
   Infection present Prophylactic 
treatment 







Antibacterial class       
Aminoglycosides 474 (1.0) 10.0 388 (81.8) 67 (14.1) 5 (1.1) 6 (1.3) 
Ansamycins 268 (0.5) 5.7 230 (85.8) 9 (3.4) 13 (4.9) 15 (5.6) 
Carbapenems 4488 (9.1) 94.7 3438 (76.6) 697 (15.5) 221 (4.9) 110 (2.5) 
1st gen. cephalosporins 2939 (6.0) 62.0 - - - 2939 (100) 
2nd gen. cephalosporins 1192 (2.4) 25.1 398 (33.4) 324 (27.2) 169 (14.2) 301 (25.3) 
3rd gen. cephalosporins 1955 (4.0) 41.2 1343 (68.7) 400 (20.5) 143 (7.3) 63 (3.2) 
Fluoroquinolones 5385 (11) 113.6 3268 (60.7) 1285 (23.9) 367 (6.8) 448 (8.3) 
Folate pathway inhibitor 3105 (6.3) 65.5 896 (28.9) 319 (10.3) 142 (4.6) 1747 (56.3) 
Glycopeptides 2966 (6.0) 62.6 2163 (72.9) 438 (14.8) 172 (5.8) 169 (5.7) 
Glycylcyclines 319 (0.6) 6.7 242 (75.9) 63 (19.7) 11 (3.4) 2 (0.6) 
Lincosamides 806 (1.6) 17.0 564 (70.0) 140 (17.4) 42 (5.2) 60 (7.4) 
Macrolides 1421 (2.9) 30.0 834 (58.7) 215 (15.1) 84 (5.9) 284 (20.0) 
Monobactams 150 (0.3) 3.2 33 (22.0) 28 (18.7) 10 (6.7) 79 (52.7) 
Nitrofurans 59 (0.1) 1.2 19 (32.2) 16 (27.1) 7 (11.9) 17 (28.8) 
Nitroimidazoles 1289 (2.6) 27.2 976 (75.7) 147 (11.4) 61 (4.7) 92 (7.1) 
Oxazolidinones 1780 (3.6) 37.6 1434 (80.6) 212 (11.9) 53 (3.0) 69 (3.9) 
Penicillins 1504 (3.1) 31.7 1212 (80.6) 188 (12.5) 86 (5.7) 15 (1.0) 
Penicillins + beta-
lactamase inhibitor 




10342 (21.0) 218.2 6405 (61.9) 2292 (22.2) 808 (7.8) 800 (7.7) 
Phosphonic acids 27 (0.1) 0.6 3 (11.1) 17 (63.0) 6 (22.2) 1 (3.7) 
Polymyxins 469 (1.0) 9.9 311 (66.3) 97 (20.7) 19 (4.1) 42 (9.0) 
Tetracyclines 95 (0.2) 2.0 82 (86.3) 1 (1.1) 1 (1.1) 11 (11.6) 
Total antibacterial 49169 (100) 1037.3 27506 
(55.9) 
8560 (17.4) 3080 (6.3) 9858 (20.0) 
       
Antifungal class       
Azoles 7684 (83.1) 162.1 2123 (27.6) 415 (5.4) 222 (2.9) 4809 (62.6) 
Echinocandins 1354 (14.6) 28.6 1022 (75.5) 176 (13.0) 93 (6.9) 56 (4.1) 
Polyenes 206 (2.2) 4.3 138 (67.0) 37 (18.0) 29 (14.1) - 
Total antifungal 9244 (100) 195.0 3283 (35.5) 628 (6.8) 344 (3.7) 4865 (52.6) 
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Table 7b: Antimicrobial utilization per antimicrobial class and per year 
  DOT/1000 patient days 
 DOT (%) 2013-2016 2013 2014 2015 2016 
Antibacterial class       
Aminoglycosides 474 (1.0) 10.0 8.0 13.0 8.6 10.4 
Ansamycins 268 (0.5) 5.7 6.0 6.4 6.7 3.6 
Carbapenems 4488 (9.1) 94.7 102.6 90.0 90.8 95.0 
1st gen. cephalosporins 2939 (6.0) 62.0 56.8 63.5 61.1 66.8 
2nd gen. cephalosporins 1192 (2.4) 25.1 36.0 28.8 20.2 15.1 
3rd gen. cephalosporins 1955 (4.0) 41.2 41.0 37.0 39.5 47.4 
Fluoroquinolones 5385 (11) 113.6 116.9 120.5 94.8 121.5 
Folate pathway inhibitor 3105 (6.3) 65.5 76.8 68.4 55.9 60.2 
Glycopeptides 2966 (6.0) 62.6 66.8 61.1 67.1 55.3 
Glycylcyclines 319 (0.6) 6.7 6.7 4.2 7.2 8.9 
Lincosamides 806 (1.6) 17.0 17.3 15.2 15.2 20.3 
Macrolides 1421 (2.9) 30.0 18.2 29.7 37.0 35.5 
Monobactams 150 (0.3) 3.2 3.1 3.5 3.9 2.1 
Nitrofurans 59 (0.1) 1.2 1.7 1.4 1.0 0.8 
Nitroimidazoles 1289 (2.6) 27.2 26.9 26.3 28.4 27.1 
Oxazolidinones 1780 (3.6) 37.6 32.6 38.6 35.5 43.6 








10342 (21.0) 218.2 215.8 219.3 220.5 217.2 
Phosphonic acids 27 (0.1) 0.6 - - 0.9 1.4 
Polymyxins 469 (1.0) 9.9 12.1 14.3 7.0 5.9 
Tetracyclines 95 (0.2) 2.0 - 0.7 7.5 - 
Total antibacterial 49169 (100) 1037.3 1054.8 1029.6 1012.5 1051.2 
       
Antifungal class       
Azoles 7684 (83.1) 162.1 151.2 176.4 159.2 161.7 
Echinocandins 1354 (14.6) 28.6 29.3 19.2 35.7 30.3 
Polyenes 206 (2.2) 4.3 3.3 6.3 3.3 4.5 
Total antifungal 9244 (100) 195.0 183.8 201.9 198.2 196.5 
       
TOTAL 58413 
(100) 
1232.3 1238.6 1231.4 1210.7 1247.7 





Figure 10a) Pathogens linked to bacterial respiratory infection(n=1828)
 
Enterobacteriaceae = Citrobacter spp., Enterobacter spp., Escherichia coli, Hafnia spp., Klebsiella 
spp., Morganella spp.., Proteus spp., Providencia spp., Serratia spp. 
Non-fermenting Gram-negative bacilli = Achromobacter spp., Acinetobacter spp., 
Stenotrophomonas spp., Pseudomonas spp., other non-fermenting Gram-negative bacilli 
Streptococcus spp.= Streptococcus pneumoniae, Streptococcus pyogenes, Viridans streptococci, 
other streptococci 
Other = culture results of referral hospital 
Serologic diagnosis = Legionella pneumophila antigen, Streptococcus pneumoniae antigen 
Figure 10b) Pathogens linked to bacterial abdominal infection (n=1403)
 
Enterobacteriaceae = Citrobacter spp., Enterobacter spp., Escherichia coli, Hafnia spp., Klebsiella 
spp., Morganella spp., Proteus spp., Providencia spp., Salmonella spp., Serratia spp., Yersinia spp. 
Enterococcus spp. = Enterococcus faecalis, Enterococcus faecium, other enterococci 
Other = culture results of referral hospital 
Non-fermenting Gram-negative bacilli = Achromobacter spp., Stenotrophomonas spp., 
Pseudomonas spp., other non-fermenting Gram-negative bacilli 
Streptococcus spp.= Streptococcus pneumonia, Viridans streptococci, other streptococci 
Staphylococcus spp. = Staphylococcus aureus, coagulase-negative staphylococci, other 
Other Gram-negative = e.g. Bacteroides spp., Prevotella spp., Aeromonas spp., Campylobacter spp.  










































In this manuscript, we demonstrate the versatility of a detailed database on antibiotic use and 
infection diagnosis which is prospectively built by linking prescription, clinical and 
microbiological data of individual ICU patients during clinical workflow. This allows various 
analyses which respectively center on patient admissions, prescription indication and infection 
diagnosis, antibiotic utilization and microbiology and as such may be useful to support various 
aspects of hospital infection control and antibiotic stewardship. To the best of our knowledge, 
our study is the largest single center study providing epidemiological data on antibiotic 
consumption and infections treated in the ICU in terms of number of ICU beds (36) and time (4 
years). 
Our study confirms that the antibiotic burden is very high, with exposure to at least one 
antibiotic class in 66% of all admitted patients and 84% of patients with an ICU stay of more 
than 48 h, respectively. These figures are consistent with the results of the one-year prospective 
surveillance study of Bergmans et al. and with the EPIC II point prevalence study.2, 6 
The need for detailed antibiotic prescription surveillance and feedback to the clinician was 
already acknowledged in the very early stages of antimicrobial stewardship, but up until now 
literature is riddled with discussion about which appropriate measures to select.25, 27, 122, 123, 126 In 
2016, the consensus results of an expert panel on metrics assessing the impact of stewardship 
interventions on a patient-level in an acute-care setting were published.122 Potential metrics 
were evaluated for four distinct criteria, one of them being the feasibility to monitor the metric 
in any hospital with an electronic health record. Only six metrics were retained by the expert 
panel as suitable for ready implementation: incidence of healthcare-facility and hospital-onset 
Clostridium difficile infection, rates of antibiotic-resistant pathogens, days of antibiotic 
therapy/number of admissions, days of antibiotic therapy/patient days, and redundant therapy 
events. All of these metrics may be derived from separate electronic data sources (clinical, 
pharmacy, microbiology) and a connection between the different elements is not mandatory; 
however, these metrics are quite crude and unable to provide insight in antibiotic prescription. 
By linking these sources a deeper understanding of the different factors driving antimicrobial 
use in the ICU can be obtained, as illustrated by this study. 
For example, the respiratory system accounts for half of identified sources of infection and more 
than one third of the total antibacterial DOT. Compared to the abdominal infections, which 
represent the second largest group of infections and destination for antibiotic consumption, 
respiratory infections were less frequently categorized as highly probable (75% versus 50% 




highly probable infections (85% of the total DOT of abdominal and 56% of the total DOT of 
respiratory infections). One quarter of the infections that is diagnosed in our ICU is ICU-
acquired, which is in contrast with the study of Bergmans et al. where half of the infections were 
ICU-acquired and almost exclusively occurred in ventilated patient. Whereas the authors of the 
previous study concluded that stewardship should be focused on the prevention of ventilator-
associated respiratory infections, this statement may less apply to our ICU population. In 
addition, restricting duration of antibiotic therapy in VAP of high probability will offer little gain, 
as the median treatment duration was only 7 days. In contrast, a more restrictive use of 
antibiotics in suspected respiratory tract infections with cultures remaining negative and/or a 
swift clinical resolution, could result in a more profound reduction of antibiotic consumption. In 
addition, we observed that prophylactic treatment accounted for one fourth of the total DOT. 
Although duration of prophylactic treatment is still a matter of debate for some conditions, clear 
guidelines and new study results recommending on indication and duration have become 
available over the last years.127-131 We believe that introduction of guidelines on non-
perioperative prophylaxis, which are currently unavailable in our hospital and ICU, could lead to 
a reduction in antibiotic use. 
Despite the recognition of the importance of high-quality surveillance data to support antibiotic 
stewardship, few studies have provided detailed data of ICU global antibiotic consumption and 
infection diagnosis over an extended period of time.6, 52, 132 This may reflect the difficulties in 
continuous prospective merging of infection related data due to personnel and time restraints. 
In fact, while the authors of the study of Bergmans et al. felt that their proposed surveillance 
model in which they categorize antibiotic indications as either prophylaxis, bacteriologically 
proven or non-bacteriologically proven (clinical suspicion), would be suitable for a more 
widespread use, few publications offering a similarly wide scope on antibiotic use in the ICU 
have followed since.6 In our ICU, the COSARA software platform facilitated the integration of 
antibiotic, clinical and microbiological information during the workflow of daily bedside clinical 
rounds and weekly multidisciplinary staff meetings, hereby illustrating that sustained 
prospective detailed surveillance is an achievable ambition with the help of information 
technology.102, 124 The sustainability of this surveillance is probably to a certain extent due to the 
rather intuitive approach of labeling infections by the physician choosing from a drop-down 
menu of possible diagnoses and categorization by infection probability. While the result closely 
reflects physician’s judgment and attitude in daily practice, it does not formally adhere to 
criteria such as provided by the CDC or Hospitals in Europe Link for Infection Control through 
Surveillance (HELICS). A previous analysis assessing the validity of the diagnostic information 
recorded as such in COSARA compared to conventional surveillance data gathered by using 
checklists based on CDC-NHSN criteria showed good agreement between both surveillance 
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methods.124 However, a lack of precision may hamper comparisons between centers (as 
required for benchmarking) and over time (changing perception). This may to a certain extent 
be remedied by filtering sets of infection labels for the fulfillment of objective criteria as e.g. 
presence of positive microbiological cultures, biochemical findings exceeding a given threshold 
and noting of clinical signs in a computerized medical file. 
Our study has limitations. First, building up the database starting from computerized physician 
order entry depends on adequate filling in of the ‘pop-up’ questions that are triggered by it, and 
by the persistent commitment of attending physicians or infection control personnel in linking 
the various information sources and finalizing infection diagnosis. Second, as stated before, the 
lack of adhering to strict criteria in labeling infection diagnosis in the current design hampers 
multicenter application.124 Probably a trade-off has to be found between practical feasibility of 
continued infection registration at one hand, and precision in diagnosis at the other. In addition, 
while COSARA software is compatible with various Intensive Care Information Systems, it has 
not been formally tested whether our surveillance is applicable over differing ICU settings and 
staffing structures. Third, it remains to be tested to what extent high-quality surveillance may 
translate in effective stewardship intervening with treatment decisions of the attending ICU 
physician. 
Conclusions 
We were able to get a bird’s eye view on global antibiotic use and infection diagnosis in our ICU 
over a 4-year time period by analysis of a multifaceted dataset which was collected during the 
daily clinical workflow of ICU physicians with the help of information technology. Grouping of 
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C. DEVELOPMENT OF ANTIBIOTIC TREATMENT ALGORITHMS BASED ON LOCAL 
ECOLOGY AND RESPIRATORY SURVEILLANCE CULTURES TO RESTRICT THE USE OF 
BROAD-SPECTRUM ANTIMICROBIAL DRUGS IN THE TREATMENT OF HOSPITAL-
ACQUIRED PNEUMONIA IN THE INTENSIVE CARE UNIT: A RETROSPECTIVE 
ANALYSIS 
 
Liesbet De Bus, Lies Saerens, Bram Gadeyne, Jerina Boelens, Geert Claeys, Jan J De Waele, 
Dominique D Benoit, Johan Decruyenaere and Pieter O Depuydt 
 
Critical Care, 2014; 18: R152






Timely administration of appropriate antibiotic therapy has been shown to improve outcome in 
hospital-acquired pneumonia (HAP). Empirical treatment guidelines tailored to local ecology 
have been advocated in antibiotic stewardship programs. We compared a local ecology based 
algorithm (LEBA) to a surveillance culture based algorithm (SCBA) in terms of appropriate 
coverage and spectrum of antimicrobial activity. 
 
Methods: 
We retrospectively assessed 2 hypothetical empirical antibiotic treatment algorithms for HAP on 
an existing high-quality prospectively collected database in a mixed 36-bed tertiary intensive 
care unit (ICU). Data on consecutive episodes of microbiologically confirmed HAP were collected 
over a period of 40 months and divided in a derivation (1 July 2009 to 31 October 2010) and 
validation (1 November 2010 until 31 October 2012) cohort. On the derivation cohort we 
constructed a LEBA, based on overall observed bacterial resistance patterns, and a SCBA, which 
targeted therapy to surveillance culture (SC) in the individual patient. Therapy was directed 
against pathogens found in respiratory SC collected two to five days before HAP, and in the 
absence of these, presence or absence of multidrug-resistant (MDR) pathogens in other SC 
dictated broad-spectrum, respectively narrow-spectrum antibiotic therapy. Subsequently, LEBA 
and SCBA were retrospectively reviewed and compared with actually prescribed antibiotics in 
the validation cohort. 
 
Results: 
The first 100 HAP episodes made up the derivation cohort and the subsequent 113 HAP 
episodes the validation cohort. Appropriate antibiotic coverage rates by applying LEBA and 
SCBA were 88.5% and 87.6%, respectively, and did not differ significantly with respect to 
appropriateness of the actually prescribed initial therapy (84.1%). SCBA proposed more narrow 
spectrum therapy as compared to LEBA and the actually prescribed antimicrobials (P <0.001). 
SCBA recommended significantly less combination therapy and carbapenems compared to LEBA 
(P <0.001). SCBA targeted antibiotics to recent respiratory SC in 38.1% (43 out of 113 episodes) 





Rates of appropriate antimicrobial coverage were identical in LEBA and SCBA. However, in this 
setting of moderate MDR prevalence, the use of SCBA would result in a significant reduction of 
the use of broad-spectrum drugs and may be a preferential strategy when implementing 
antibiotic stewardship programs. 
 
4.C.2 Introduction 
Antibiotic stewardship refers to efforts both made to improve appropriateness of antibiotic 
prescription and to reduce antibiotic selection pressure by limiting unnecessary use of 
antibiotics, especially those with a broad spectrum.26, 133 As hospital-acquired pneumonia (HAP) 
is a frequent indication for antibiotic prescription as well as a manifestation of antibiotic 
resistance, antibiotic policy for HAP is an important target area for antibiotic stewardship. Early 
appropriate antibiotic therapy is a major determinant of outcome in HAP: early refers usually to 
the time of the initial clinical diagnosis or suspicion of pneumonia.11, 80, 134 As at this early stage, 
microbial etiology is still unknown and potentially multidrug-resistant (MDR), broad-spectrum 
antibiotics, often in combination schemes, are advocated as empirical therapy. As the microbial 
and resistance patterns are variable across ICUs, these empirical schemes have to be matched to 
the local situation in order to achieve high rates of appropriate coverage whilst avoiding 
unnecessary broad-spectrum antibiotics.135, 136 In addition, algorithms may contribute to 
antibiotic stewardship as they assist to rationalize antibiotic choices and reduce prescription 
variability, improve overall appropriateness and restrain use of certain drug classes such as 
carbapenems. As a more controversial approach, early antibiotic therapy may be guided by 
surveillance cultures (SC) to improve its appropriateness.87, 137-139 With this approach, antibiotics 
are essentially selected in order to cover colonizing pathogens in the individual patient. 
In this study, we developed two algorithms for initial antibiotic prescription in ICU patients with 
suspected HAP. We aimed a) to assess the potential of an algorithm to aid in antibiotic 
stewardship in our setting and b) quantify the contribution of SC to antibiotic stewardship as 
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4.C.3 Materials and methods 
 
Clinical setting and design 
This retrospective analysis was conducted at the 14-bed Medical ICU and the 22-bed Surgical 
ICU of the Ghent University Hospital (1,056 beds). With the aid of the software application, 
Computer-based Surveillance and Alerting of infections, Antimicrobial Resistance and Antibiotic 
consumption in the ICU (COSARA), all episodes of pneumonia were registered prospectively 
from 1 July 2009 to 31 October 2012. COSARA assists the attending ICU-physician in acquiring 
an overview of the various daily collected data related to infection diagnosis (trends in 
laboratory values, temperature, oxygenation et cetera) and treatment. This includes a graphical 
display of current and past antibiotic treatments as a timeline and provides direct links to a real-
time copy of the various source records. The graphical interface allows the user to label 
infectious episodes during daily clinical rounds and interdisciplinary staff meetings to a 
predefined list of diagnoses in all patients admitted to the ICU. As such, the program facilitates 
the build-up of an extensive data-warehouse on antibiotic use and infection in the ICU.102 During 
the study period treating physicians were not guided in the choice of the empirical antimicrobial 
by treatment algorithms. The Ghent University Hospital ethics committee approved the study 
and waived informed consent as prospective registration did not affect treatment decisions, and 
all subsequent analyses were performed retrospectively on an anonymized database. Only 
patients aged 16 years or above were included. 
 
Definition of hospital-acquired pneumonia 
Pneumonia was defined to be hospital-acquired if it occurred 48 h or more after admission to 
the hospital. HAP was defined clinically as the presence of new and/or progressive and 
persistent pulmonary infiltrates on the chest radiograph, in combination with two or more of the 
following criteria: worsening of oxygenation, increase in purulent tracheobronchial secretions, 
presence of fever (≥38.5°C) or hypothermia (≤36°C). Only microbiologically confirmed HAP was 
included: confirmation consisted of the isolation of a respiratory pathogen with at least 1+ 
semiquantitative growth of a good quality respiratory sample (defined as <3 squamous 
epithelial cells per low-power field) obtained within one calendar day prior or after clinical 
diagnosis of HAP. In our hospital, microbiological analysis of respiratory samples routinely 
consists of semiquantitative culture of endotracheal aspirate (ETA) in the ventilated patient or 
sputum in the non-intubated patient. For logistic reasons, bronchoalveolar lavage (BAL) is not 




previously found that BAL and ETA had good qualitative and quantitative concordance in a 
cohort of patients with suspected ventilator-associated pneumonia (VAP). Positive and negative 
predictive values of a semiquantitative growth score of 1+ of a pathogen in ETA to identify the 
same pathogen in a quantity of at least 104 colony-forming units (CFU)/ml in BAL were 81% and 
87%, respectively.106 HAP was defined to be ventilator-associated if at the time of diagnosis, 
patients were under mechanical ventilation for 48 h or longer, or had been extubated for less 
than 48 h after mechanical ventilation for at least 2 days. 
Development of the algorithms 
The collected data were divided into a derivation and a validation cohort. The first 100 HAP 
episodes (1 July 2009 to 31 October 2010) made up the derivation cohort for the development of 
the local ecology based algorithm (LEBA) and the surveillance culture based algorithm (SCBA), 
both aiming to achieve a minimum of 85% appropriate coverage rate. For LEBA (Figure 11), we 
started from the clinical framework of the revised American Thoracic Society-Infectious 
Diseases Society of America (ATS-IDSA) guidelines and our previously recorded antimicrobial 
resistance patterns.80 Clinical risk factors for MDR pathogens were defined as prior 
antimicrobial therapy during the current hospitalization, a hospital stay of 5 days or more, and 
previous hospitalization for 2 days or more in the preceding 6 months. SCBA (Figure 12) 
combined the same clinical risk factors for MDR with microbiological information from 
systematically collected SC. The SC consisted of oral, nasal and rectal swabs and urinary cultures 
upon admission, followed by thrice-weekly urinary and once-weekly oral, nasal and rectal 
samples in all patients, as well as thrice-weekly sputum in the non-intubated patient or ETA in 
the ventilated patient. In the case of positive respiratory SC (oral swabs or respiratory samples) 
2 to 5 days before diagnosis of HAP, the antibiotic with the narrowest spectrum possible 
covering this (these) pathogen(s) was proposed (see also Table 8). In the absence of these, an 
alternative algorithm was proposed guided by clinical risk factors as in LEBA, but with 
upgrading to include all pathogens isolated from other SC collected within the last 6 months 
(respiratory SC more than 5 days before HAP and non-respiratory SC) (see also Figure 12). Both 
algorithms were retrospectively reviewed and compared with the actually prescribed 
antimicrobial therapy in the validation cohort.
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Figure 11: Local ecology based algorithm 
 
 
a Clinical risk assessment for multidrug-resistant pathogens: high risk if one of the following 
characteristics is present: prior antimicrobial therapy during the current hospitalization; current 
hospitalization ≥ 5 days; hospitalization for ≥2 days in the preceding 6 months. 
b Septic shock was defined as systolic arterial blood pressure <90 mmHg or mean arterial blood pressure 





Figure 12: Surveillance culture based algorithm 
 
 
a Respiratory  pathogen defined as: Acinetobacter spp., Enterobacteriaceae, Haemophilus spp., 
Pseudomonas spp., Staphylococcus aureus, Stenotrophomonas spp., Streptococci. 
b Clinical risk assessment for multidrug-resistant pathogens: high risk if one of the following 
characteristics is present: prior antimicrobial therapy during the current hospitalization; current 
hospitalization ≥5 days; hospitalization for ≥2 days in the preceding 6 months. 
c Septic shock was defined as systolic arterial blood pressure <90 mmHg or mean arterial blood pressure 
<65 mmHg despite adequate fluid resuscitation. 
SC, surveillance cultures; HAP, hospital-acquired pneumonia; MDR, multidrug-resistant.
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Appropriateness and spectrum of antimicrobial therapy 
We compared rates of appropriateness and spectrum between LEBA, SCBA and actually 
prescribed antimicrobial therapy by the treating physician. Therapy was considered appropriate 
when all pathogens involved in the HAP episode were covered by the antibiotic, or by at least 
one component of the antibiotic combination. To quantify the antimicrobial spectrum, we 
constructed a scale ranging from 1 - the most narrow-spectrum of empirical therapy, lacking 
anti-pseudomonal activity - to 5 - a combination therapy of two or more antibiotic agents (Table 
8). We ranked fluoroquinolones higher than broad spectrum anti-pseudomonal beta-lactam 
antibiotics other than carbapemens, based upon the knowledge that exposure to 
fluoroquinolones is particularly associated with rapid emergence of MDR pathogens such as 
methicillin-resistant Staphylococcus aureus (MRSA),140 and with Clostridium difficile-associated 
diarrhea,141 and by our aim to preserve the use of fluoroquinolones for directed therapy of 
Stenotrophomonas spp. and Pseudomonas aeruginosa. In case of appropriate therapy, the 
antimicrobial spectrum was expressed as x steps in excess to the most narrow-spectrum therapy 
possible covering all causative pathogens isolated in the HAP episodes. 
 





 Non-antipseudomonal penicillins (amoxicillin-clavulanate) 
 Second generation or third generation non-antipseudomonal 
cephalosporins (cefuroxime, ceftriaxone)  
 Trimethoprim/sulfamethoxazole  
 
Step 2  Anti-pseudomonal penicillins (piperacillin-tazobactam) 
 Third generation anti-pseudomonal cephalosporins (ceftazidime) 
 
Step 3  Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) 
 
Step 4  Anti-pseudomonal carbapenems (meropenem) 
 








Continuous variables are described as mean (±standard deviation) or median (interquartile 
range) for normal or non-normal distribution, respectively. To compare paired proportions the 
McNemar test for related samples was used. Differences in medians were checked using the 
Wilcoxon signed-rank test. All statistical analyses were performed with SPSS® software (SPSS, 
version 21, Chicago, IL, USA). Statistical significance was defined as P <0.05. 
 
4.C.4 Results 
All data reported apply to the validation cohort of 113 episodes of HAP, including 52 (46%) 
episodes of VAP, registered between 1 November 2010 and 31 October 2012 in 104 patients. 
There was need for subsequent mechanical ventilation in 39/61 (64%) of the non-VAP patients. 
The median age of the patients was 64 years (54 to 74), and 74% were male. In 99 (87.6%) of 
the HAP episodes, clinical risk factors for MDR pathogens were present: prior antibiotics in 81%, 
current hospitalization for 5 days or more or hospitalization in the previous 6 months in 82%. 
Septic shock was present in 23% of the HAP episodes. The length of ICU stay following diagnosis 
of HAP was 10 days (6 to 22) when appropriate antibiotics were administered, 7 days (2 to 16) if 
the prescribed antibiotics were inappropriate (P = 0.10). The overall ICU mortality was 30.1% 
and did not differ between patients with or without appropriate antimicrobial therapy (28.4% 
versus 38.9%, P = 0.375). 
A total of 140 pathogens were isolated, 84% of which were Gram-negative bacteria (Table 9). 
HAP was mono-microbial in 89 (79%) and poly-microbial in 24 (21%) episodes.
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Table 9: Pathogens (n=140) associated with HAP 
Pathogen n (%) 
Gram-positive bacteria  
Staphylococcus aureus 14 (10%) 
MRSA 7 
Streptococcus pneumoniae 5 (3.6%) 
Other streptococci 1 (0.7%) 
Gram-negative bacteria  
Enterobacteriaceae 70 (50%) 
Escherichia coli 31 (22.1%) 
Enterobacter sp. 13 (9.3%) 
Klebsiella sp. 12 (8.6%) 
Serratia sp. 6 (4.3%) 
Morganella morganii 4 (2.9%) 
Citrobacter sp. 2 (1.4%) 
Hafnia alvei 1 (0.7%) 
Proteus sp. 1 (0.7%) 
ESBL- producing enterobacteriaceae 8 
Non-fermenters 35 (25%) 
Pseudomonas aeruginosa 27 (19.3%) 
Ceftazidim resistance 7 
Carbapenem resistance 9 
Stenotrophomonas maltophilia 5 (3.6%) 
Acinetobacter baumannii* 3 (2.1%) 
Other gram-negative bacteria  
Haemophilus influenzae 12 (8.6%) 
Moraxella catarrhalis 3 (2.1%) 
Total 140 
HAP, hospital-acquired pneumonia; MRSA, methicillin-resistant Staphylococcus aureus; ESBL, Extended-
spectrum beta-lactamase producing enterobacteriaceae 







Appropriateness and spectrum of antimicrobial therapy 
Appropriate antibiotic therapy was prescribed in 95 (84.1%) HAP episodes. Antimicrobial 
choices proposed by LEBA and SCBA were appropriate in 88.5% and 87.6%, respectively. Paired 
analysis showed no significant difference in adequacy for the different strategies (prescribed 
therapy versus LEBA: P = 0.33; prescribed therapy versus SCBA: P = 0.5; LEBA versus SCBA: P = 
0.99). Pathogens associated with inadequate empirical therapy are detailed in Table 10. 
 




Acinetobacter baumannii 3 - 1 
Escherichia coli 4 - 2 
Enterobacter sp. 2 - - 
Klebsiella sp. - - 1 
MRSA - 4 3 
Pseudomonas aeruginosa 4 3 4 
Serratia sp. 2 2 2 
Stenotrophomonas maltophilia 3 5 2 
MRSA, methicillin-resistant Staphylococcus aureus 
 
In significantly more episodes, SCBA proposed antibiotics of a narrower spectrum as compared 
to both the prescribed therapy and the regimen suggested by LEBA (P <0.001) (Figure 13). 
Significantly less combination therapy was proposed by SCBA (7.1%) in comparison with LEBA 
(81.4%) (P <0.001). SCBA recommended carbapenems in significantly fewer episodes than LEBA 
(24 (21.2%) versus 92 (81.4%), respectively (P <0.001)).
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Figure 13: Evaluation of the spectrum of antimicrobial therapy 
 
LEBA: Local ecology based algorithm; SCBA: surveillance culture based algorithm 
LEBA: 3 (1.25-4) steps in excess; SCBA: 0 (0-1) steps in excess; Prescribed therapy: 1 (0-2) steps in excess 
 
Surveillance culture based algorithm 
Respiratory SC sampled 2 to 5 days before HAP onset were available in 63 episodes (55.8%) of 
HAP, of which 43 (68%) grew at least one pathogen. As such, SCBA suggested targeted 
antimicrobial therapy in 43/113 (38.1%) of HAP episodes: HAP for which targeted therapy was 
suggested was ventilator-associated in 72% (31/43), occurred more than 5 days after ICU 
admission in 77% (33/43) and was caused by the following pathogens (n = 53): S. aureus (6/53, 
3 methicillin-susceptible S. aureus and 3 MRSA), S. pneumoniae (1/53), Enterobacteriaceae 
(29/53), P. aeruginosa (10/53), other Gram-negative bacteria (7/53). Recent respiratory SC 
accurately predicted all causative pathogens in 81.4% (35/43) of HAP; SCBA-targeted 
antimicrobial therapy would appropriately cover all causative pathogens (including those not 
predicted by SC) in 93% (40/43) of cases. 
In the case of negative or absent respiratory SC 2 to 5 days before start of HAP (n = 70, 61.9%), 
SCBA took into account both respiratory SC more than 5 days prior to infection and non-
respiratory SC. In 28/70 (40%) of these HAP episodes positive SC were available, leading to 






































inappropriate to appropriate antibiotic proposals in 10 episodes. By not upgrading our therapy 




Both guidance by SC as well as the use of ICU-specific empirical schemes that incorporate local 
microbiology data have been shown to increase appropriate empirical prescription and reduce 
the use of broad-spectrum antimicrobials as compared to general guidelines.80, 84, 136, 137, 142, 143 
Our study is the first to demonstrate the benefit of SC in surplus to tailoring guidelines to local 
susceptibility data. We found that incorporating results of SC (SCBA) in a clinical algorithm 
(LEBA) to help the choice of an empirical antibiotic regimen in suspected HAP would allow 
reduction in the use of broad-spectrum antimicrobials for equal rates of appropriate coverage. 
In particular, a 60% decrease in the empirical use of carbapenems would be attained, which is an 
important achievement in terms of antibiotic stewardship. Similarly, as compared to actually 
prescribed antibiotics, which were at the discretion of the attending physician with access to SC 
results but without guidance by a treatment algorithm, stricter adherence to SCBA would lead to 
further constraint of empirical use of broad-spectrum drugs. We measured the expenditure of 
antibiotics in terms of extension of spectrum by ranking antimicrobial classes along a scale of 
increasingly broad antimicrobial coverage. While this scale artificially translates a complex 
phenomenon into a simplified score, it allows some quantification of ecological selection 
pressure between different antibiotic schemes. 
Two observations underlie the construction of SCBA. First, previously we found high negative 
predictive values of negative SC for the presence of MDR pathogens in HAP,87 allowing a 
narrower-spectrum antibiotic even in patients with clinical risk factors for MDR. Second, we 
followed the paradigm that ICU-acquired pneumonia is often preceded by colonization of the 
upper and lower airways by the same pathogen, going through a possible intermediate stage of 
ventilator-associated tracheobronchitis.144 Following Bayes’ theorem, the positive and negative 
predictive values of SC were then applied to the ATS-IDSA guideline-based clinical risk 
categories for MDR HAP. Although there are no reports suggesting resistant micro-organisms 
cause more septic shock, we opted for broader therapy in these cases to minimize the risk of 
harm caused by inappropriate therapy. 
In hospital-acquired infection, narrowing the spectrum of antibiotic therapy is usually done as 
de-escalation following an initially broad-spectrum therapy aimed at maximal chance for 
appropriate coverage. However, limiting antimicrobial therapy upfront may offer several 
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advantages. First, aminoglycosides and glycopeptides, which carry an important toxicity 
profile,145, 146 were abandoned in the SCBA if there were no SC results supporting their need. A 
study in patients with pneumonia found increased mortality in patients who were treated with 
strict adherence to the ATS-IDSA guideline, including the recommendations for combination 
therapy, as compared to patients in whom treatment deviated from the recommendations.147 
The authors proposed the toxic effects of combination antimicrobial therapy as a potential 
explanation. Second, although prolonged exposure to antibiotic therapy has been clearly 
associated with the emergence of resistance,148 there is no proof that a short course is 
ecologically harmless and devoid of selection pressure. Finally, there exists a gap between the 
concept of de-escalation and what is achieved in practice. In several observational studies, the 
authors found rates of de-escalation to be fairly low,149-151 with lack of an identifiable microbial 
agent as the main barrier. SCBA partially circumvents this, as in case of negative diagnostic 
cultures and SC, a narrower spectrum empirical therapy, is recommended as compared to LEBA. 
Restricting the number of empirical combination therapies will reduce direct antibiotic costs. On 
the other hand one fulltime-equivalent microbiology laboratory technician is assigned to process 
SC of all patients admitted to our 36-bed ICU and the cost for the laboratory material is 
estimated at 33 euro per week. However, not all of this cost is exclusively for surveillance 
purposes, as few additional respiratory cultures for diagnostic purposes are required under this 
SC regime. Additionally, it can be argued that SC are a cornerstone in infection control in settings 
where MDR pathogens are endemic and that their guidance of antibiotic therapy is only an 
added benefit.152, 153 
A number of limitations have to be addressed. First, our study is evidently monocentric and our 
SCBA is site-specific. However, the concept of SCBA may be more universally applicable, as the 
predictive values of SC as reported in several recent studies are fairly consistent, provided that 
SC are regularly and at least twice weekly sampled.84 Our SCBA could serve as a template, which 
has to be translated into antibiotic recommendations depending on local ecology and carefully 
assessed before implementation. Second, resistance rates are moderate in our setting and the 
added value of SC in combination with guidelines tailored to local susceptibility data has to be 
re-evaluated in settings with higher resistance rates. As targeted antimicrobial therapy was 
proposed by SCBA in more than one third of HAP episodes, we suspect that implementing this 
algorithm would also lead to reduction in empirical broad-spectrum combination antibiotic 
therapy in these high-resistance environments. Third, it would be safe to regularly test the 
algorithms in order to match potentially changing ecology. Fourth, this analysis was performed 
retrospectively, subsequently the algorithms and adherence by the treating physicians to the 




in reality be different from what is anticipated. Finally, our study design does not allow us to 
conclude whether an empirical strategy with de-escalation, as compared to a strategy that is 
more targeted to colonizing pathogens translates into a different patient outcome or 
microbiological selection pressure. 
 
Conclusion 
As compared to an algorithm based upon clinical risk factors for MDR and adapted to local 
susceptibility results, an algorithm with additional guidance from SC could achieve comparably 
high rates of appropriate coverage with the use of fewer broad-spectrum antibiotics. Antibiotic 
therapy specifically targeted to respiratory pathogens identified in recent SC would be possible 
in 38% of HAP episodes. SC guided algorithms may constitute a component of antibiotic 
stewardship programs. Additional studies should be performed in ICU settings with higher 
levels of antibiotic resistance. 
 
Key messages 
• Addition of surveillance culture results in empirical antibiotic treatment algorithms for 
hospital-acquired pneumonia could restrict the use of broad-spectrum antimicrobial drugs. 
• Targeting empirical treatment to recent respiratory surveillance cultures could be 
achieved in more than one third of hospital-acquired pneumonia. 
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Antibiotic de-escalation is promoted to limit prolonged exposure to broad-spectrum antibiotics, 
but proof that it prevents the emergence of resistance is lacking. We evaluated determinants of 
antibiotic de-escalation in an attempt to assess whether the latter is associated with a lower 
emergence of antimicrobial resistance. 
Methods: 
Antibiotic treatments, starting with empirical beta-lactam prescriptions, were prospectively 
documented during 2013 and 2014 in a tertiary intensive care unit (ICU) and categorized as 
continuation, de-escalation or escalation of the empirical antimicrobial treatment. Determinants 
of the de-escalation or escalation treatments were identified by multivariate logistic regression; 
the continuation category was used as the reference group. Using systematically collected 
diagnostic and surveillance cultures, we estimated the cumulative incidence of antimicrobial 
resistance following de-escalation or continuation of therapy, with adjustment for ICU discharge 
and death as competing risks. 
Results: 
Of 478 anti-pseudomonal antibiotic prescriptions, 42 (9 %) were classified as escalation of the 
antimicrobial treatment and 121 (25 %) were classified as de-escalation, mainly through 
replacement of the originally prescribed antibiotics with those having a narrower spectrum. In 
multivariate analysis, de-escalation was associated with the identification of etiologic pathogens 
(p < 0.001). The duration of the antibiotic course in the ICU in de-escalated versus continued 
prescriptions was 8 (range 6–10) versus 5 (range 4–7) days, respectively (p < 0.001). Mortality 
did not differ between patients in the de-escalation and continuation categories. The cumulative 
incidence estimates of the emergence of resistance to the initial beta-lactam antibiotic on day 14 
were 30.6 and 23.5 % for de-escalation and continuation, respectively (p = 0.22). For the 
selection of multidrug-resistant pathogens, these values were 23.5 (de- escalation) and 18.6 % 
(continuation) respectively (p = 0.35). 
Conclusion: 
The emergence of antibiotic-resistant bacteria after exposure to anti-pseudomonal beta-lactam 









Selection of the appropriate antimicrobial therapy for critically ill patients is challenging in the 
context of the increasing prevalence of antimicrobial resistance. International and local 
guidelines advocate the use of broad-spectrum antibiotics in severe healthcare-associated 
infections for maximal empirical coverage, coupled with antibiotic de-escalation to reduce 
overall exposure to broad-spectrum antibiotics and its detrimental ecological effects.90, 91 De-
escalation may be achieved through replacing broad-spectrum antibiotics by narrow-spectrum 
drugs, through stopping components of an antibiotic combination, or by early withdrawal of 
antibiotics in the absence of infection.90, 92, 93, 96, 154-156 The widely promoted strategy of de-
escalation is backed up by only a few studies which used heterogeneous definitions of de-
escalation and provided equivocal results.93, 96 The survival benefit related to de-escalation 
which was reported in some observational trials 157-159 could not be confirmed in other studies 
160, 161, nor in a recent multicenter randomized trial,95 although none showed increased mortality 
associated with de-escalation. Furthermore, there is a lack of microbiological data in support of 
the presumption that de-escalation limits the emergence of multidrug-resistant (MDR) 
pathogens.93 
In the observational study reported here, we describe treatment changes (de-escalation and 
escalation) following empirical beta-lactam antibiotic prescription in intensive care unit (ICU) 
patients and identify determinants of the different treatment patterns. We subsequently relate 
these patterns to patient outcome, focusing on the effect of de-escalation of anti-pseudomonal 
beta-lactam antibiotics on the emergence of antibiotic resistance. 
 
4.D.3 Materials and methods 
The study was conducted at the 14-bed medical ICU and the 22-bed surgical ICU (SICU) of Ghent 
University Hospital (1056 beds). From 1 January 2013 to 31 December 2014, we prospectively 
registered all infections requiring antibiotics with the aid of the software application COSARA 
(Computer-based Surveillance and Alerting of infections, Antimicrobial Resistance and 
Antibiotic consumption in the ICU), developed in collaboration with the Department of 
Information Technology of Ghent University.102, 124 COSARA facilitates the build-up of an 
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extensive data warehouse by allowing linkage between automatically collected clinical and 
biochemical variables, antimicrobial prescription data, microbiology results and clinical 
diagnoses of infection. During the study period, no strict empirical antibiotic protocol was used, 
and all empirical choices and subsequent changes were at the liberty of the senior ICU-physician, 
working together in close collaboration with microbiologists and conferring three times weekly. 
As described previously,162 empirical antibiotic choices are essentially guided by systematically 
collected surveillance cultures (SC). Piperacillin–tazobactam, ceftazidime, and meropenem were 
administered as a continuous infusion, and non-antipseudomonal beta-lactam antibiotics and 
non-beta-lactam antibiotics were administered intermittently. Standard dosing regimens are 
provided in Electronic Supplemental Material (ESM) Table 1. 
From the COSARA data warehouse, we retrospectively analyzed all beta-lactam antibiotic 
courses of at least a 48 h duration that were prescribed as first-line treatment of an infection. 
Only episodes in the ICU of at least a 96 h duration were included as antibiotic changes were 
unlikely to occur in shorter episodes. Antibiotic changes were classified as de-escalation or 
escalation depending on whether the changes represented a move up or down, respectively, a 
predefined ranking system of agents according to increasing order of Gram-negative 
antimicrobial activity (ESM Table 1). Roughly outlined, this ranking system was: step 1: “beta-
lactam antibiotics without anti-pseudomonal activity or fluoroquinolones advocated as 
empirical treatment for severe community-acquired infection”; step 2: “non-carbapenem beta-
lactam antibiotics with anti-pseudomonal activity or fluoroquinolones targeted at 
Pseudomonas”; step 3: “carbapenems”; step 4: “carbapenems in combination with a second 
antibiotic with Gram-negative coverage”. We did not evaluate changes in Gram-positive coverage 
(such as adding or withholding glycopeptides or linezolid). The ranking system was modified 
according to the focus of infection and the consequent need for anaerobic coverage (for example, 
as required in complicated intra-abdominal infections). Levofloxacin was classified as a step 1 
antibiotic despite the anti-pseudomonal activity as it is a recommended treatment choice for 




Electronic Supplementary Material - Table 1a: Ranking of agents by increasing order of Gram-
negative antimicrobial activity: no need for anaerobic coverage; e.g. respiratory, urinary, catheter 
infection (standard dosing) 
Step 1 
 
 Non-antipseudomonal penicillins 
 ampicillin (1g q4h) 
 amoxicillin-clavulanate (1g q6h) 
 temocillin (2g q8h) 
 Second generation or third generation non-antipseudomonal cephalosporins 
o cefuroxime (1.5g q8h) 
o ceftriaxone (1g q12h or 2g q12h in case of meningitis) 
o cefotaxime (2g q8h) 
 Fluoroquinolones 
o levofloxacin (500mg q12h) 
o moxifloxacin (500mg q24h) 
 Trimethoprim/sulfamethoxazole (160mg/800mg q12h) 
Step 2  Anti-pseudomonal penicillins: piperacillin-tazobactam (16g over 24h) 
 Third generation anti-pseudomonal cephalosporins: ceftazidime (6g over 24h) 
 Fluoroquinolones: ciprofloxacin (400mg q8h) 
Step 3  Anti-pseudomonal carbapenems: meropenem (3g over 24h) 
Step 4  Anti-pseudomonal carbapenems (meropenem) + other antibiotic with Gram-
negative coverage 
 
Electronic Supplementary Material - Table 1b: Ranking of agents by increasing order of Gram-




 Non-antipseudomonal penicillins: amoxicillin-clavulanate  
 Fluoroquinolones  
o levofloxacin + metronidazole (500mg q8h) 
o moxifloxacin 
 Tigecycline (50mg q12h) 
Step 2  Anti-pseudomonal penicillins: piperacillin-tazobactam 
 Third generation anti-pseudomonal cephalosporins: ceftazidime + metronidazole 
 Fluoroquinolones: ciprofloxacin + metronidazole 
Step 3  Anti-pseudomonal carbapenems: meropenem 
Step 4  Anti-pseudomonal carbapenems (meropenem) + other antibiotic with Gram-
negative coverage 
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We registered patient demographics, co-morbidities, focus and severity of the infection, and 
daily sequential organ failure assessment (SOFA) scores. Microbiology results from 10 days 
prior to ICU admission until 10 days following ICU discharge were taken into consideration, 
comprising SC and additional cultures upon clinical suspicion of infection. SC consisted of oral, 
nasal, and rectal swabs upon admission, followed by once-weekly nasal samples and twice-
weekly oral and rectal samples in all patients, as well as twice weekly sputum in the non-
intubated patient or endotracheal aspirate in the ventilated patient. Cultured pathogens were 
classified as etiologic if these were considered to represent the causal pathogen of the infection 
and as colonizing in other cases. In case of microbiologically documented infection, antibiotic 
treatment was considered to be appropriate if all etiologic pathogens were covered. 
For the outcome analysis, patients were included once, and the first beta-lactam prescription 
was considered. The following outcome parameters were recorded: ICU mortality, in-hospital 
mortality, subsequent infections requiring antibiotic therapy, and total antibiotic consumption 
in the ICU, defined as the total number of days that a patient received an antibiotic during 
his/her stay in the ICU. In case of combination therapy, the total antibiotic consumption equaled 
the sum of the number of days of the individual components of the treatment. Antibiotic-free 
days were noted in the subgroup of patients with a length of stay (LOS) in the ICU of at least 14 
days. In addition, emergence of pathogens resistant to the initial beta-lactam antibiotic and 
emergence of MDR pathogens was registered. Pathogens isolated in any culture from day 2 
following the start of the antibiotic treatment under study and not present before that time were 
defined as having emerged after treatment. The following pathogens were categorized as MDR: 
methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, 
Stenotrophomonas maltophilia, Achromobacter spp., MDR Enterobacteriaceae, MDR Pseudomonas 
aeruginosa, and MDR Acinetobacter spp. modified from the publication of Magiorakos et al., in 
accordance with the MDR definition employed by the multicenter research project R-GNOSIS, 
work package 6 (ESM Table 2).164, 165 In addition, we included Enterobacteriaceae resistant for 




Electronic Supplementary Material - Table 2: 
Defining MDR Enterobacteriaceae, MDR Pseudomonas aeruginosa and MDR Acinetobacter spp. 
MDR Enterobacteriaceae 






o Cefotaxime or ceftriaxone 
o Trimethoprim-sulfamethoxazole 
 Meropenem or colistin resistant Enterobacteriaceae 
 Extended-spectrum beta-lactamase producing Enterobacteriaceae 
 Carbapenemase producing Enterobacteriaceae 
MDR Pseudomonas aeruginosa 
 Pseudomonas aeruginosa resistant against at least three antibacterial agents from the below 





o Ciprofloxacin  
 Colistin resistant Pseudomonas aeruginosa  
MDR Acinetobacter spp.  






o Ciprofloxacin  
 Meropenem or colistin resistant Acinetobacter spp. 
Used by permission of Prof. Marc Bonten, coordinator of the multicenter research project R-GNOSIS, work 
package 6; MDR, multidrug-resistant. 
The Ghent University Hospital Ethics Committee approved the study (registration number 
B670201524161) and waived informed consent. Only patients aged 16 years or older were 
included. 




Categorical variables were expressed as frequencies (percentages), continuous variables were 
described as median values with the interquartile range (IQR; 25–75th percentile). Continuation 
of the antibiotic treatment was defined as the standard to which de-escalation and escalation 
were compared. Differences in categorical variables were calculated using Pearson Chi-square 
test or Fisher’s exact test as appropriate. The Mann–Whitney U test was used to compare 
continuous variables. A multivariate logistic regression model was used to identify factors 
associated with de-escalation and escalation. All variables with a p value of 0.15 or lower and 
considered to be clinically important were entered into the model. The Hosmer–Lemeshow test 
was used to evaluate goodness-of-fit. Statistical significance was defined as p < 0.05. As 
systematic SC are no longer performed in patients discharged from ICU or in patients who die 
during their stay in the ICU, and hence the non-informative censoring assumption is likely to be 
violated, a competing risk analysis was performed when estimating the cumulative incidence of 
the emergence of antibiotic resistance.166-168 Cumulative incidence functions (CIFs) of de-
escalation and continuation were compared using a modified Chi-square test, with statistical 
significance defined as p < 0.05.169 All statistical analyses were performed with SPSS® software 
(SPSS, version 23; IBM Corp., Armonk, NY), and the R 3.2.2 software package.170 The competing 
risk analysis was performed using the “cuminc” routine available in the “cmprsk” package 
developed by Gray.171 
 
4.D.4 Results 
In total, we included 782 prescriptions of beta-lactam antibiotics for 615 patients in our analysis. 
Changes that could not be categorized as de-escalation or escalation [n = 50 (6.4%)] were 
omitted from the analysis. Of the remaining prescriptions (n = 732), 254 (35 %) had no anti-
pseudomonal activity [amoxicillin–clavulanate, n = 178 (24 %); cefuroxime, n = 53 (7 %), 
ceftriaxone n = 23 (3 %)]. Piperacillin–tazobactam was the most frequently used anti-
pseudomonal antibiotic [n = 343 (47 %)], followed by meropenem [n = 111 (15 %)] and 
ceftazidime [n = 24 (3 %)]. Treatment changes are detailed in Fig. 14a, b. Anti-pseudomonal 
beta-lactam antibiotics were de-escalated in 25 % of the treatments and escalated in 9 %; 
subsequent changes occurred in 26 % of treatments; de-escalation was maintained in 81 % of 
the treatment courses. Initial beta-lactam therapy was continued during the entire treatment 
course in 66 % of treatments; 67 % of continued treatments for microbiologically documented 





Figure 14a: Treatment changes subsequent to the initial beta-lactam 
antibiotic prescription (all beta-lactam prescriptions included) 
 
Figure 14b: Treatment changes subsequent to the initial beta-lactam 
antibiotic prescription (only beta-lactam prescriptions with activity 
























Other change 3 (7%)
478
Prescriptions
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Determinants of de‑escalation and escalation 
To identify the determinants of de-escalation and escalation we included prescriptions with 
anti-pseudomonal activity only (n = 478). The median time interval to antibiotic change was 3 
days (IQR for de-escalation and escalation was 3–5 and 2–7 days, respectively). De-escalation 
was achieved by narrowing the Gram-negative spectrum in 111 treatments, by reducing the 
number of antimicrobials in three treatments, and by a combination of both in seven treatments. 
In 63 % of de-escalations the empirical beta-lactam antibiotic was changed to another beta-
lactam antibiotic. Levofloxacin was the most frequently prescribed non-beta-lactam antibiotic in 
the case of de-escalation (21 %) (Tables 11, 12) 
Factors associated with de-escalation or escalation are detailed in Table 12. In the multivariate 
analysis, de- escalation was significantly associated with the identification of etiologic pathogens 
(p < 0.001), and escalation of therapy was significantly associated with severe sepsis or septic 
shock at presentation (p = 0.03), worsening SOFA score (p = 0.008), the presence of additional 
(non-etiologic) isolates resistant to the initial antibiotic (p = 0.01), admission to the SICU (p = 




Table 11: Baseline characteristics and univariate analysis on determinants of de-escalation and 
escalation of anti-pseudomonal beta-lactam therapy* 



















Baseline characteristics        






80 (72.1%) 28 (80%) 
 
0.51 0.17 
Apache II scorea 23 [18-29] 22 [17-28] 23 [18-30] 23 [20-31]  0.31 0.34 
SAPS II scoreb 56 [42-71] 56 [42-70] 59 [45-73] 56 [41-74]  0.14 0.66 
Hospitalisation duration prior to 
initiation of BL therapy (days) 
7 [3-19] 9 [4-23] 6 [2-15] 3 [1-9] 
 
0.008 <0.001 
Antibiotic exposure during ICU stay 





39 (35.1%) 8 (22.9%) 
 
0.01 0.003 
 ICU department      0.05 0.001 





42 (37.8%) 7 (20%) 
 
  





69 (62.2%) 28 (80%) 
 
  
Co-morbidities        
 Diabetes 76 (17.8%) 47 (16.2%) 19 (18.3%) 10 (30.3%)  0.62 0.04 






50 (48.5%) 15 (45.5%) 
 
0.29 0.75 
 Coronary disease 82 (19.4%) 52 (18.1%) 23 (22.5%) 7 (21.2%)  0.33 0.66 
 Chronic kidney disease 86 (20.3%) 62 (21.5%) 22 (21.4%) 2 (6.3%)  0.98 0.04 
 Malignancy 97 (22.7%) 68 (23.4%) 22 (21%) 7 (21.2%)  0.6 0.77 
 Chronic respiratory disease 84 (20%) 59 (20.8%) 18 (17.5%) 7 (21.9%)  0.47 0.89 
        
Infection characteristics        
Initial BL therapy      0.02 0.4 






72 (64.9%) 30 (85.7%) 
 
  
 Meropenem  
102 
(22.5%) 
62 (20.2%) 36 (32.4%) 4 (11.4%) 
 
  
Focus of infection      0.2 0.03 
 Abdominal 91 (20.1%) 51 (16.6%) 25 (22.5%) 15 (42.9%)    






59 (53.2%) 14 (40%) 
 
  
 Skin and soft tissue 16 (3.5%) 12 (3.9%) 4 (3.6%) 0    
 Urinary 19 (4.2%) 14 (4.6%) 4 (3.6%) 1 (2.9%)    
 Other 74 (16.3%) 54 (17.6%) 15 (13.5%) 5 (14.3%)    





42 (38.2%) 21 (60%) 
 
0.89 0.01 
ΔSOFAc 0 [-1,2] 0 [-1, 2] 1 [-1,2] -1 [-4,1]  0.35 0.001 







80 (72.1%) 19 (54.3%) 
 
<0.001 0.06 
Presence of (non-etiologic) isolates 
resistant to the initial BL therapy 
124 
(27.4%) 
71 (23.1%) 39 (35.1%) 14 (40%) 
 
0.01 0.03 
 in microbiologically 











 in non-microbiologically 











*patients with inadequate empirical therapy in microbiologically documented infections were excluded for 
analysis; a Apache II score, Acute Physiology and Chronic Health Evaluation score; b SAPS II score, 
Simplified Acute Physiology Score; BL therapy, beta-lactam therapy; ICU, intensive care unit; SOFA, 
Sequential Organ Failure Assessment score. c ΔSOFA is SOFA score on day 0 minus SOFA score on day 2 of 
infection.
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Table 12: Multivariate analysis on determinants of de-escalation and escalation of anti-
pseudomonal beta-lactam therapy 
 
 




Escalation versus continuation 
 
 Adjusted OR (95% CI)* P value  Adjusted OR (95% CI)** P value 
      
ICU department 
(medical/surgical ICU) 
0.81 (0.5-1.3) 0.39  0.24 (0.1-0.61) 0.003 
Hospitalisation duration prior 
to initiation of BL therapy 
(days) 
0.99 (0.98-1) 0.11  0.96 (0.92-0.99) 0.04 
Antibiotic exposure during ICU 
stay prior to initiation of BL 
therapy 
0.68 (0.41-1.15) 0.15  0.52 (0.2-1.34) 0.17 
Type of initial BL therapy 0.98 (0.75-1.28) 0.88  1.17 (0.67-2.1) 0.59 
Focus of infection 0.98 (0.86-1.12) 0.76  0.92 (0.73-1.17) 0.5 
Severe sepsis/septic shock 1.1 (0.65-1.85) 0.72  0.38 (0.15-0.9) 0.03 
Δ SOFAa 1.01 (0.94-1.08) 0.83  0.87 (0.79-0.97) 0.008 
Microbiologically documented 
infection 
3.96 (2.4-6.55) <0.001  1.4 (0.62-3.15) 0.42 
Presence of (non-etiologic) 
isolates resistant to the initial 
BL therapy 
1.46 (0.87-2.48) 0.16  3 (1.26-7.11) 0.01 
      
°patients with inadequate empirical therapy in microbiologically documented infections were excluded 
for analysis *Hosmer-Lemeshow test=1.520, p=0.99, ** Hosmer-Lemeshow test=3.483, p=0.9; ICU, 
intensive care unit; BL therapy, beta-lactam therapy; SOFA, Sequential Organ Failure Assessment score. 
aΔSOFA is SOFA score on day 0 minus SOFA score on day 2 of infection 
 
Outcome after de‑escalation of therapy 
Both de-escalation and escalation were associated with a longer antibiotic course [8 (IQR 6–10) 
(de-escalation) vs. 11 (IQR 8–19) (escalation) vs. 5 (IQR 4–7) (continuation) days; p < 0.001] and 
a higher total antibiotic consumption while in the ICU [12 (7–22) (de-escalation) vs. 24 (13–39) 
(escalation) vs. 7 (4–15) (continuation) days; p < 0.001]. As compared to the LOS in the ICU of 
patients who continued on the original therapy [continuation: 8 (IQR 5–15) days], that of 
patients in the de-escalation and escalation categories was significantly longer [11 (6–19) days, 
p = 0.001 and 17 (10–23) days, p < 0.001, respectively]. The number of antibiotic-free days on 
day 14 was significantly lower for patients in the de-escalation and escalation categories [1 (0–
3) (de-escalation), p = 0.04 vs. 0 (0–1) (escalation), p < 0.001 vs. 2 (0–6) (continuation) days]. A 
subsequent infection in the ICU was more frequent following escalation of treatment than 
following continuation (55.3 vs. 33 %, respectively; p = 0.008). Neither ICU mortality nor 




Table 13: Patient outcome after de-escalation and escalation of anti-pseudomonal beta-lactam 
therapy 
















Antibiotic treatment duration in the ICU 
for the infection under study (days) 
6 [5-9] 5 [4-7] 8 [6-10] 11 [8-19]  <0.001 <0.001 
Total antibiotic consumption in the ICU 
(days) 
10 [5-20] 7 [4-15] 12 [7-22] 24 [13-39] 
 
<0.001 <0.001 
Antibiotic-free days (14 days after onset 
of infection) ° (n=116) 
1 [0-4] 2 [0-6] 1 [0-3] 0 [0-1] 
 
0.04 <0.001 
Subsequent nosocomial infection during 
ICU stay (% of patients) 
127 
(36.9%) 
73 (33.0%) 33 (38.8%) 21 (55.3%) 
 
0.34 0.008 
 Etiologic pathogen is resistant to the 






















LOS in ICU following start of the infection 
under study (days) 
9 [6-17] 8 [5-15] 11 [6-19] 17 [10-23] 
 
0.001 <0.001 
ICU mortality 76 (22.1%) 47 (21.3%) 19 (22.4%) 10 (26.3%)  0.84 0.49 
Hospital mortality 117 (34%) 73 (33%) 28 (32.9%) 16 (42.1%)  0.99 0.28 
        
Emergence of pathogens resistant to 
the initial BL therapy 
112 
(32.6%) 
68 (30.8%) 29 (34.1%) 15 (39.5%)  0.57 0.29 
Time interval to isolation of pathogens 
resistant to initial BL (n=112) 
5 [3-11] 5 [4-12] 3 [2-10] 7 [3-8] 
 
0.01 0.58 
        
Emergence of MDR pathogensa* 99 (28.8%) 61 (27.6%) 24 (28.2%) 14 (36.8%)  0.91 0.25 
 MRSA 5 (1.5%) 2 (0.9%) 3 (3.5%) 0  0.13 1 
 VRE 3 (0.9%) 2 (0.9%) 0 1 (2.6%)  1 0.38 
 Clostridium difficile 6 (1.7%) 5 (2.3%) 1 (1.2%) 0  1 1 
 Piperacillin-tazobactam and 3rd 
generation cephalosporins R 
Enterobacteriaceae 
28 (8.1%) 16 (7.2%) 7 (8.2%) 5 (13.2%)  0.77 0.21 
 MDR Gram negative pathogens 72 (20.9%) 44 (19.9%)  17 (20%) 11 (28.9%)  0.99 0.21 
▪ MDR Enterobacteriaceae 45 29 12 4  0.82 0.80 
∟  ESBL-producing Enterobacteriaceae 18 15 2 1  0.17 0.48 
∟  Carbapenem R Enterobacteriaceae 0 0 0 0  - - 
▪ MDR Pseudomonas aeruginosa 12 7 1 4  0.45 0.06 
∟  Carbapenem R Pseudomonas 
aeruginosa 
9 6 0 3 
 
0.19 0.13 
▪ MDR Acinetobacter spp. 1 0 0 1  - 0.15 
∟  Carbapenem R Acinetobacter spp. 0 0 0 0  - - 
▪ Achromobacter spp. 2 1 1 0  0.48 1 
▪ Stenotrophomonas maltophilia 12 7 3 2  1 0.62 
ICU, intensive care unit; BL therapy, beta-lactam therapy; MDR, multidrug-resistant; LOS, length of stay; 
MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococcus; R, resistant; 
ESBL, extended-spectrum beta-lactamases; °in subgroup of patients with an ICU LOS ≥ 14 days after onset 
of infection; a MDR defined modified from the publication of  Magiorakos et al., in accordance with the MDR 
definition employed by the multicenter research R-GNOSIS project164, 165; * patients are included once if 
multiple MDR pathogens are present.
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Pathogens with in vitro resistance to the initial anti-pseudomonal beta-lactam antibiotic 
emerged in 32.6% of patients, and MDR pathogens emerged in 28.8% of patients; these values 
did not differ significantly when the initial beta-lactam therapy was continued, de-escalated, or 
escalated. The cumulative incidence estimate (CIE) of emergence of pathogens resistant to the 
initial beta-lactam on day 14 was 23.5% when the initial beta-lactam was continued and 30.6% 
when therapy was de-escalated (p = 0.22). The CIE of emergence of MDR pathogens on day 14 
was 18.6 and 23.5% for continuation and de-escalation of therapy, respectively (p = 0.35). Both 
CIF curves are displayed in Fig. 15 a, b. Equally, subgroup analyses on microbiologically 
confirmed infections (ESM Fig. 15 c, d) or on only those including antibiotic courses of >5 days 
(ESM Fig. 15 e, f) found no differences in the CIFs of antibiotic resistance when de-escalation was 




Figure 15a: Cumulative incidence function (after adjustment for ICU 
discharge and death as competing risk events) of emergence of pathogens 
resistant to the initial anti-pseudomonal beta-lactam antibiotic (p=0.09, 
DF=1); ICU, intensive care unit 
 
 
Figure 15b: Cumulative incidence function (after adjustment for ICU 
discharge and death as competing risk events) of emergence of MDR 
pathogens (p=0.38, DF=1); ICU, intensive care unit; MDR, multidrug-resistant
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ESM figure 15c: Cumulative incidence function (after adjustment for ICU 
discharge and death as competing risk events) of emergence of pathogens 
resistant to the initial anti-pseudomonal beta-lactam antibiotic in patients 
with microbiologically documented infections (p=0.67, DF=1); ICU, intensive 
care unit 
ESM figure 15d: Cumulative incidence function (after adjustment for ICU 
discharge and death as competing risk events) of emergence of MDR 
pathogens in patients with microbiologically documented infections (p=0.88, 





ESM figure 15e: Cumulative incidence function (after adjustment for ICU 
discharge and death as competing risk events) of emergence of pathogens 
resistant to the initial anti-pseudomonal beta-lactam antibiotic in patients 




ESM figure 15f: Cumulative incidence function (after adjustment for ICU 
discharge and death as competing risk events) of emergence of MDR 
pathogens in patients with an ICU treatment duration > 5 days (p=0.79, 
DF=1); ICU, intensive care unit; MDR, multidrug-resistant 




To date no data have been published which confirm a beneficial effect of de-escalation on MDR 
emergence.93 Previous studies that were not designed to investigate this subject were unable to 
demonstrate an impact of de-escalation on the selection of resistance.95, 160, 172 Our analysis of 
routinely collected diagnostic and surveillance cultures is the first study to address this topic 
systematically. Our data show no impact of the de-escalation of empirical anti-pseudomonal 
beta-lactam therapy on the emergence of resistance to antibiotics. 
De-escalation of anti-pseudomonal beta-lactam antibiotics was performed in one-quarter of the 
prescriptions, which is low in comparison with the rates reported in previous studies, ranging 
from 30 to 60 %.93, 150, 157-161, 172 However, comparison between studies is hampered by the lack 
of a universal definition for de-escalation. Our definition of de-escalation was strict and limited 
to Gram-negative coverage only. Gonzalez et al. reported a de-escalation rate of 51 %, with 
>90% achieved by a reduction in the number of antimicrobials.160 In contrast, the majority of de-
escalations in our study resulted from substitution of the initial antibiotic by an antibiotic with a 
more limited spectrum [111/121 (92 %)]. 
Microbiological documentation of the infection has been identified as a prerequisite for de-
escalation in many studies.95, 149, 150, 158, 159, 161, 172 Although 27 % of the de-escalations in our study 
were for the treatment of culture-negative infections, multivariate analysis of the determinants 
of de-escalation found that identification of the etiologic pathogen was the single factor 
promoting de-escalation. However, a high number (67 %) of continued treatments for 
microbiologically documented infections were not de-escalated despite this being 
microbiologically possible, indicating that other, unresolved barriers for de-escalation may 
exist.173 In contrast with prior observations we did not find an association between de-escalation 
and clinical improvement or less severity of the infection.149, 157, 159, 174 Interestingly, factors 
associated with escalation were more complex. Escalation was significantly associated with a 
higher clinical severity upon presentation and unfavorable evolution under treatment, an 
observation which was also reported by Garnacho-Montero et al.157 Additionally, the presence of 
resistant colonizing pathogens triggered the physician to escalate therapy. As the presence of 
resistant colonizing pathogens did not inhibit de-escalation, we suspect that during the 
treatment course SC are mainly used to alter the treatment in the case of severe and sustained 
infections. Escalation of therapy was also associated with the ICU department (surgical/medical) 
regardless of focus of infection, suggesting that the decision to alter the therapy may be related 
to more subjective characteristics or attitudes of the physician.173 
An unexpected finding of our analysis was that the treatment duration was significantly longer 




analysis in different subgroups of patients (i.e., with the antibiotic course completed in the ICU, 
with etiologic pathogens identified) and calculated antibiotic-free days in the subgroup with a 
LOS in the ICU of ≥14 days after initiation of the infection and obtained the same result. One 
possible explanation is that de-escalation under the form of early antibiotic discontinuation may 
be hidden in the subgroup of patients who continued treatment. However, as the results are 
identical in different subgroups, we assume that this last reasoning cannot fully explain our 
observation. Alternatively, prolonged antibiotic treatment may be an unwanted side-effect of de-
escalation. Although we have no firm explanation, it is tempting to propose a few potential 
explanations. The first is that physicians may not take the first days of empirical therapy into 
account when determining the full treatment duration. A second plausible explanation is the 
subjective perception that extending a course of a narrow-spectrum antibiotic for a few days 
may have fewer harmful ecological consequences than extending that of a broad-spectrum drug. 
The total antibiotic consumption in the ICU was also significantly higher in our de-escalated 
patients, but these results were mainly determined by the initial infectious episode. In contrast 
to our findings, Leone et al. observed an increased number of superinfections in patients 
following de-escalation, leading to a significantly higher total antibiotic consumption.95 Clearly, 
de-escalation may itself provoke subsequent attitudes or behavior, an aspect of this study which 
deserves further attention. 
Cumulative incidence functions were analyzed both for the emergence of pathogens resistant to 
the initial anti-pseudomonal beta-lactam antibiotic and for emergence of MDR pathogens, 
adjusting for ICU discharge and death as competing risks for the selection of resistance, and did 
not differ significantly between patients in the de-escalation and continuation categories. The 
increased emergence (although not reaching significance) of resistance in patients in the de-
escalation category, as compared to those who continued the therapy, disappeared altogether 
when the analysis was restricted to microbiologically confirmed infections, as well as in the 
subgroup of antibiotic courses of >5 days; as such this increased resistance might be due to the 
higher number of short antibiotic exposures in the continuation group. The observation that 
pathogens resistant to the prescribed beta-lactam antibiotic were isolated after a median time 
interval of 5 days of treatment suggests that there is a widespread reservoir of resistance which 
rapidly results in detectable colonization even after short treatment courses. Our results find 
support in the study of Armand-Lefèvre et al.21 who describe an odds ratio of 5.9 for colonization 
with imipenem-resistant Gram- negative bacilli in the intestinal flora of ICU patients after 1–3 
days of exposure to imipenem. These findings suggest that a reduction of the number of 
exposures to broad-spectrum antibiotics may be a better approach to limit the emergence of 
resistance. An alternative hypothesis for the rapid selection of resistance is derived from 
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simulation studies that demonstrate a lower probability to achieve adequate 
pharmacokinetic/pharmacodynamic targets for more narrow-spectrum agents.175 
De-escalation on the second or third day of therapy is recommended.90, 91, 156 In our study we de-
escalated therapy after a median treatment duration of 3 (IQR 3–5) days, which is in accordance 
with previous reports.95, 160, 172 As physicians rely on microbiology results for their decision to 
de-escalate, it seems almost impossible to narrow this time-frame due to the limitations of 
current microbiology practices. 
Our study has a number of limitations. First, it is a retrospective study, although all antibiotic-
related data were recorded prospectively. Second, our study is monocentric in a setting with 
relatively low resistance levels, and the impact of de-escalation may be different in other 
ecologies. Third, our ranking system of incremental Gram-negative antimicrobial activity is only 
one of many possible approaches. In previous papers focusing on the subject, ranking of 
antimicrobials by their spectrum of activity has proven to be difficult, resulting in conflicting 
definitions.176, 177 Moreover, most prior observational studies do not provide the ranking of the 
treatments that was used, which makes interpretation and comparison difficult.157, 160, 161, 172 
Fourth, we lack information regarding the antibiotic exposition prior to ICU admission. 
However, keeping in mind that in the univariate analysis de-escalated patients had significantly 
shorter hospitalization duration before the initiation of the beta-lactam treatment and 
significantly less previous antibiotic exposure in the ICU, it is unlikely that prior antimicrobial 
consumption was higher in the de-escalated population. Finally, it is reasonable that different 
de-escalation strategies are not comparable with respect to patient outcome and impact on 
microbial ecology. 
In conclusion, in our study population, de-escalation of anti-pseudomonal beta-lactam 
antibiotics, as performed by the replacement of antibiotic treatment by a more narrow-spectrum 
agent, was mainly driven by the presence of etiologic cultures. We did not observe a beneficial 
effect of de-escalation on the emergence of resistance. Consequently, we conclude that de-
escalation should not be considered to be a safe strategy underpinning the unlimited empirical 
use of broad-spectrum therapy. Our results confirm the urgent need for a uniform definition on 
de-escalation and for future randomized controlled trials to determine the most optimal de-
escalation strategy and, by extension, the most optimal antibiotic strategy for reducing overall 
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Take-home message: 
The results of this study do not confirm the expected favorable effect of de-escalation of anti-
pseudomonal beta-lactam antibiotic treatment on the selection of antimicrobial resistance. De-
escalation should therefore not be considered to be a safe strategy underpinning an unlimited 
empirical use of broad-spectrum combination therapy. Future research to determine the most 
optimal de-escalation strategy and by extension the most optimal antibiotic strategy reducing 
overall antibiotic exposure and antimicrobial selection pressure is essential.
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E. LINKING ANTIBIOTIC, MICROBIOLOGY AND CLINICAL DATA THROUGH AN 
ELECTRONIC PLATFORM ENABLES IDENTIFICATION OF ANTIMICROBIAL 
STEWARDSHIP TARGETS: A PROOF-OF-CONCEPT STUDY 
 
Liesbet De Bus, Bram Gadeyne, Jerina Boelens, Geert Claeys, Dominique Benoit, Johan 







Longitudinal surveillance of infection treatment facilitates identification and prioritization of 
stewardship interventions. Antibiotic prescription in patients admitted to the Intensive Care 
Unit of Ghent University Hospital (January 1st 2013 - December 31st 2016), was merged with 
microbiology and clinical data during clinical workflow through a designated software program. 
Prolonged courses (>3 days of therapy) of glycopeptides, oxazolidinones and carbapenems that 
were potentially unjustifiable by previously defined criteria were identified. Thirteen percent of 
glycopeptide/oxazolidinone versus 33 % of carbapenem consumption was classified as 
potentially unjustified. Linking of antibiotic, microbiology and clinical data during daily routine 
may facilitate targeting of stewardship interventions.




The need for a well-designed antibiotic stewardship program (ASP) is universally recognized, 
especially in the intensive care unit (ICU) which is a hotspot for antibiotic use.2, 3 As healthcare 
resources have to be used judiciously, potential stewardship intervention targets have to be 
weighed carefully.122 The computerization of the patient chart has offered the potential to record 
healthcare processes, including antibiotic treatment, as complete data of high resolution in a 
way that minimally interferes with the healthcare deliver’s workflow.102 
In the ICU of Ghent University Hospital, a locally developed software program automatically 
integrates all infection related data from distributed stand-alone vendor specific systems. A 
concise overview is presented to the physician in a graphical form for each ICU patient. As such, 
this software facilitates manual linking of antimicrobial prescription data, microbiology data and 
clinical information during daily routine.102 The aim of the current study is to illustrate the 
potential of this longitudinal surveillance strategy to target possible stewardship interventions 
through an example case assessing antimicrobial overuse. 
 
4.E.3 Materials and methods 
 
Setting 
This study was conducted from January 1st 2013 until December 31st 2016 at the medical and 
surgical (36 beds) ICU of Ghent University Hospital (1054 beds). The hospital Ethics Committee 
approved the study (registration number B670201628197) and waived informed consent based 
on the non-interventional nature of this study. Patients aged 16 years or older were included. 
Patients are managed in a closed ICU. Antibiotic prescriptions are at the discretion of the 
attending ICU physician, without the use of stringent protocols or antibiotic restrictions. 
Interdisciplinary staff meetings take place on a regular basis. Treatment duration and 
opportunities for de-escalation are evaluated daily. 
An Intensive Care Information System (Centricity Critical Care, GE Health Care) integrating 
physician order entry, medication administration recording and patient monitoring data is 
available bedside. A software program, COSARA (Computer-based Surveillance, Alerting of 
infections, antimicrobial Resistance and Antibiotic consumption in the ICU) was developed by a 
consortium of the Ghent University Hospital ICU department and the Department of Information 
Technology (INTEC) of the Faculty of Engineering of Ghent University.102 COSARA automatically 




graphic overview (Supplemental Digital Content 1). The antibiotic prescription is presented as a 
horizontal bar running along a timeline (antibiotic bar). This bar is accompanied by a second bar 
describing the indication for this antibiotic (infection bar). A preliminary version of the infection 
bar is fed by data from a questionnaire that ‘pops up’ in real-time after any antibiotic 
prescription and inquires the prescriber about indication, severity, focus and probability of 
infection and presence of microbiological data guiding the antibiotic choice. This preliminary bar 
can be altered when more data concerning the origin and clinical evolution of the infection 
become available. In addition, the coupled antibiotic-infection bars can be linked to 
microbiological culture results. All preliminary infection bars were reviewed and modified if 
necessary by the investigators LDB and PD after consultation of the ICU physician or the patient 
charts. 
 
Drill-through-to-detail analysis of antimicrobial use 
In accordance with the recommendations of the Centers for Disease Control and Prevention 
(CDC), days of therapy (DOT) was defined as the number of days with systemic administration of 
at least one dose of an antimicrobial agent as recorded by COSARA.36 We focused on three ‘last-
resort’ antibiotics for which a restricted use is recommended: carbapenems, glycopeptides and 
oxazolidinones.20, 178, 179 We combined utilization data with clinical and microbiology info by 
drill-through-to-detail analysis of our database (figure 16). To demonstrate the flexibility of our 
dataset we focused on the identification of unjustified sustained treatment courses. We assumed 
that prolonged (> 3 DOT) use would be potentially unjustified in one of the following conditions: 
(1) prolonged prophylactic therapy, (2) prolonged therapy in low probability infections, (3) 
prolonged empirical therapy (negative diagnostic cultures) in moderate/high probability 
infections and (4) prolonged broad-spectrum therapy in microbiologically confirmed infections 
when de-escalation is possible based on susceptibility results of causative pathogens.




Figure 16: Drill-through-to-detail analysis of antimicrobial use 
 
4.E.4 Results 
A total of 10743 ICU admissions were recorded in 8763 patients resulting in a total of 47403 
patient days from January 1st 2013 until December 31st 2016. ICU and hospital mortality was 
10.7% (n=936) and 15% (n=1314) respectively. Median APACHE II score at admission was 18 
(IQR 13-25). Methicillin resistance was present in 23% of the Staphylococcus aureus isolates in 
our ICU population. Vancomycin resistance was present in 1.9% of the Enterococcus species 
isolates. Extended spectrum beta-lactamase production (ESBL) was present in 33% of 
Enterobacteriaceae isolates, whereas carbapenemase production was present in 1.2%. 
A total of 14908 antibiotic courses were administered, resulting in 58413 DOT (1232 DOT/1000 
patient days). Overall consumption of carbapenems, glycopeptides and oxazolidinones was 
respectively, 94.7, 62.6 and 37.6 DOT/1000 patient days. All three antibiotic classes were 
principally used to treat high probability infections. Thirty-three percent of the carbapenem 
consumption and 13 % of the combined glycopeptides and oxazolidinones use was identified as 




Type of potentially unjustified antibiotic use Carbapenem Glycopeptides + 
Oxazolidinones 
 n DOT in excess  
(% of total DOT/ class) 
n DOT in excess  
(% of total DOT/ class) 
   
Type 1: Prolonged prophylactic therapy 12 (0.3%) 32 (0.7%) 
Type 2: Prolonged therapy in low probability infections 66 (1.5%) 52 (1.1%) 
Abdominal infection 5  26 
Catheter related infection - 3 
Neutropenic fever 7 1 
Respiratory infection 28 1 
Other infection focus 2 5 
Unknown infection focus 24 16 
Type 3: Prolonged empirical therapy in moderate/high probability infections without positive diagnostic 
cultures 
691 (15.4%) 369 (7.8%) 
Abdominal infection 347 165 
Catheter related infection 2 14 
Neutropenic fever 28 12 
Respiratory infection 169 65 
Skin & soft tissue infection 21 27 
Uro-genital infection 4 3 
Other infection type 16 22 
Unknown infection focus 104 61 
Type 4: Prolonged broad-spectrum therapy in microbiologically confirmed moderate/high  probability 
infections when de-escalation is possible 
721 (16.1%) 146 (3.1%) 
Abdominal infection 309 58 
Catheter related infection 9 1 
Neutropenic fever 14 - 
Respiratory infection 140 25 
Skin & soft tissue infection 28 10 
Uro-genital infection 9 - 
Other infection type 25 28 
Multiple infection foci 144 7 
Unknown infection focus 43 17 
Total of unjustified antibiotic use (% of total DOT/antibiotic class) 1490 (33.2%) 599 (12.6%) 
 
Table 14: Potentially unjustified antibiotic use 




In this manuscript we demonstrate the added value of a detailed database which is built up by 
continuously linking antimicrobial prescription data, microbiology data and clinical diagnostic 
information of ICU patients during clinical workflow to support antibiotic stewardship decision-
making. 
A detailed insight in the aspects driving antimicrobial use is desirable to support the selection of 
potential stewardship targets.122 In this study we focused on carbapenems and 
glycopeptides/oxazolidinones as ‘last resort drugs’. Consumption figures of the same magnitude 
were observed during a 4-year period. Supplementing these data with microbiology and clinical 
info to identify potentially unjustified sustained antibiotic courses learned that 33 % of the 
carbapenem DOT/patient-days was deemed to be redundant, as compared to only 13 % of the 
glycopeptides/oxazolidinones utilization. Based on these results an intervention targeting 
carbapenem overuse seems to take priority over handling glycopeptides/oxazolidinones 
overconsumption in our institution. Accurately combined information on three different aspects 
of an individual treatment course (antibiotic prescription, infection diagnosis and microbiology) 
was mandatory to come to this conclusion. 
Continuous merging of infection related data which is elementary for our surveillance strategy 
may seem insurmountable due to personnel and time restraints. Over the last years, ICU staff 
members integrated this process in their workflow by the use of COSARA.102, 124 Two basic 
principles underlie our registration. First, we map the motivation for each electronic antibiotic 
prescription through a questionnaire at the point of care. Second, COSARA presents all 
information on infection in a concise, visually attractive and user-friendly format which 
promotes incorporation of the merging process in clinical tasks. 
Our study has limitations. First, computerized physician order entry is crucial to implement this 
stewardship proposal, but at the same time the persistent commitment of dedicated physicians 
is vital for its chances of success. Integrating the linking in daily routine, real-time presentation 
of this information during ward rounds and staff meetings and employment of the collected data 
for computerized decision support are ways to increase its sustainability. Second, the value of all 
surveillance systems depends largely on the quality of the data that is incorporated. A previous 
analysis assessing the validity of the diagnostic information recorded in COSARA compared to 
conventional surveillance data showed good agreement between both methods.124 Bearing these 
first two limitations in mind, a multicenter application of our system will be needed to assess its 
general applicability. Finally, we have to acknowledge that successful implementation of a 
stewardship intervention is not guaranteed solely by the identification of an area of potential 




time out’) is recommended by the CDC, many barriers may withhold a physician to act upon a 
recommendation for discontinuation.36, 180 Future interventions at the point of care are required 
to evaluate and refine our strategy. 
 
Conclusion 
Continuously connecting antimicrobial prescription data, microbiology data and diagnostic 
information during workflow leads to the build-up of a comprehensive dataset which may 
facilitate internal stewardship decision-making. 
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The key objective of this PhD project was twofold. On the one hand, we evaluated the feasibility 
and validity of our locally designed software program, COSARA, to assist in surveillance. On the 
other hand, based on the information that was captured through the use of COSARA, we aimed to 
acquire more insight in our local antibiotic prescription practices and microbiological resistance 
patterns to support the design of an ASP. 
 
A. USE OF A COMPUTER-ASSISTED REGISTRATION PROGRAM TO FACILITATE 
SURVEILLANCE IN THE ICU 
Confronted by clinical problems during daily workflow as ICU physicians, we sought to develop 
and design a software program assisting in everyday infection management. The time-
consuming process of collecting a patient’s data in case of a complex history of infection was an 
important incentive for the development of a clinical data visualization dashboard. The absence 
of easy accessible and detailed information on antibiotic utilization in the ICU emphasized the 
need for the construction of a registration tool. For this purpose, multidisciplinary discussions 
harmonizing the aspirations of ICU personnel with IT possibilities were held, which finally 
resulted in the build-up of the COSARA software. 
COSARA is situated among a wide variety of existing electronic or automated surveillance tools 
but has many particularities. As mentioned previously, patient and infection related data are 
assembled through the software and presented in a graphical format to the user. This 
information needs to be supplemented with clinical information which is introduced by 
physicians: a) a pop-up questionnaire at the moment of antibiotic prescription and b) a 
reassessment and fine-tuning of these pop-up data during the course of the treatment. 
Subsequently, COSARA is an indispensable facilitator of the surveillance process, but at the same 
time, a substantial amount of manual input is required. As such, COSARA has to be categorized as 
a semi-automated ESS. 
As explained before, clinical information has proven to be a valuable data source in the context 
of surveillance.46, 49 This is not unsurprising as clinical signs and symptoms are a crucial 
component in the majority of traditional surveillance definitions. Most fully automated ESS 
struggle with the collection of clinical information from EHRs and as a rule this information is 
not available in a structured format. In a study on SSI surveillance, however, highly sensitive and 




structured clinical data.181 When linking a diagnosis to an antibiotic prescription in COSARA, 
physicians are asked to select an infection from a predefined limited list which leads to the 
build-up of a structured dataset. No specific rules or definitions are followed during this process. 
A subsequent assessment of infection probability is asked for each treatment course as 
antibiotics are commonly prescribed for prophylactic reasons or in patients with a low suspicion 
of infection. Our approach differs significantly from traditional surveillance following formal 
checklists and criteria, therefore a comparison of both strategies was deemed essential. 
Surveillance through COSARA was compared with PBS for three infection types: BSI, RTI and 
UTI.124 Good agreement, reflected by an overall kappa score of 0.74 was recorded. Not 
unexpectedly, inter-observer variability was the major reason for disagreement between CAS 
and PBS, which is inherent to the use of different diagnostic criteria by both surveillance 
methods. Test characteristics of CAS through COSARA fall within the range of the results 
reported in other studies on electronic surveillance; high sensitivity (72-100%) and diverging 
specificity (37-100%) results for BSI, comparable figures for UTI (sensitivity and specificity of 
respectively 86-100% and 59-100%) and RTI (sensitivity and specificity of respectively 71-99% 
and 61-100%).37 Importantly, due to time and personnel restraints which limited PBS, the 
validity of COSARA as surveillance tool was only evaluated for these 3 selected infection types. 
COSARA, as it is currently in use in our ICU, aims to integrate surveillance in the daily workflow 
of the ICU physician. Collecting structured clinical information without adhering to strict 
diagnostic criteria was a well-considered decision to ensure practical feasibility of sustained 
data collection. Redefining the preliminary infection diagnosis and linking of microbiology 
results to an antibiotic-infection combination can be done by each physician involved in patient 
care and requires only a minimal effort. Over the last few years however, we decided to appoint 
designated COSARA users in our ICU that devote extra time to the reassessment of infection 
diagnoses and linking of microbiological information; a trade-off that has been made to 
guarantee completeness and consistency of data collection. The design of COSARA, however, 
permits less or more standardized surveillance approaches. For instance, dedicated surveillance 
personnel may be assigned to perform surveillance, supported by COSARA, using traditional 
international definitions. Alternatively, additional objective criteria can be paired with the 
captured clinical infection diagnoses to increase specificity of our surveillance system (see 
below). Performance and time expenditure need to be reevaluated if one should decide to 
employ COSARA in this alternative manner. 
Semi-automated ESS require a persistent commitment of both the prescribing physician and the 
dedicated COSARA user to ensure registration of correct clinical diagnostic information. We 
observed that completion of the pop-up questionnaires, although this takes less than one 
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minute, is sometimes performed incorrectly. We hypothesize that this is mainly the result of an 
incomplete understanding of the antibiotic decision-making process by physicians in training or 
the fact that some physicians consider this act to be of minor importance in the treatment 
process of their patient. Semi-automated systems are inherently subject to the pitfalls of 
traditional manual surveillance i.e. human error, inter-observer variability and incomplete data 
capture. As a result COSARA seems less fit for benchmarking purposes compared to fully 
automated ESS. The use of additional filters when querying the COSARA database may partially 
overcome this problem. In the case of VAP for instance, worsening of oxygenation, presence of 
fever or hypothermia and the isolation of a respiratory pathogen 48 h before or after the 
initiation of a new antimicrobial treatment are all objective and easy accessible data. The clinical 
diagnosis which is stored in the COSARA database can be matched to these objective criteria and 
as such the specificity of our surveillance approach may be increased. 
Identification of an infection by COSARA is triggered by the initiation of antibiotic treatment. A 
CLABSI which is simply treated by catheter removal or an infection which is untreated in the 
setting of therapeutic restrictions, is thus not captured by means of COSARA. On the other hand, 
each and every electronic antibiotic prescription has a diagnostic label assigned to it. The 
resulting global overview on antimicrobial consumption is unique in its kind. One of the 
incentives for the continuing development of ESS over the last decade, is the fact that manual 
surveillance is often limited to specific conditions or pathogens due to time and personnel 
restraints. Unfortunately, the number of ESS that covers a wide range of infections or treatments 
is still limited. Only one study, performed in a tertiary care teaching hospital in Finland, reported 
on a continuous hospital-wide surveillance system covering all infection types.52 Similarly to 
COSARA, the described system required manual input by the treating physician and dedicated 
surveillance personnel, case finding was treatment-based and performance of the system was 
only tested for a subset of infection types. An additional limitation of most ESS is made up by 
their dichotomous classification methods. Detection of ‘borderline’ infections is hampered by 
their design. MONI-ICU, an ESS using fuzzy set theory and fuzzy logic, has gained experience 
with non-dichotomous infection surveillance.58 A significant number of borderline infections (or 
clinical suspicion of infection) was detected by this system, particularly when clinical 
information was incorporated in the algorithm. The authors state that their findings reflect the 
diagnostic difficulties of ICU physicians. Although this aspect is not touched in the article, it 
would be interesting to know in how many of these cases antibiotics were initiated. COSARA 
records information on infection probability. Identification of low and intermediate probability 
infections is just as important as registration of definite infections as these borderline cases 




analysis of antibiotic use in our ICU and will be discussed further in the second part of this 
discussion. 
Performance standards of ESS are largely determined by their data access time which has to be 
held as short as possible.68 A distinct COSARA module allows real-time autonomous execution of 
a wide range of predefined analyses. Additional data extraction from the COSARA database can 
be performed within limited time frames but requires the assistance of an IT specialist. The 
architecture of the database, on the other hand, allows physicians to address complex research 
questions through flexible merging of these raw COSARA data. 
The validity of COSARA as surveillance tool may differ between different ICU settings. The 
COSARA software has been deployed in a second university hospital ICU (Antwerp University 
Hospital). Software implementation was not hindered by the fact that both hospitals use an ICIS 
from a different manufacturer. Until now, further information on performance status and clinical 
implication of COSARA is unavailable for this center. Theoretically, the basic requirements for 
the implementation of the software merely consist of the use of CPOE for antibiotic prescription 
and accessibility of microbiology results in an electronic format. However, we need to stress 
once more that data quality and consistency depends largely on the input of accurate clinical 
information. The level of data fine-tuning and data control will determine the performance level 
of our ESS and its usefulness in patient care. As mentioned before, validity and time expenditure 
of COSARA as surveillance tool need to be reassessed if it is deployed in a different ICU setting. 
Advantages and limitations of the current COSARA concept as a surveillance tool are 
summarized in table 15. 
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Advantages and disadvantages of COSARA as surveillance tool 
Advantages 
 Use of a data visualization dashboard to promote information management and 
manual linking of antibiotic, clinical diagnostic and microbiology data 
 Surveillance is not limited to a selected subgroup of antibiotics or infections 
o Possibility to generate a global overview of antibiotic use 
o Non-dichotomous assessment of the presence of infection 
(captures spectrum of infection probability: low-intermediate-high) 
 Captures nuances, complex diagnostic info and clinical judgement 
 Allows to capture many-to-many relationships between antibiotics, infection 
diagnoses and microbiology (e.g. one infection can be treated by multiple antibiotics, 
one antibiotic can be used to treat multiple infections) 
 Information is stored as structured data 
 Easy and timely access to data warehouse 
Disadvantages 
 Substantial amount of manual input required 
o Dedication of physicians / healthcare personnel is mandatory 
o Subject to interrater variability and human error 
 Less suited as benchmarking tool 
 Infections not treated with antibiotics are not captured 
 




B. INVESTIGATION OF ANTIBIOTIC PRESCRIPTION AND ANTIBIOTIC RESISTANCE IN 
THE ICU TO SUPPORT THE DESIGN OF AN ASP 
COSARA is designed to support infection management in our ICU and ultimately, improve 
bedside patient care. The potential of COSARA as facilitator of antibiotic stewardship was clearly 
demonstrated throughout this PhD project by its ability to construct large longitudinal datasets 
on infection. As explained above, hospital ASP truly rely on monitoring for the identification of 
potential stewardship intervention targets and the subsequent evaluation of a stewardship 
action (figure 1).36 A descriptive analysis of a dataset covering four years of surveillance was 
performed to get a bird’s eye view of local antibiotic prescribing practices. Subsequently, we 
selected 3 ASP interventions that are recommended by the CDC for further exploration in our 
ICU. These general recommendations were reformulated to more specific ASP targets which 
were considered to be clinically relevant in our setting (table 16). Clear outcome measures for 
the selected antibiotic stewardship actions were defined and subsequently assessed by the use 
of COSARA. The results of these analyses enabled us to calculate presumed or actual impact of 
these stewardship actions. Until now, we have used this information mostly for research 
purposes and actual stewardship actions were not yet linked to our data. The next level of 
stewardship, active interference in the clinical workflow based on the aforementioned 
evaluations, falls out of the scope of this PhD project, and will be touched in the future 
perspectives section. 
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ASP interventions recommended by CDC Evaluation of targeted ASP interventions in 
Ghent University Hospital ICU 
Outcome measures extracted by means of 
COSARA 
Develop facility-specific treatment 
recommendations based on national 
guidelines and local susceptibility data 
Evaluation of: 
a) current empirical AB prescription in HAP 
b) added value of a facility-specific treatment 
guideline for empirical AB prescription in 
HAP 
c) added value of the incorporation of SC 
results in a facility-specific treatment 
guideline for empirical AB prescription in 
HAP 
a) Appropriate antibiotic coverage rate 
b) Consumption of broad-spectrum 
antibiotic agents 
Evaluate the possibility of using a more 
targeted antibiotic to treat an infection (de-
escalation) 
Evaluation of: 
a) determinants of de-escalation and 
escalation of empirical beta-lactam AB 
prescription 
b) the effect of de-escalation on patient 
outcome 
a) AB treatment duration / AB-free days 
b) Nosocomial infection 
c) Length of stay 
d) Mortality 
e) Emergence of antibiotic resistance 
Reassess the continuing need and choice of 
antibiotics 48 hours after antibiotics are 
initiated (antibiotic ‘time-out’) 
Evaluation of prolonged courses of 
glycopeptides, oxazolidinones and 
carbapenems 
Percentage of glycopeptide, oxazolidinone and 
carbapenem courses that is potentially 
unjustifiable 
Table 16: Summarizing overview of antibiotic stewardship program interventions that were explored 
ASP: antibiotic stewardship program; CDC: Centers for Disease Control and Prevention; ICU: intensive care unit; AB: antibiotic; HAP: hospital-acquired pneumonia; 




5.B.1 A complete and multifaceted overview of antibiotic use and infection diagnosis in 
the ICU 
Evaluation of antibiotic prescription in our ICU during a four-year period, revealed that 
consumption figures were high: 1232 DOT/1000 patient days; two-thirds of all ICU patients 
were exposed to at least one antibiotic class; one-third of patients with an ICU length of stay 
(LOS) of 48 h or more, were exposed to three or more antibiotic classes. The majority of studies 
on antibiotic use and infection diagnosis focus on a specific targeted antibiotic class or infection 
type. As a rule, a lot of attention is given to infections that are ICU-acquired, as these infections 
are considered to be (at least partially) preventable. In our setting, however, an infection was 
diagnosed within the first 48 h of admission in 54% of patients with an ICU LOS of 48 h or more. 
In general, these infections are considered to be acquired in the community or the hospital and 
as such they cannot be prevented by optimization of ICU care. On the other hand, we observed 
that a significant amount of our antibiotic consumption is used to treat infections with a 
moderate to low probability, and antibiotics were often started on an empirical basis in order 
not to miss a potentially treatable condition in an unstable patient. In order to reduce antibiotic 
exposure in this context, interventions in our ICU will need to focus more on enhancing 
diagnostic accuracy prior to the start of antibiotics and on the antibiotic trajectory following its 
initiation. As long as the use of rapid diagnostic tools is in its infancy, restricting antibiotic use 
‘upstream’ , however, will remain more challenging compared to ‘downstream’ restriction at a 
time when more diagnostic information becomes available. A systematic reevaluation of ongoing 
treatment need and duration, 48-72 h following the initiation of a treatment (‘antibiotic time 
out’), could thus serve as a meaningful stewardship action.35, 182 A more detailed calculation of 
the antibiotic sparing potential of this strategy was conducted for 3 selected antibiotic classes: 
carbapenems, glycopeptides and oxazolidinones (see below). 
Quite surprisingly, prophylactic treatment accounted for 25% of the overall antibiotic 
consumption. As guidelines on non-perioperative prophylaxis, e.g. prophylaxis following trauma 
or aspiration are not available in our ICU, we feel that implementation of guidelines on this 
matter may lead to a significant reduction in antibacterial use. As regards the antifungals, clear 
recommendations on the prophylactic use of azoles will probably significantly restrain its 
overall consumption. 
The unique intuitive approach of categorizing infections by its probability was once more 
stressed as an important prerequisite to permit data collection on global antibiotic consumption 
over prolonged periods of time. Although this strategy may complicate comparison between 
different centers, the detailed insight in overall antibiotic use is of inestimable value in the 
construction of an ASP. In addition, when required, inter-institution evaluation may be improved 
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by the additional use of a set of objective criteria such as laboratory and microbiology results 
and radiology reports when assessing specific types of infections. 
 
5.B.2 Empirical antibiotic prescription in hospital-acquired pneumonia and the added 
value of the use of surveillance cultures 
Analysis of 113 episodes of HAP, acquired in our ICU in the period between November 1st 2010 
and October 31st 2012, learned that causative pathogens were mainly Gram-negative (84%). 
Clinical risk factors for the involvement of MDR pathogens were present in 87.6% of HAP 
episodes. These finding are not surprising given the complex history of our patients with 
frequent prior hospitalization and antibiotic exposure. It emphasizes however, that the choice of 
an adequate antibiotic treatment is challenging in the absence of diagnostic culture results. Over 
the last few years, the use of systematic SC was incorporated into our clinical workflow, aiming 
to predict involvement of MDR pathogens and to guide empirical antibiotic choice.87 
As outlined before, our study evaluated the potential of a formal treatment algorithm based on 
local ecology data in our ICU (LEBA). Furthermore, we assessed the added value of incorporating 
SC results in such an algorithm (SCBA). We pursued at least 85% appropriate coverage rate 
when constructing both algorithms. While this number is somewhat arbitrarily, we aimed to set 
a rate which is in the highest range of what is practically achievable yet avoids non-
discriminative combination therapy. There is increasing appreciation of the fact that aiming for 
maximal coverage rates may no longer be justified if this is at the expense of inducing further 
resistance and jeopardizing our future empirical treatment possibilities.183 At our center, 
maximal appropriate coverage rates would only be possible with the non-discriminative use of 
aminoglycoside combination schemes: apart from ecological issues, this may not lead to better 
patient outcome.184 
LEBA and SCBA were retrospectively applied on the cohort of 113 HAP episodes. Appropriate 
antibiotic coverage rate did not differ significantly between the actual prescribed treatment 
(84.1%), the antimicrobial choices that were proposed by LEBA (88.5%) and those suggested by 
SCBA (87.6%). In other words, it is unlikely that appropriateness of empirical treatment will be 
influenced by the implementation of the proposed treatment algorithms. However, major 
differences were seen when evaluating the spectrum of the administered or proposed treatment 
schemes. LEBA suggested to use significantly more combination therapy and carbapenems 
compared to SCBA. Eliminating the use of aminoglycosides and glycopeptides in the LEBA would 
lead to a reduction in appropriate coverage rate from 88.5% to 81.4% (p=0.008) (unpublished 




not significantly differ from the use that was proposed by SCBA (respectively, 13.3% versus 
7.1% (p=0.12) and 15.9% versus 21.2% (p=0.35)) (unpublished results). SCBA does not 
recommend the use of combination therapy, unless this is motivated by the presence of MDR 
pathogens in the SC results. These results suggest that physicians in our ICU already rely upon 
the high negative predictive value of SC and withhold broad-spectrum therapy in the absence of 
MDR. 
As compared to actually prescribed treatment, strict adherence to SCBA would reduce 
administration of broad-spectrum therapy even more. It is important, however, to recognize that 
the scale we constructed to quantify the spectrum of the antibiotic treatment is artificial. Until 
now, there is no general consensus on the spectrum and resistance promoting potential of 
individual antibiotic regimens nor on combinations thereof. We ranked combination therapy 
and carbapenems respectively highest and second highest, in accordance with the prevailing 
opinion in the current literature.176, 177 Ranking of the remaining antibiotic agents proved to be 
more challenging. Our ranking of beta-lactam antibiotics is in line with the consensus definition 
of an international expert panel.177 The position of fluoroquinolones on the other hand may be 
challenged. As fluoroquinolone treatment comprised only 10% of empirical antibiotic choices, 
altering its position on the scale will probably not affect main study results. 
To definitively confirm or refute whether the implementation of an empirical antibiotic 
algorithm would have benefit in terms of appropriate coverage and antibiotic consumption, a 
prospective study is needed. Barriers and facilitators of a physician’s adherence to the algorithm 
will need to be assessed as these will influence performance status of the algorithm. The future 
role of COSARA as an active computerized clinical decision support system (CDSS) interfering 
with empirical antibiotic decision-making at the point of care, provides another intriguing new 
field of research (see future perspectives). 
 
5.B.3 Local antibiotic de-escalation practices and impact on the emergence of antibiotic 
resistance 
De-escalation is an appealing antibiotic stewardship strategy as it permits the empirical use of 
broad-spectrum agents up until the moment that more clinical, diagnostic and microbiological 
information becomes available. For years, de-escalation has been widely promoted in our ICU. 
The possibility to de-escalate an empirical treatment is evaluated and encouraged on daily ward 
rounds and during multidisciplinary discussions with clinical microbiologists and infectious 
diseases specialists. Publication of the first multicenter randomized non-inferiority trial in 2014 
by Leone et al., comparing de-escalation with continuation of therapy triggered a discussion 
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(that is still ongoing) regarding the safety of this strategy.95 Unexpectedly, de-escalation was 
inferior to continuation of treatment in terms of ICU LOS. Additionally, de-escalation was 
associated with an increased number of superinfections in this non-blinded trial. This study was 
not designed to evaluate the effect on microbiological selection pressure. As the ecological 
impact of de-escalation was a largely unexplored domain, we decided to assess the emergence of 
antibiotic resistance following de-escalation through analysis of the COSARA dataset combined 
with routine SC results. The results of our trial, including longer treatment durations in de-
escalated patients and no impact of de-escalation on emergence of antibiotic resistance, were 
unforeseen and added to the vivid discussion that was initiated earlier. 
As for all studies on de-escalation, our results need to be evaluated in the light of the definitions 
that were used. A ranking system of antibiotic agents by increasing order of Gram-negative 
spectrum was created and a movement down on this scale was perceived as antibiotic de-
escalation. De-escalation was performed in only 25% of anti-pseudomonal beta-lactam antibiotic 
prescriptions, consisted mainly of replacement of one antibiotic by another with a smaller 
spectrum and was significantly associated with the identification of an etiological pathogen. 
However, based on the susceptibility data of the presumed etiologic pathogen, 67% of continued 
treatments for microbiologically documented infections could have been de-escalated according 
to our ranking system. Clinical appreciation may have influenced the subjective decision 
whether or not to de-escalate. To identify these barriers for de-escalation, however, one would 
need a prospective study with interviewing. 
Both emergence of resistance to the initial beta-lactam antibiotic and emergence of MDR were 
explored. The visual aspect of the cumulative incidence functions curves suggests increased 
emergence of resistance associated with de-escalation, although this did not reach statistical 
significance. Two additional subgroup analyses, one in patients with microbiologically 
documented infections and one in patients with a treatment duration of more than 5 days, 
showed that the trend towards more resistance in de-escalation versus continuation 
disappeared altogether. It is likely that the inclusion of a higher number of short antibiotic 
exposures in the continuation group introduced bias in the original analyses. As such, we 
hypothesized that emergence of resistance appears to be directly related to overall antibiotic 
exposure. 
In conclusion, from our analysis, it is clear that in real life (for which observational data are 
arguably more appropriate than controlled trials), the ecological benefits of de-escalation may 
be less than what theoretically could be expected. Its effects may be diluted by numerous other 
factors in the complex setting of intensive care and, moreover, may be offset by unintended 




that the overall larger total antibiotic exposure that we observed in de-escalation episodes may 
not be due to slower resolution of infection but rather to the physician’s perceptions and 
behavior. In this regard, we also speculate that the higher number of superinfections observed in 
the de-escalation arm of the randomized, controlled, but unblinded trial by Leone et al. could be 
due to different judgement of the physician, biased by knowledge of the de-escalation status: i.e., 
larger uncertainty lowering the barrier for restarting antibiotics. The major problem involved in 
all antibiotic overuse in healthcare is uncertainty about whether infection is present, which 
pathogens are involved, and what amount of antibiotic therapy is necessary to give the patient 
the best chance for a favorable outcome. 
We believe that, in order to limit the emergence of resistance, antibiotic use should be restricted 
on several fronts. Targeting empirical antibiotic therapy to local flora or patient’s colonizing 
status, withholding antibiotics in low-probability infections, shortening overall antibiotic 
courses, and optimizing pharmacokinetics/pharmacodynamics may have more effect than de-
escalation in the narrow definition (see future perspectives). Probably, de-escalation has a place 
in longer antibiotic courses; yet, exactly how this has to be done (which antibiotic, which dose, 
which timing and duration) requires further study. 
 
5.B.4 Facilitation of internal stewardship decision-making: identification of potentially 
unjustified prolonged antibiotic treatment courses 
Uncertainty about the presence of an infection in its early phase and the potential involvement 
of MDR pathogens, has become a recurring theme throughout this thesis. ICU physicians often 
err on the side of caution in the critically ill patient with suspected infection and as a result the 
threshold to start antibiotics is rather low. Curtailing overall antibiotic consumption, however, 
has shown to be primordial in the fight against antibiotic resistance. Over the last few years the 
focus of the CDC shifted from merely reducing the antibiotic spectrum to a more global antibiotic 
treatment optimization.29, 91 Clinicians are encouraged to do a systematic reevaluation of 
ongoing treatment need, duration, antibiotic spectrum and dosing, 48-72 h following the 
initiation of an antibiotic treatment (‘antibiotic time out’).35, 182 
Over a four-year period, we calculated the percentage of potential overuse of carbapenems, 
glycopeptides and oxazolidinones. We defined 4 categories of potentially unjustified antibiotic 
use; (1) prolonged prophylactic therapy, (2) prolonged therapy in low probability infections, (3) 
prolonged empirical therapy (negative diagnostic cultures) in moderate/high probability 
infections and (4) prolonged broad-spectrum therapy in microbiologically confirmed infections 
when de-escalation is possible based on susceptibility results of causative pathogens. Merging of 
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antimicrobial prescription data, microbiology data and diagnostic information was essential to 
enable the drill-through-to-detail analysis which was needed to calculate the percentage 
potentially unjustifiable courses. We found that up to one third of the carbapenem DOT/patient-
days was deemed to be redundant, compared to 13% of glycopeptides/oxazolidinones 
consumption. The toxicity profile of prolonged glycopeptide and oxazolidinone use driving the 
physician to earlier omission of these agents once culture results become available or remain 
negative, is only one possible explanation for this observation. It is again important, however, to 
acknowledge the fact that many factors may influence a physicians’ prescribing behavior which 
may not have been captured in this study. The actual savings in antibiotic use after 
implementation of this ‘antibiotic time out’ may eventually turn out to differ from what is 
anticipated by our calculations. Our results on the other hand guide potential future stewardship 
actions by giving an estimate of the maximum gain that is potentially achieved by a successful 




C. THE ROLE OF DATA VISUALIZATION THROUGH COSARA 
Aggregation of all infection related data and presentation of this information in a clear overview 
aims to improve adequate antibiotic decision-making. Previous reports suggest that merely 
presenting data in an orderly and comprehensive manner at the point of care may improve the 
performance status of the physician. Evaluation of the clinical impact of data visualization 
through COSARA, however, is not straightforward. A retrospective analysis comparing antibiotic 
prescribing practices before and after the implementation of COSARA seems to serve little 
purpose. First of all, important shifts in antibiotic prescription have taken place over the past 
few years, driven by multiple factors that may confound our results. In addition, relevant 
performance metrics e.g. adequacy of empirical antibiotic prescription, antibiotic treatment 
duration, the emergence of antibiotic resistance or the acquisition of superinfections are very 
difficult to capture longitudinally without the use of an ESS. The fact that detailed, longitudinal 
data collection was not in place before the implementation of COSARA hampers meaningful 
retrospective research. The design of a randomized controlled trial to explore the effect of data 
visualization raised further concerns; conceptual issues such as the inability to blind physicians 
and the risk of introducing bias when randomizing physicians or patient (ICU) populations, but 
also ethical issues such as withholding important information that is uniquely captured through 
COSARA to a treating physician. Intuitively, the use of clinical dashboards could have improved 
infection management in our ICU, however until now, clear evidence to confirm this assumption 






“I think the biggest innovations of the 21st century will be at the intersection of biology 
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6 FUTURE PERSPECTIVES 
A. FACILITATION OF THE IMPLEMENTATION PROCESS OF STEWARDSHIP 
INTERVENTIONS 
In the introduction of this thesis we outlined the crucial steps in the implementation process of a 
stewardship intervention (figure 1). Until now, our research has focused on monitoring and the 
use of large longitudinal datasets to design an ASP. The potential future role of COSARA in the 
actual implementation of a stewardship action, reporting and education will be touched in the 
next section. 
 
6.A.1 Active clinical decision support to enhance implementation of a stewardship 
intervention 
Clinical decision support systems (CDSS) are computer systems designed to optimize clinical 
decision-making at the point of care.185-187 Correct antibiotic prescribing has proven to be a 
complex task, especially in the critically ill patient, which requires interpretation and integration 
of information from different sources and formats. In addition, this process is often hampered by 
a high degree of uncertainty about the probability of infection, its focus and the causative 
pathogen. The potential of CDSS in antibiotic stewardship is recognized by infectious diseases 
societies and further development is encouraged.188 Over the last few years we have seen a rapid 
growth in the number of CDSS.185, 189 These systems range from basic electronic prescribing 
systems to more advanced decision support tools. The COSARA software lends itself for further 
development of more complex decision support tasks. In table 17 we list some suggested active 
interventions in continuation of the ASP interventions that were explored throughout this PhD 
project (table 16). The interventions are divided in general-theoretical, institution specific and 
patient specific support. Implementation of each of these interventions must be prepared 
carefully to increase its chances of success. Additionally, close monitoring after implementation 
is paramount. 
An increased use of COSARA by less experienced end-users and a more active role in antibiotic 
stewardship, entails some important considerations and responsibilities. We need to 
acknowledge that until now, COSARA is no commercially available software package. The 
software will need continuous development, frequent updates and a swift clearance of bugs to 




the system. Furthermore, efforts to increase accessibility and user-friendliness of COSARA will 
have to be made to maximize its potential benefit. 
Potential future antibiotic stewardship program interventions 
General-theoretical support 
Provide easy accessible hyperlinks to educational content: 
 Spectrum of activity per antibiotic agent 
 Toxicity profile per antibiotic agent 
 Intrinsic resistance to antibiotic agents per pathogen 
 Websites of key organizations in critical care, infection and microbiology 
 Landmark papers on critical care, infection and microbiology 
Institution specific support 
Provide easy accessible hyperlinks to institution specific guidelines: 
 Per infection diagnosis: CAP, HAP, urinary tract infection, meningitis, candidemia, etc. 
 Per antibiotic agent:  
o Dosing and therapeutic drug monitoring advice 
o Ranking with de-escalation advice in case of known susceptibility results 
Provide access to executive summary reports on: 
 Local antibiotic consumption 
 Local resistance patterns per pathogens and/or linked infection type 
Patient specific support 
Present treatment algorithm and recent SC to the prescribing physician after completion of 
the pop-up questionnaire in case of a respiratory infection 
Alert as soon as diagnostic culture results and susceptibility patterns become available 
Suggest the use of institution specific hyperlinks based on patient’s specific diagnosis, 
administered antibiotic agents and known microbiology results 
Alert on day 3 following treatment initiation (‘antibiotic time-out’) 
Suggest thorough re-evaluation of ongoing treatment need on day 3 following treatment 
initiation in case of: 
 prophylactic therapy 
 low probability infection 
 negative diagnostic cultures 
Table 17: Overview of potential future antibiotic stewardship program interventions 
CAP: community-acquired pneumonia, HAP: hospital-acquired pneumonia; SC: surveillance culture 
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6.A.2 Education and reporting 
Regular reporting of information on antibiotic prescription and antibiotic resistance to 
physicians, nurses and other healthcare personnel is recognized as an important component of 
antibiotic stewardship.29, 190 Information can be communicated through e.g. educational sessions, 
interdisciplinary staff meetings and repetitive email correspondence. Regular database queries 
can be performed and provide the essential information. However, it is important to realize that 
merely extracting the data from COSARA and presenting this information to healthcare workers 
will probably not lead to improved clinical care. Additional data processing followed by a 
multidisciplinary assessment of these results will be needed. It has been demonstrated that 
education needs to be combined with active stewardship interventions to attain the desired 
effects.91 
One-on-one education and individualized feedback may influence antibiotic prescribing even 
more profoundly.29, 191, 192 To increase acceptance of these stewardship practices, it is important 





B. INVESTIGATION ON THE CAUSAL RELATION BETWEEN INFECTION, ANTIBIOTIC, 
MICROBIOLOGY AND OUTCOME THROUGH ANALYSIS OF DETAILED DATASETS 
Electronic health records (EHR) offer the potential to document the process of care in a 
longitudinal and detailed way. Through the use of COSARA we were able to compile a 
comprehensive relational dataset on antibiotics, infection and microbiology. High-quality data 
are available since January 1st 2013 and collection will continue in the future. The large volume 
of data offers the opportunity to acquire actionable insight into the complex relationship 
between antibiotic, infection, microbiology and selected outcome measures. Our data are 
observational and therefore causal inference is challenging. More advanced statistical models, 
adjusting for time-varying confounding and complex feedback relationships are required.193 
Close collaboration between statisticians and physicians is essential to produce valid and 
meaningful results. 
Prior cooperation between the Department of Applied mathematics, computer science and 
statistics and the ICU of the Ghent University Hospital focusing on the causal analysis of 
longitudinal ICU data, provided controversial, new knowledge on the attributable mortality of 
VAP.193, 194 The COSARA dataset permits high level follow-up research in this field. 
 
C. ASSESSMENT OF ANTIBIOTIC PRESCRIBING BEHAVIOR 
The concept of antibiotic stewardship was already introduced more than 20 years ago. However, 
until now, the problem of antibiotic resistance is still far from being contained and many 
interventions fail to produce sustainable positive effects. In his lecture series, the future of 
medicine, the US surgeon Dr. Atul Gawande stated that failure in medicine is more likely to be 
the result of ineptitude (our inability to deliver on existing knowledge) than it is due to 
ignorance (our lack of knowledge).There is a growing awareness that personal views and social 
context may have a huge impact on antibiotic prescribing behavior. In order to achieve the 
desired stewardship results these aspects deserve more attention.195, 196 COSARA may facilitate a 
better understanding of the key drivers of prescribing behavior through active querying of 
prescribers in selected treatment scenarios. As such, we can not only detect certain 
implementation barriers of stewardship interventions, but we can also try to adjust these 
interventions to ensure that they are in line with local practices, needs and expectations. A close 
collaboration between ICU physicians, software engineers and researchers in the behavioral and 
social sciences will be required. 
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7 ADDITIONAL SCIENTIFIC ABSTRACTS AND PUBLICATIONS 
RELATED TO THE SUBJECT OF THE THESIS 
A. ABSTRACTS PRESENTED AT NATIONAL AND INTERNATIONAL CONGRESSES 
 
7.A.1 Can we still use beta-lactam antibiotic monotherapy in complicated intra-
abdominal infection? 
 
Isabel De Baere, Liesbet De Bus, Pieter Depuydt, Jan De Waele, Geert Claeys 
 
Poster presented at the 33rd Annual Meeting of the Belgian Society of Intensive Care Medicine. 
Brussels, June, 2013 
 
Introduction: 
Beta-lactam antibiotics with activity against anaerobic bacteria are the cornerstone of empirical 
and targeted therapy for complicated intra-abdominal infections (cIAI). However, increasing 
prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae, both in 
community and hospital-acquired infections, and of beta-lactam-resistant enterococci and 
staphylococci, in hospital-acquired infections, may challenge their appropriateness as empirical 
therapy. 
Objectives: 
Comparison of susceptibility of pathogens involved in cIAI to beta-lactam antibiotics in a 2011-
2012 dataset with previous data from 2005-2006. 
Methods: 
We studied antimicrobial susceptibility, as reported from disk diffusion antibiograms, of 
pathogens isolated from intra-operative, sterile puncture or blood cultures in patients with cIAI 
admitted to the medical and surgical ICU of Ghent University Hospital in 2011-2012. We 
compared these recent findings to susceptibility of cIAI pathogens from a 2005-2006 dataset. 




meropenem. We distinguished between community-acquired and hospital-acquired cIAI. We 
calculated rates of appropriate coverage by amoxicillin-clavulanic acid or piperacillin-
tazobactam monotherapy in community-acquired cIAI and of piperacillin-tazobactam or 
meropenem monotherapy in hospital-acquired cIAI. Appropriate coverage required that all 
pathogens isolated were susceptible to the administered antibiotic. Enterococci and coagulase-
negative staphylococci were considered as pathogens in hospital-acquired cIAI only. 
Results: 
A total of 132 pathogens were identified in 81 patients admitted in 2011-2012; 45 episodes 
were polymicrobial. Pathogens involved in community-acquired infection (Gram-negatives only, 
n=22) were susceptible for amoxicillin-clavulanic acid in 78%, for piperacillin-tazobactam in 
93% and for meropenem in 100%. Pathogens involved in hospital-acquired infection (Gram-
negatives, n=84, and Gram-positives, n=26) were susceptible for amoxicillin-clavulanic acid in 
45%, for piperacillin-tazobactam in 72% and for meropenem in 88%. Amoxicillin-clavulanic acid 
and piperacillin-tazobactam monotherapy would have adequately covered 86% , respectively 
93% of community-acquired infections in 2011-2012. Coverage rates of amoxicillin-clavulanic 
acid and piperacillin-tazobactam monotherapy for community-acquired infections in the 2005-
2006 dataset (n=39) were 81%, respectively 88%. Amoxicillin-clavulanic acid, piperacillin-
tazobactam and meropenem would have adequately covered 37%, respectively 73% and 93% of 
hospital-acquired infections in 2011-2012; coverage rates of amoxicillin-clavulanic acid, 
piperacillin-tazobactam and meropenem monotherapy for hospital-acquired infection in the 
2005-2006 dataset were 43%, respectively 74% and 87%. 
Conclusions: 
Susceptibility of cIAI pathogens for beta-lactam antibiotics has remained fairly constant over the 
last five years in our tertiary care hospital. Empirical monotherapy with a beta-lactam antibiotic 
is still a viable option in cIAI as piperacillin-tazobactam for community-acquired and 
meropenem for hospital-acquired cIAI. Subsequent de-escalation of piperacillin-tazobactam to 
amoxicillin-clavulanic acid and of meropenem to piperacillin-tazobactam would be possible in 
the majority of microbiologically documented cases.
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7.A.2 VAP: microbial etiology and outcome 
 
Arif Karakaya, Liesbet De Bus, Bram Gadeyne, Johan Decruyenaere, Pieter Depuydt 
 
Poster presented at the 34th Annual Meeting of the Belgian Society of Intensive Care Medicine. 
Brussels, June, 2014 
 
Introduction: 
A definite diagnosis of ventilator-associated pneumonia (VAP) requires the identification of a 
microbial pathogen as likely cause of the infection. However, in daily clinical practice at the 
Intensive Care Unit (ICU), antibiotics are commonly prescribed for a clinical suspicion of VAP in 
the absence of an identifiable microbial cause. 
Objectives: 
We compared clinically suspected VAP with documentation of a likely microbial etiology and 
suspected VAP without microbiological documentation. 
Methods: 
This study was a retrospective analysis of prospectively collected data between July 1st 2010 and 
February 28th 2014 in the 36-bed medical and surgical ICU of Ghent University Hospital. We 
prospectively registered the indication of all antibiotic prescriptions in ICU admitted patients 
with the aid of the software program COSARA. A clinical suspicion of VAP as reason for the 
antibiotic therapy required the presence, in a patient ventilated for at least 48 h, of a new or 
worsening chest infiltrate together with at least two of the following conditions: (1) fever >38.3 
°C, (2) leucocytosis >12.000/µl, (3) worsening gas exchange, (4) purulent endotracheal 
secretions. Microbiological documentation required the presence of a pathogen at least growing 
1+ semiquantitatively in a good quality endotracheal aspirate or bronchoalveolar lavage fluid 
specimen, or isolated from a blood culture at the time of clinical suspicion. Only the first episode 
of VAP was considered for analysis. 
Results: 
VAP was clinically suspected in 473 patients, with microbiological confirmation in 250 (53%). A 
non-fermenting pathogen (NFP) was identified in 84 VAP episodes (18%). Probability of 




with and without microbiological confirmation (p<0.001). Duration of antibiotic therapy was 
significantly longer in microbiologically confirmed VAP (7d (5-11) vs. 6d (3-8) (p<0.001)). In 
patients with and without microbiological confirmation, the number of patients with severe 
sepsis (15% vs. 10%) or septic shock (16% vs. 11%) was not significantly different (Chi-squared 
test p=0.12). 
ICU mortality was 29% in patients with and 30% in patients without microbiological 
confirmation (p=0.77) and length-of-stay following VAP diagnosis was 13 (6-22) days and 13 (6-
23) days (p=0.8), respectively. Comparing NFP VAP with all other episodes, we found 
significantly increased mortality (43% vs. 27%, p=0.003) and similar length-of-stay (12 (6-23) 
days and 13 (6-23) days, p=0.75). After adjustment for severity of infection (sepsis, severe 
sepsis, septic shock), ICU-mortality was not statistically different between patients with VAP 
with or without microbiological confirmation, but was significantly higher in NFP VAP patients 
(OR 1.9 (p=0.014). 
Conclusion: 
In our center, microbiological confirmation increased the clinician’s confidence in the diagnosis 
of VAP and was associated with a longer duration of antibiotic therapy. A NFP as likely pathogen 
was associated with increased mortality.
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7.A.3 Antibiotic prescription during weekday, night and weekend shifts 
 
Joris Vermassen, Liesbet De Bus, Bram Gadeyne, Johan Decruyenaere, Pieter Depuydt 
 
Poster presented at the 27th Congress of the European Society of Intensive Care Medicine. 
Barcelona, October, 2014 
 
Introduction: 
Antibiotic prescription in the ICU is complex and may be influenced by organizational factors as 
well as prescriber’s subjectivity. During night shifts and weekend shifts, antibiotic prescription 
may be different from that of weekday shifts due to time pressure, less in-depth knowledge of 
complex patient files, or lower availability of up-to-date microbiological information. Knowledge 
of physician’s prescription behavior may help to identify potential areas for antibiotic 
stewardship interventions. 
Objectives: 
To compare total antibiotic prescription and type of antibiotic prescribed between weekday 
shifts, night shifts and weekend shifts in a large medical and surgical ICU. 
Methods: 
From January 1st 2013 to March 31st 2014, all antibiotic prescriptions for newly diagnosed 
infections at the 36 bed ICU of the Ghent University Hospital were prospectively registered with 
the aid of the software program COSARA. COSARA was developed to assist the ICU physician in 
collecting data about antibiotic prescriptions and infection characteristics of ICU patients. 
Combination therapy was defined as beta-lactam plus a quinolone, glycopeptide or 
aminoglycoside. Time of prescription was defined as weekday shift (Monday to Friday 8 am to 6 
pm), night shift (Monday to Friday 6 pm to 8 am) and weekend shifts (from Friday 6 pm to 
Monday 8 am or on holidays). 
Results: 
A total of 1921 infections requiring antibiotic therapy were identified. Total antibiotic 
prescriptions amounted to 3.12/12 h during weekday shifts, 1.2/12 h during night shifts and 
2.4/12 h during weekend shifts. Of these, 25.8 % were associated with severe sepsis or septic 




weekend shifts (p = 0.003). Carbapenems and piperacillin-tazobactam made up 10.2 %, 
respectively 31 % of weekday prescriptions, as compared to 14.7 %, respectively 41.7 % of night 
and 10.1 %, respectively 35.6 % of weekend prescriptions (p = 0.022 for carbapenems, p = 0.002 
for piperacillin-tazobactam). The percentages of other antibiotics or of combination therapy did 
not differ between the three time periods. In a bivariate analysis, carbapenem prescription was 
associated with severe sepsis (OR 2.791; p < 0,001) and septic shock (OR 2.628; p < 0,001), but 
not with time of prescription. In contrast, piperacillin-tazobactam prescription was associated 
with night shift (OR 1.602; p = 0.005), severe sepsis (OR 2.735; p < 0.001) and septic shock (OR 
3.443; p < 0.001). 
Conclusions: 
In our ICU, prescription of carbapenems and piperacillin-tazobactam was more frequent in night 
shifts as compared to weekday and weekend shifts. Prescription of piperacillin-tazobactam was 
associated with night shifts when corrected for severity of infection.
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7.A.4 Colonization/infection by ESBL producing Enterobacteriaceae in ICU 
 
Hannah Schaubroeck, Liesbet De Bus, Bram Gadeyne, Jerina Boelens, Pieter Depuydt 
 
Poster presented at the 37th Annual Meeting of the Belgian Society of Intensive Care Medicine. 
Brussels, June, 2017 
 
Introduction: 
Extended spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) are increasingly 
cultured from patients admitted to the intensive care unit (ICU) worldwide.88, 197, 198 Detailed 
epidemiological data are necessary to assess the impact of ESBL-E in critically ill patients and to 
evaluate the role of ICU admission in the acquisition of these strains. 
Objectives: 
We provide a detailed epidemiology of ESBL-E colonization and infection in a mixed adult 
tertiary ICU population over an 18-month period. We distinguish between import and 
acquisition in the ICU by taking into account the timing of the first ESBL-E positive culture. 
Methods: 
We retrospectively analyzed clinical and microbiological data from adult patients admitted to 
the ICU of Ghent University Hospital between July 2014 and December 2015. Patients who were 
hospitalized for at least 48 h or who died in the ICU and who had one culture or more yielding 
ESBL-E were included. All data were prospectively collected using the COSARA software 
providing linkage between microbiological and clinical data. ESBL-E cultures were considered as 
early acquired/imported or late acquired when they were isolated within, respectively after two 
calendar days of ICU admission. 
Results: 
Out of a total population of 1671 patients, 239 (14.3%) had ESBL-E cultured. In ESBL-E positive 
patients, ESBL-E was classified as early acquired/imported in the ICU in 69%. The most 
prevalent ESBL-E species were Escherichia coli (80%) and Klebsiella pneumoniae (11%). In 
ESBL-E positive patients, antibiotic therapy for presumed infection was prescribed in 176 
(73.6%); in 105 patients, a causative pathogen was identified, which was ESBL-E in 36 (15% of 




the respiratory tract (53%), intra-abdominal cavity (18%) and urogenital tract (8%); for 
infection caused by ESBL-E, these foci accounted for respectively 33%, 31% and 19%. In ESBL-E 
positive patients, ICU mortality rates in patients with infection caused by ESBL-E and other 
pathogens were not significantly different (17% and 14%, respectively). 
Conclusions: 
In our ICU, ESBL-E are mainly acquired early or imported, and their contribution to infection 
appears to be limited.
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Introduction: 
Early postoperative respiratory complications (EPRC) are common in cardiac surgery patients 
and empirical antibiotic therapy is frequently prescribed for this indication. Antimicrobial 
stewardship demands restriction of empirical antibiotic therapy in non-infectious EPRC and a 
good match of empirical choice to local microbiological flora. To assess whether an antimicrobial 
stewardship intervention might be warranted, we performed a retrospective analysis of 
antibiotic therapy for presumed EPRC in our cardiac surgery intensive care unit (CSICU). This 
included an estimation of the probability of infection in EPRC treated with antibiotics and an 
assessment of pathogen susceptibility to empirical antibiotic therapy. 
Methods: 
With the help of the software program COSARA, all antibiotic prescriptions in patients admitted 
to the ten beds CSICU of Ghent University Hospital in 2016 were prospectively recorded, 
including a preliminary notification of the indication. Presumed infectious EPRC was defined as 
any antibiotic prescriptions within 72 h of cardiac surgery with a preliminary notification as 
‘respiratory infection’: these were retrospectively classified as postoperative pneumonia of 
respectively high, moderate and low probability, or as tracheobronchitis; in addition, the 
absence or presence of diagnostic microbiological cultures was noted and in vitro susceptibility 
of isolated pathogens to empirical antibiotics was assessed. 
Results: 
Out of a total of 814 patients admitted to CSICU following cardiac surgery, 118 (14.5%) had 
presumed infectious EPRC. Of these episodes, 17 (14.4%), 22 (18.6%) and 56 (47.5%) were 
classified as pneumonia of high, respectively moderate and low probability, and 23 (19.5%) as 
tracheobronchitis. The most frequently prescribed antibiotics in presumed infectious EPRC were 




Diagnostic microbiological cultures were available in 64 (54%) patients: in 26 (22%), only 
commensal flora was found. The most frequent pathogens were Enterobacteriaceae and 
Pseudomonas spp., present in respectively 21 and 9 patients. Empirical antibiotic therapy was 
appropriate in 49 (77%) patients and had a too broad spectrum in 34 (53%) patients. 
Conclusions: 
In our CSICU, more than half of EPRC treated with antibiotics could be classified as pneumonia of 
low probability or as tracheobronchitis, where the benefit of antibiotic therapy is probably 
limited. On the other hand, empirical antibiotics only had a moderate match with identified 
microbial pathogens. Both aspects of antibiotic therapy might benefit from an antibiotic 
stewardship intervention.
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Introduction: 
Antibiotics are life-saving drugs and among the most important therapeutic weapons of the 
intensive care unit (ICU) physician. In severe bacterial infection, community-acquired, 
healthcare-associated and hospital-acquired, timely administration of antibiotic therapy active 
against the causal pathogen is one of the main determinants of a favorable patient outcome. On 
the other hand, it is an undeniable fact that antibiotics need to be used judiciously, as the 
induction and rapid spread of resistance threatens to reduce their lifespan. Trying to spare our 
current antibiotic armamentarium has become urgent, as development of new antibiotics has 
lagged completely behind the emergence of resistance.199 As such, the ICU physician faces a daily 
dilemma: Using antibiotics may improve individual patient outcome (inasmuch as clinical 
deterioration is due to bacterial infection), but will induce selection pressure and potential harm 
to future patients or to the same patient in the future, whereas withholding antibiotics will avoid 
selection pressure but may put the individual patient at increased risk of harm caused by an 
untreated infection. This dilemma is made worse by the fact that, in critically ill patients, clinical 
presentation of hospital-acquired infection may be subtle or atypical at the time when the 
decision of whether or not to start antibiotics has to be made. Moreover, at that time, the 
causative pathogen is usually not identified but assumed to be potentially resistant to multiple 
antibiotics. These uncertainties lead ICU physicians to err on the side of caution for the 
immediate benefit of the individual patient and to accept a certain overuse of broad-spectrum 
antibiotics. However, as the ecological impact of antibiotic consumption is escalating, efforts 
have been made to reconcile maximum short-term patient safety (the least number of ‘missed’ 
infections or ‘missed’ pathogens) with a reduction in overall antibiotic use. 
As no biomarkers have been identified that can reliably distinguish bacterial infection from 
other disease at an early stage, the general approach to antibiotic decision-making in the ICU is 
that of an upfront broad-spectrum regimen followed by de-escalation. Basically, this strategy 




clinical suspicion of infection, covering a wide spectrum of potential pathogens and resistance 
mechanisms, and subsequently reevaluating when microbiological data become available. This 
reevaluation considers whether there is a need to continue antibiotic therapy and, if so, whether 
the initial broad-spectrum antibiotic can be replaced by a narrower-spectrum drug tailored to 
the identified causal pathogen but causing less selection pressure.80 The main concept 
underlying this approach is to strike a balance between immediate patient safety (‘more 
antibiotics’) and preserving ecology (‘less antibiotics’) at each time point, using all the 
information that progressively becomes available.200 Although this strategy sounds attractive 
and logical, there is general agreement that antibiotics are overused in critical care. Indeed, 
many empirical antibiotic treatments include broad-spectrum agents and de-escalation is 
performed in only a minority of patients; overall treatment duration is also often longer than 
deemed necessary. Antibiotic stewardship programs have been introduced to counter these 
trends and have been advocated by several societies. Practical implementation of these concepts 
at the bedside is difficult, however. In this chapter, we propose a time-based approach to 
antibiotic use including the concept of dynamic reevaluation, and we present four key time 
points at which to (re)consider antibiotic therapy in the ICU (Fig. 17). In this way, antibiotic 
stewardship philosophy is integrated into the clinical decision-making process. 
 
Fig. 17 Opportunities for stewardship during antibiotic decision-making in the ICU 
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Time point 1: Day 0 – start of empirical antibiotic therapy 
Obviously the start of empirical therapy is a first crucial moment of the antibiotic course. The 
first hurdle to take in an ICU environment is to distinguish sepsis, severe sepsis or septic shock 
from a systemic inflammatory response syndrome (SIRS) (with or without one or more organ 
dysfunctions) caused by a non-infectious condition, e.g., in surgical, burn, pancreatitis and 
trauma patients. If the infectious origin is obvious, there is no doubt that initiation of antibiotics 
should be an integral component of early treatment. There may be situations, however, in which 
the infectious origin of the clinical picture is not (yet) clear, and antibiotics may be withheld. The 
Surviving Sepsis Campaign (SSC) recommendation is largely based on a retrospective cohort 
study of septic shock patients in which mortality increased per hour delay in administration of 
adequate antibiotic therapy201, and should not be lightly extrapolated to patients without septic 
shock. A recent meta-analysis that included 11,017 patients with severe sepsis or septic shock 
could not confirm the mortality benefit of starting antibiotics within 1 h of shock recognition and 
challenges the current SSC recommendation.202 A multicenter randomized controlled trial (RCT) 
suggested that the exact timing of antibiotics may be less important when early aggressive 
resuscitation is achieved.203 These data support the concept that prompt resuscitation is 
primordial in any unstable patient, but also that a watchful waiting strategy regarding antibiotic 
administration beyond the proposed 1 h timeframe may be safe in selected patients when the 
likelihood of infection is low. 
Fears of missing this window of presumed opportunity for life-saving treatment and peer as well 
as societal pressure to start antibiotics, together with the difficulties in the early recognition of 
infection, may tempt the physician to take the ‘safe and easy’ path and start antibiotic therapy 
from the moment a suspicion of infection is raised. Essentially, the SSC recommendations are for 
patients who present with severe sepsis or septic shock. On the other hand, patients can suffer 
from an obvious infection, e.g., peritonitis due to gastrointestinal perforation, without the 
necessary SIRS criteria, and the need for early antibiotic treatment is not really questioned. 
However, infection may not always be evident. A before and after observational cohort study – 
excluding septic shock patients – compared aggressive initiation of antibiotic treatment with a 
treatment strategy where initiation was withheld until more objective data, particularly 
microbiological evidence, were obtained.204 The rate of initial appropriate therapy was higher in 
the less aggressive arm and mortality was lower, suggesting that a more reserved approach to 
starting antibiotics in the hemodynamically stable patient with possible infection may be 
justified. In the Sepsis Occurrence in Acutely ill Patients (SOAP) study, more than half of the 




implying that a substantial number of patients may in fact be candidates for a more restricted 
antibiotic initiation as described above. 
If the decision to start antibiotics is made, it is important to select an adequate antibiotic 
regimen covering all expected pathogens. Inevitably in a setting where multidrug-resistance 
(MDR) is problematic, this will require an antibiotic scheme that includes all potential pathogens 
even if this exceeds the spectrum of the pathogens that are eventually identified. As an example, 
international guidelines, such as those published by the Infectious Diseases Society of America 
(IDSA), propose empirical broad-spectrum and, as a rule, combination therapy for hospital-
acquired pneumonia.80 However, it is pointless to cover microorganisms that are very unlikely 
given the patient profile and local ecology. Guidelines tailoring empirical therapy to local 
susceptibility data resulted in increased appropriateness and reduced use of broad-spectrum 
combination therapy.136, 142 Furthermore, mapping the patient’s colonization status by 
surveillance cultures may reduce the use of broad-spectrum regimens.137, 162 Therefore, in the 
current situation of a worldwide, but very inhomogeneous spread of MDR, customizing these 
(inter)national guidelines to local institutional and patient ecology may offer an opportunity to 
reduce antibiotic use from the very start. 
This decision-making process is complex and, as such, should be carefully recorded in the 
patient’s file. To facilitate decision-making later in the course of therapy, it is essential to obtain 
all relevant microbiological cultures at this stage and preferably before the start of antibiotics to 
document the infection and identify the causative pathogen. 
 
Time point 2: Day 1 – early reevaluation 
After 24 h of antibiotic therapy, we advocate a systematic clinical reevaluation of the patient to 
confirm (or not) the presence of infection. As signs and symptoms suggesting infection in 
critically ill patients may be non-specific, alternative diagnoses should always be considered 
from the very start, whether or not clinical deterioration calls for immediate start of antibiotics. 
A 24 h window may be a good moment to reevaluate the patient, as the evolution of the clinical 
picture often allows better differentiation between infectious and non-infectious causes of 
deterioration or SIRS. This offers an opportunity to discontinue antibiotics that were –in 
retrospect – initiated inappropriately and will depend on the level of certainty that infection was 
present when antibiotics were initiated. In patients who are not improving, a careful search for 
an alternative diagnosis is important and is to be preferred to blind escalation of antibiotic 
therapy when clinical signs and symptoms do not respond favorably early after start of 
antibiotics. If there is another clear cause of the current condition or deterioration of the patient, 
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then antibiotics should not be continued. A typical example of this would be a patient with 
pancreatitis, who may present with acute abdominal pain and who may receive early empirical 
antibiotic therapy for suspected infection but who is found to have pancreatitis only, without 
signs of infection and without the need for antibiotic therapy. 
At this point also, the results of microbiological studies may become available, which can help to 
guide therapy. These include simple techniques such as direct examination with Gram-stain and 
direct antibiogram but also more sophisticated techniques, including matrix assisted laser 
desorption ionization time-offlight (MALDI-TOF) and polymerase chain reaction (PCR) based 
techniques. The cost-effectiveness of these techniques at this point is unclear. Using this 
approach creates a second opportunity to treat less obvious pathogens and may also allow the 
identification of MDR pathogens, such as Acinetobacter and Stenotrophomonas spp. or fungi, 
which may not be covered by the spectrum of the antibiotic administered. 
Direct Examination and Gram-stain of Samples 
Although the information that can be obtained from a Gram-stain may appear limited, it may 
assist the clinician in directing empirical antibiotic therapy as well as in assessing the need for 
other interventions. This technique can be applied to several types of samples, including 
respiratory and abdominal samples. Direct examination may suggest the presence of 
microorganisms that are not covered by the initial treatment strategy and this is, therefore, 
particularly helpful in a restricted empirical antibiotic strategy. 
Direct Susceptibility Testing 
Rather than the susceptibility of one pathogen, direct susceptibility testing reflects the 
susceptibility of the microbial community in a sample. Although there are some limitations to 
this technique, direct susceptibility testing using direct inoculation of the clinical sample may 
provide early information on susceptibility and reduce turnaround time by 24 h.206 
MALDI-TOF 
This recently introduced proteomics-based technique allows rapid determination of pathogens 
after culture.207 Again this may not provide any details on susceptibility but may point the 
clinician to the presence of unexpected pathogens. 
PCR-based Techniques 
Several commercial tests have been developed in recent years and most allow identification of 
pathogens with 8 h of sampling. A recent systematic review and meta-analysis of the available 




in the critically ill;208 nevertheless, this test may allow identification of pathogens that have 
limited susceptibility to the empirical regimen. Susceptibility information is not available from 
these PCR-based techniques (except for the presence of the MecA gene for methicillin-resistant 
Staphylococcus aureus (MRSA)). It should be noted that most of the studies in this field have 
been conducted in patients with bloodstream infection only and the value in other infections 
remains to be determined. 
 
Time point 3: Day 3 – microbiological turnaround 
At 72 h the picture is usually complete, with all relevant culture results available in most 
situations. This is the pivotal moment for reassessing likelihood of infection as well as 
streamlining antibiotic therapy. 
Similar to the 24 h time point, the presence of infection may be reconfirmed but again 
alternative diagnoses may be considered. Clinicians may decide, based on the available 
information, that infection may not have been present, and stopping antibiotics is definitely an 
option in selected patients. Although there is often reluctance to stop antibiotic therapy once 
started, an RCT from 2000 already showed this to be safe.209 
This is usually also the time point when the susceptibility pattern of the pathogen is available 
and definite antibiotic therapy can be decided. Apart from changing the antibiotic in case of 
resistance to the pathogen, this offers an opportunity to stop unnecessary antibiotics – 
antibiotics that do not cover the pathogen involved but were part of multidrug empirical 
antibiotic therapy, e.g., vancomycin as part of an empirical broad-spectrum regimen for hospital-
acquired pneumonia. Similarly, in patients who have been treated with combination therapy, 
e.g., a beta-lactam antibiotic plus an aminoglycoside, it may be the appropriate time to stop the 
more toxic antibiotic. 
De-escalation of antibiotic therapy, or changing the antibiotic to another agent with a smaller 
spectrum, has been advocated as an essential element of antibiotic stewardship programs.90 As 
such, it will reduce the use of broad-spectrum agents and presumably reduce selection pressure. 
In clinical practice, however, de-escalation is only used in 13 to 43% of patients in most 
studies.94 De-escalation has been associated with decreased mortality in critically ill patients but 
a causal effect is unlikely.157 
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Time point 4: from day 5 onwards – end of the antibiotic course 
If antibiotics are continued beyond 72 h, it is assumed that infection is present and that a 
complete antibiotic course is necessary. However, the optimal duration of such a course is at 
present not known and is probably dependent on pathogen load and susceptibility, focus and 
tissue extension of the infection, host defense mechanisms and whether or not some form of 
source control can be achieved. Extending antibiotic therapy must balance the possible benefit 
of achieving better microbial control against the harm of promoting resistance by prolonging 
selection pressure. As most of the current evidence relates patient outcome to treatment 
determinants that appear at the ‘head’ of antibiotic therapy (timing/initiation of therapy, 
appropriate empirical choice), the ‘tail’ of antibiotic therapy may offer the best opportunities to 
reduce overall antibiotic exposure without compromising patient outcome. As such, in the more 
recently published literature, there is a clear tendency to decrease duration of antibiotic courses. 
This trend is best documented for pneumonia. A landmark RCT in patients with ventilator-
associated pneumonia (VAP) found that an 8-day antibiotic course did not result in worse 
patient outcome as compared to a 15-day course; the rate of infection recurrence was higher for 
Pseudomonas infections, but this was not associated with increased mortality or length of stay.210 
This result provides firm ground for the recommendation to set a stop at day 8 of antibiotic 
therapy for pneumonia, counting from the first day of appropriate therapy. Although data from 
RCTs are lacking, the SSC recommend a similar 7 to 10 day course of antibiotic therapy as a 
standard for all nosocomial infections, to be modified in the light of clinical response and 
microbiological data.90, 211 However, these guidelines are only slowly changing daily practice, as 
the mean duration of a ‘usual care’ antibiotic course in the ICU (gleaned from observational 
studies and control arms of interventional studies) still exceeds these times.212, 213. 
Recommendations for shorter antibiotic treatment courses may be most effective when 
translated into a default stop date for antibiotic therapy, with continuation of antibiotics beyond 
this date only for selected indications or clinical situations. Apart from some clearly defined 
clinical infections for which prolonged antibiotic treatment is standard of care (such as 
endocarditis or prosthetic joint infection), longer antibiotic courses may be required in 
situations with extensive and persistent tissue inflammation together with lack of microbial 
eradication, such as necrotizing pulmonary infections, persistent gastrointestinal leaks or 
inaccessible infection foci. For this latter category, however, it should be recognized that there is 
no evidence that prolonged antibiotic courses improve outcome beyond standard courses, and 
continued efforts to achieve source control (preferably as early as possible in the course of the 
treatment) may be more effective.214 As mentioned before, a decision to stop or continue 





Several RCTs have compared antibiotic courses prescribed as usual care with an approach 
focusing on antibiotic stopping, using algorithms taking into account the evolution of biomarkers 
or clinical parameters. Serial measurements of procalcitonin (PCT) with an algorithm 
recommending that antibiotics be stopped when PCT concentrations decrease below a certain 
threshold or percentage from its peak value, can be used to reduce the duration of the antibiotic 
course to a median of 6 days.215 When PCT is not available, serial clinical evaluations may 
achieve the same goal, at least for respiratory infections.216 Most importantly, during daily 
clinical rounds in the ICU, all ongoing antibiotic prescriptions should receive a critical evaluation 
by the attending physician. 
 
Conclusion: 
Decision-making about initiation, changing and stopping antibiotic therapy in the ICU is a 
complex activity due to its dual goal – eradicating pathogenic bacteria causing serious infection 
versus minimizing promotion of antimicrobial resistance caused by selection pressure – and due 
to the uncertainties surrounding clinical diagnosis of infection and its causal pathogen(s). There 
are, however, several opportunities to reduce unnecessary antibiotic exposure while preserving 
patient outcome. The principle of de-escalation is currently the main answer to this diagnostic 
and therapeutic problem. However, it is important to tailor this principle to the individual 
clinical case and avoid unnecessary antibiotics as much as possible. This goal is best achieved by 
a dynamic approach with critical reassessments of the need for and choice of antibiotics at 
preset time points while actively pursuing diagnostics and integrating all the available 
information. This proposed time-based approach is a convenient way to translate different 
aspects of antimicrobial stewardship into clinical practice at the bedside.
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Ventilator-associated pneumonia (VAP) is a major complication of mechanical ventilation and 
represents the most common reason for antibiotic prescription in ventilated patients. Incidence 
ranges from 1.2 to 8.5 cases per 1000 ventilator days or 9 to 27% cases per mechanically 
ventilated patient; attributable mortality rates vary between 0% and 70%.217, 218 The large 
variability of these figures stems from the fact that both development and outcome of VAP result 
from a complex interplay between pathogens and host under the influence of many factors: 
comorbidities, severity and cause of the underlying critical illness, its treatment and its 
evolution over time. Additionally, uncertainty surrounds diagnosis of VAP and many different 
diagnostic strategies and criteria prevail. Clinical signs and symptoms, biochemical markers of 
inflammation and radiological signs of alveolar consolidation, which are highly accurate for a 
diagnosis of pneumonia in a walking patient in the community are much less so in the critically 
ill patient under mechanical ventilation. Clinical and biochemical alterations may be absent, or 
may have an alternative cause that can be infectious or non-infectious. An infiltrate on chest X-
ray is required for diagnosis, as it has high sensitivity, but is remarkably non-specific. Inter-
observer variability of chest X-ray interpretation is large, especially when it comes to deciding 
whether or not an infiltrate is ‘new’, ‘evolving’ and represents alveolar consolidation. Increasing 
the number of diagnostic criteria required for diagnosis gains specificity at the cost of reduced 
sensitivity. The Clinical Pulmonary Infection Score (CPIS) is a quantification of these criteria in a 
summary score: a higher CPIS score increases the likelihood that VAP is present, but no single 
cut-off combining a high sensitivity with a high or acceptable specificity can be identified.219 
Despite decades of study and an impressive amount of published data, the question of how VAP 
can be accurately diagnosed is not definitively settled. In this contribution, four controversies 





Invasively obtained microbiology allows accurate diagnosis of VAP 
Adding microbiological data increases specificity of VAP diagnosis.217 However, the presence of a 
potential pathogen in a respiratory sample of a mechanically ventilated patient is in itself no 
proof for VAP, as it may represent colonisation of lower respiratory airways or contamination by 
flora residing in the upper respiratory tract or in the biofilm on the endotracheal tube. Invasive 
diagnostics in VAP refer to the use of fiberoptic or blind bronchoalveolar lavage (BAL) or 
protected specimen brush in order to sample more selectively the distal airways and alveoli. 
Using these samples for direct examination for the presence of intracellular pathogens in 
alveolar macrophages or polymorphonuclears and for quantitative culturing further helps to 
distinguish between colonisation and infection.217, 220, 221 As such, quantitative cultures of 
invasively obtained samples may improve the specificity of VAP diagnosis more than qualitative 
culture of routinely obtained endotracheal aspirates. However, the selection of a threshold for 
quantitative cultures to discriminate between infection and colonisation again must strike a 
balance between specificity and sensitivity. Thresholds for diagnosing VAP may differ between 
populations. For example, some authors have argued in favor of using a higher threshold (>105 
colony-forming units (CFU)/ml) in BAL samples of trauma patients than the one usually applied 
in medical patients (>104 CFU/ml), to reduce the number of false positives.222 On the other hand, 
in patients who received antibiotics prior to their BAL, the quantitative threshold for VAP 
diagnosis should probably be lowered to limit the number of false negatives. However, in the 
absence of a true gold standard for the diagnosis of VAP, test characteristics of invasive 
microbiological techniques are not well established. Quantitative cultures themselves are often 
used as a form of gold standard to which other diagnostic tests are compared, which may lead to 
a form of circular reasoning.221 Regardless of the higher specificity of invasive microbiology, 
clinical characteristics must always be taken into account for a diagnosis of VAP, as many 
patients with prolonged mechanical ventilation have a high burden of bacteria in the lower 
airways without signs of infection.223 
 
Invasively obtained microbiology improves outcome in VAP 
Proponents of invasive diagnostic strategies in VAP have argued that these techniques improve 
patient outcome. The outcome benefit is attributed to the higher diagnostic specificity, which 
helps the attending physician to avoid unnecessary antibiotics and/or direct a search for 
alternative diagnosis if VAP is refuted.224 In a recent study, diagnostic workup of clinically 
suspected VAP with invasively obtained quantitative cultures below threshold led to an 
alternative diagnosis in 60% of cases.225 Proponents of noninvasive diagnostics state that the 
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main treatment factor influencing outcome is timely and appropriate empirical antibiotic 
therapy directed at all likely involved pathogens; microbiological data serve only to guide 
subsequent de-escalation of antibiotics. For this purpose, routine endotracheal samples and 
semiquantitative cultures may suffice.226 In this view, invasive sampling adds little benefit for 
the patient and has the disadvantage of increased costs and potentially delayed effective 
therapy. A meta-analysis comparing invasive and noninvasive strategies for VAP diagnosis found 
no difference in outcome, but this has not settled the controversy.227 Recently, the need for 
antibiotic stewardship measures in VAP management has revived the discussion. Identification 
of the causal pathogen of VAP has been identified as the main factor promoting de-escalation of 
empirical antibiotics. As invasively obtained microbiological cultures are more likely to 
represent the true causal pathogens of VAP compared to cultures from noninvasive samples, the 
physician may be given greater confidence to de-escalate. Giantsou et al. indeed found higher de-
escalation rates in patients subjected to BAL instead of endotracheal aspirates.158 In addition, the 
higher specificity of quantitative cultures in suspected VAP, translating into fewer false positives, 
would also lead to fewer unnecessary antibiotic treatments.228 However, in the Canadian Critical 
Care Trials Group trial, which randomized between an invasive and a noninvasive strategy for 
VAP diagnosis, no differences in the rate of de-escalation or antibiotic stop were found between 
both arms, nor was patient outcome different.226 In addition, increased focus on antibiotic 
stopping whenever possible, using repeated clinical evaluations, or a protocol guided by 
sequential procalcitonin measurements may achieve a major effect without the use of invasive 
microbiology.209, 216, 229 
 
Ventilator-associated tracheobronchitis (VAT) is a separate condition of VAP 
The observation that patients may have all clinical signs and symptoms of VAP and respond to 
the microbiological criteria of VAP in the absence of unambiguous infiltrates on chest X-ray has 
led to the concept of ventilator-associated tracheobronchitis (VAT). VAT represents a more 
limited infection of the lower respiratory tract in ventilated patients. The association between 
VAT and mortality is less obvious than in VAP, yet VAT appears to be associated with a longer 
duration of mechanical ventilation.230 It is not clear whether VAT represents a precursor or early 
stage of VAP, i.e. whether untreated it proceeds to VAP, or whether it is a milder stage of 
infection, sitting in the continuum between lower respiratory tract colonisation and clear-cut 
VAP.231 Moreover, as the absence of a new or worsening infiltrate on chest X-ray makes the only 
distinction between VAT and VAP, inter-observer variability may lead to false classification of 
VAP as VAT. VAT may progress to VAP in a third of cases;232 antibiotic treatment of VAT thus 




the necessity to restrict antibiotics as part of antibiotic stewardship, treatment of VAT is not 
straightforward. Antibiotic therapy in VAT, e.g. as delivered by inhalation or systemically as a 
short course, may prevent full VAP and thus have an overall antibiotic-sparing effect.233, 234 On 
the other hand, a strategy in which VAT routinely is considered as an indication for antibiotic 
therapy will increase the number of antibiotic prescriptions in patients who will not directly 
benefit from it, but still are exposed to the harmful effects of antibiotics, especially increased 
selection pressure. 
 
Ventilator-associated events (VAE) are a better concept for monitoring of quality of 
intensive care 
The lack of accuracy of diagnostic criteria of VAP, and especially the inter-observer variability of 
chest X-ray interpretation hampers the use of VAP as a quality indicator for benchmarking 
intensive care unit (ICUs). Ego et al. found that VAP incidence in their ICU population varied 
tremendously according to the different sets of diagnostic criteria used.235 Reports about 
achieving zero VAP rates may thus reflect the use of overly specific (and too little sensitive) 
diagnostic criteria rather than true absence of VAP. This has led to a radical change in the 
Centers for Disease Control and Prevention (CDC) approach to surveillance of complications of 
mechanical ventilation, dismissing subjective criteria (such as chest X-ray interpretation) and 
broadening the concept of VAP to that of VAE. VAE refers to a respiratory deterioration of a 
mechanically ventilated patient after initial improvement and stabilization, and is diagnosed on 
the basis of more objective criteria such as ventilator settings and oxygenation indices: this 
deterioration may or may not be due to infection. A new definition of VAP is tied within this 
framework and is defined as VAE together with signs of inflammation or newly started 
antibiotics, purulent secretions and presence of pathogens in respiratory cultures: the label 
‘possible VAP’ and ‘probable VAP’ is applied if only one, and two respectively, of the last two 
criteria are met. Studies have shown that VAE poorly correlate with ‘traditionally diagnosed’ 
VAP: less severe VAP is missed by VAE and a large number of VAE are not due to VAP.236 On the 
other hand, Bouadma et al. found a good correlation between VAE and antibiotic consumption in 
their multicentre OUTCOMEREA database, suggesting that VAE could represent a proxy for true 
VAP.66 Whether or not VAE is preventable is a matter of discussion; this is however a cardinal 
prerequisite or its use as a quality indicator.60 
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ABSTRACT 
The management of infections in surgical intensive care unit patients poses specific challenges. 
Although the overall approach to the patient is no different from other patients, diagnosis is 
often problematic. As in other infections, multidrug-resistance is increasingly described, and 
changes in pharmacokinetics may require different dosing strategies. Also the need for source 
control adds a level of complexity to the management of the patient. Whereas source control was 
a purely surgical issue before, percutaneous drainage has emerged as an important alternative. 
Appropriate timing of source control often remains difficult to determine, but in most severe 
infections source control should not be delayed. But also the need for a multidisciplinary 
approach can make the decision making difficult. New concepts such as dedicated source control 
teams may further assist in selecting the most appropriate treatment strategy and further 




Severe infections in surgical patients may be the reason for admission in some, but may also 
develop during intensive care unit (ICU) stay in others. These infections are an important 
burden in modern critical care, in terms of morbidity, mortality and resource use. In a recent 
study from China, mortality was high in surgical ICU (SICU) patients developing severe sepsis 
(48.7%)237 and nursing workload high. 
Abdominal infections more in particular, are associated with a long ICU stay, more shock and 
acute kidney injury and a higher mortality compared to other infections 205, 238 and therefore 
deserve proper attention. 
Although there are no standardized definitions of what constitutes SICU patients, patients 




non-scheduled operation within 24 hours of the onset of symptoms or injury) are considered 
surgical 2, 205 and the focus of the current review. 
The overall approach to infections in surgical patients is comparable to other patient categories, 
with rapid administration of appropriate antibiotics as one of the most important elements. The 
role of source control however should not be underestimated and is to be considered more 
often. To this extent, communication and interaction with other specialties such as surgery and 
interventional radiology is pivotal and preferably these patients should be managed in a 
multidisciplinary way. Diagnosis, both of primary infections or infections where the initial 
therapy has failed are particularly challenging but also the application of other, newer concepts 
such as antimicrobial de-escalation may be different. 
Rather than listing antibiotic therapy schemes for commonly encountered infections, we will 
review specific aspects of the treatment of infections in SICU patients. 
 
Epidemiology of infections in surgical ICU patients 
SICU patients apparently are at the highest risk to be diagnosed with an infection, presumably 
because the infection itself was the cause for admission to the ICU more often; as an example, in 
the Sepsis Occurrence in Acutely ill Patients (SOAP) study, 89% of the abdominal infections were 
non-ICU acquired 205, the highest percentage of frequently encountered infections studied. In the 
European Prevalence of Infections in Intensive Care (EPIC)-II study, about two thirds of the 
infected patients were considered surgical patients (emergency surgery mostly, but also trauma 
and elective surgery).2 Obviously not all of these patients had typical surgical sources of 
infection. In a large study from China, abdominal infections accounted for 72 percent of the 
infections in SICU patients diagnosed with severe sepsis, with acute pancreatitis and 
gastrointestinal perforation as the leading sources of infection.237 Notably more than half of the 
cases had infections in multiple locations. 
As the sources of infections are different compared to general ICU patients, these SICU infections 
also have a distinct microbiology pattern. Cheng et al. found that 43.7% of infections were 
polymicrobial, with a comparable contribution of Gram-positive and Gram-negative bacteria.237 
Fungi were also present in a considerable number of infections in this multicenter study 
(28.3%). In the SOAP study, Gram-positive bacteria (mainly Streptococcus D) and Escherichia coli 
were more frequently isolated in surgical patients.205 
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Diagnosing infections in surgical ICU patients 
Typically, SICU patients with infectious complications are either admitted with an infection 
(mostly postoperative) or they develop it during their admission for another primary diagnosis. 
Both categories pose specific problems in terms of timely diagnosis to allow early therapy. 
Diagnostics of infections in SICU patients admitted for non-infectious reasons can be puzzling as 
the tools we tend to rely on are unreliable in many situations. SIRS criteria are non-specific and 
frequently a reflection of postoperative inflammation, trauma, burns or any other inflammatory 
process. Similarly, conventional biomarkers of inflammation are often useless to diagnose 
infections immediately after another event. Also signs of impending organ dysfunction in a 
setting of severe sepsis, such as hypotension or oliguria, may be the result of other postoperative 
complications such as bleeding, fluid losses or under-resuscitation. 
In patients admitted after surgical (or interventional) treatment, the diagnosis of recurrent 
infection due to failed source control is a problem that poses particular challenges. In a 
prospective multicenter study, Van Ruler et al. found that – contrary to what one may think – the 
extent of peritonitis, the source of the infection, the type of contamination or operative variables 
such as the presence of an anastomosis, were not associated with recurrent infection. Adding 
postoperative symptoms such as fever and parameters of organ dysfunction to the multivariate 
model, could identify patients requiring additional source control measures.239 Most commonly 
used scoring systems perform poorly in this setting, only acute organ dysfunction scores such as 
the SOFA score were somewhat useful,240 although the AUROC was only 0.61 for the best 
discriminative score. Biomarkers may be superior in identifying patients without surgical source 
control; in a small study Novotny et al. found that a ratio of PCT on day 2 to PCT on day 1 of 1.03 
or higher could discriminate failed from effective source control.241 
Clinical suspicion is probably best to track failed source control early; when available, PCT can 
be used for confirmation, but further work up remains necessary. Bedside ultrasound and 
abdominal CT scan represent the best tools; ultrasound has the advantage that it is readily 
available in most units and does not require transportation to the CT lounge and contrast 
administration. Both imaging techniques can be complemented by fine needle aspiration of 
suspected collections, or percutaneous drainage (PCD) in case of collections amenable to 








Similar to the general ICU population, the empirical antibiotic scheme should cover the probable 
pathogen(s). This knowledge needs to be supplemented with local ecology data to determine the 
most appropriate empirical antimicrobial regimen. In abdominal infections inadequate 
antimicrobial therapy is associated with an increase in mortality rates in several studies.242-244 
As in other infections involvement of multidrug-resistant (MDR) pathogens is a major concern. 
Seguin et al. found this risk to be particularly elevated in patients who were hospitalized for 5 
days or longer and after previous exposure to antibiotics; when both criteria were present MDR 
was present in 38% of the infections compared to 2% when both were absent.245 Swenson et al. 
reported an association between health-care exposure; e.g. current ICU admission, 
hospitalization for more than one week, but also including hospitalization within one month 
prior to the infection, residence in a nursing home or rehabilitation facility, and the occurrence 
of MDR pathogens.246 
When selecting empirical and directed antimicrobial therapy in the setting of surgical infections, 
we have to take some limitations of the microbiology diagnostic techniques into account. 
Abdominal infections are typically polymicrobial with both Gram-positive and Gram-negative, 
aerobe and anaerobe bacteria contributing in most patients. Depending on the techniques used, 
up to 10-15 microorganisms can be found in cultures from intra-abdominal infections, but 
pathogenicity may be difficult to assess. Anaerobe microbes are difficult to culture and even if 
these are not reported by the microbiology lab, these should be covered by the antibiotic 
therapy.131 This is equally relevant in necrotizing skin and soft tissue infections where an 
important part of infections are polymicrobial.247 
De-escalation can be a challenging issue in SICU patients. As discussed above, infections are 
often present in multiple sites, and are often polymicrobial, limiting the possibilities of de-
escalation in these patients. This was found in an earlier study from our center where abdominal 
infection and the lack of conclusive microbiology were important obstacles to de-escalation.150 
In recent years the changes in the pharmacokinetics in critically ill patients has received 
increased interest.248 Although these changes are not limited to surgical patients, again specific 
issues should be considered in SICU infected patients as it may impact outcome.249 One of the 
main determinants of decreased exposure to antimicrobial therapy is increased elimination of 
the antibiotic (mostly beta-lactam antibiotics) through a phenomenon of augmented renal 
clearance. Augmented renal clearance is a frequent finding in critically ill patients and certain 
categories of SICU patients such as trauma and burn patients.250 In specific patient populations 
e.g. following abdominal surgery, increased fluid losses though abdominal drains may further 
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decrease antibiotic concentrations.251 Different dosing strategies such as extended or continuous 




Source control frequently is an essential element of the therapy of severe infections in surgical 
patients. It refers to controlling the source of the infection and includes drainage of pus and 
inflammatory material as well as debridement of necrotic (infected) tissue. Restoration of 
anatomy and function is equally important and often these components can be combined in one 
operation. Source control should be considered in all patients with severe infections in the SICU. 
Although the relevance of source control is not limited to SICU patients, the probability that this 
patient group requires source control is higher due to the high prevalence of abdominal and 
other surgical infections.237 
As a rule of thumb, source control measures should not be delayed except in situations where 
demarcation of nonviable tissue and infection is preferable, such as infected pancreatic necrosis, 
or in situations where source control is difficult to obtain, e.g. an infected driveline of a left 
ventricular assist device (LVAD). The Surviving Sepsis Campaign (SSC) guidelines suggest that 
patients should be treated within 12 h,90 but there is no rationale to defer the intervention 
unless patient’s physiology is severely impaired and associated with an unacceptable risk of 
complications during the source control procedure such as coagulopathy or life-threatening 
metabolic disorders. Comparable to the effect of postponing initiation of antibiotic therapy in 
case of hypotension, there seems to be a linear increase in mortality when source control is 
delayed.253 Timing of source control is often debated and should be guided by the severity of 
illness (or rapidity of deterioration), the (presumed) source of infection and the physiologic 
status of the patient (Table 18). Source control interventions may include surgery but also other 




Table 18 Urgency of source control intervention (after 254) 
Level of urgency Timing of intervention Context 
1 <1-2 h after diagnosis Rapidly progressive disease e.g. necrotizing 
fasciitis, intra-abdominal infection with 
abdominal compartment syndrome 
2 As soon as patient physiology 
allows 
Limited deferral is acceptable provided 
antibiotics are administered and patient is not 
deteriorating e.g. peritonitis 
3 As soon as infectious process 
has demarcated 
Adequate source control is facilitated and 
probability of collateral damage lower e.g. 
infected pancreatic necrosis in a stable patient 
 
Therefore it is crucial that institutions that care for these severely ill patients should have 24/7 
access to all diagnostic imaging techniques as well as interventional radiology and surgery. 
Although practical issues such as operation theatre availability and the lack of expertise are 
often mentioned as reasons why source control is delayed, there is no scientific evidence that 
delaying source control is safe, even under broad-spectrum antibiotic coverage. Moreover, in the 
era of increasing MRD infections, administering antibiotics to patients in whom the source is not 
controlled could lead to the emergence of antibiotic resistance, or selection of less susceptible 
microorganisms. 
Although once considered a surgical issue, source control measures are no longer limited to the 
operating theatre. Ultrasound or CT-guided PCD is now an important tool in the early 
management of severe infections in critically ill patients. Its exact role however remains to be 
determined, and for many infections a surgical procedure still should be considered the 
standard of care. PCD however can be a helpful tool during initial resuscitation and correction of 
metabolic disorders, but also for more difficult to surgically treat infections such as infected 
pancreatic necrosis, where PCD has emerged as the preferred initial therapy and can effectively 
avoid surgery in a considerable number of patients.255 
To fully understand the impact of the role of source control in critical care, more attention to this 
aspect is urgently needed in studies reporting on the outcome of infected patients. Quantifying 
the residual infection after source control could be helpful to evaluate the role of certain 
interventions and to guide antibiotic therapy. To this extent we suggest using a classification 
system (Table 19) that allows to better describe the net effect of source control measures. In 
analogy with oncological surgery where the R classification reflects the completeness of the 
surgical procedure, the proposed categorization of residual infection reflects the effect of the 
source control intervention, supports planning of future treatment and correlates with 
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prognosis. The presence of residual infection refers to the presence of pus, infected tissue after 
the source control procedure e.g. incomplete drained abscess after PCD or residual necrotic 
material that cannot be debrided. Ongoing contamination refers to a source that maintains the 
infection, e.g. a gastrointestinal tract perforation that cannot be transformed into a fistula and 
continues to soil the abdominal cavity. 
Table 19 Source control categorization 
Source control-status Description 
S0 No residual infection 
S1 Residual macroscopic infection, no ongoing contamination 
S2 Residual macroscopic infection and ongoing contamination 
 
Source control treatment options have been poorly investigated before they entered clinical 
practice. PCD for example has been studied to some extent in severe acute pancreatitis as part of 
a step-up minimally invasive approach as opposed to open surgery but for other indications no 
randomized studies have been performed. Novel interventions should be subjected to rigorous 
clinical trials but also treatment strategies that have been taken for granted require re-
evaluation. Van Ruler et al. compared the often applied planned relaparotomy approach to a 
more restrictive on-demand relaparotomy strategy and found the latter to be superior in terms 
of morbidity and cost.256 
As source control in critically ill is becoming increasingly complex, we advocate the development 
of multidisciplinary source control teams where intensivists, infectious disease specialists, 
surgeons and interventional radiologists discuss the need for, the timing of and the preferred 




In conclusion, the management of infections in surgical patients poses specific challenges. 
Diagnosis is often problematic and the need for source control adds a level of complexity to the 
management of the patient. Also the need for a multidisciplinary approach can make the 
decision making difficult. The lack of data have so far led to vague recommendations regarding 
source control, and clinical studies need to report source control methodology and efficacy. New 
concepts such as dedicated source control teams may further assist in selecting the most 
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8 LIST OF ABBREVIATIONS 
A 
ACD:  administrative coding data 
APACHE: acute physiology and chronic health evaluation score 
ARDS:   acute respiratory distress syndrome 
ASP:  antibiotic / antimicrobial stewardship program 
ATS:  American Thoracic Society 
 
B 
BAL:  bronchoalveolar lavage 
BSI:  bloodstream infection 
 
C 
CAS:   computer-assisted surveillance 
CDC:   Centers for Disease Control and Prevention 
CDSS:  computerized clinical decision support system 
CFU:  colony-forming unit 
cIAI:  complicated intra-abdominal infections 
CIE:  cumulative incidence estimate 
CIF:  cumulative incidence functions 
CLABSI:  central line-associated bloodstream infection 
COSARA:  Computer-based Surveillance and Alerting of infections, Antimicrobial Resistance and 
Antibiotic consumption in the ICU 
CPIS: clinical pulmonary infection score 
CPOE:  computerized physician order entry 
CRP:   C-reactive protein 
CSICU: cardiac surgery intensive care unit 
 
D 
DOT:  days of therapy 
 
E 
EHR:  electronic health record 
EPRC:  early postoperative respiratory complications 




ESBL-E: extended spectrum beta-lactamase producing Enterobacteriaceae 
ESICM:  European Society of Intensive Care Medicine 
ESS: electronic surveillance system 
ETA: blind end tracheal aspirate; endotracheal aspirate 
 
F 
FiO2:  fractional inspired oxygen 
 
H 
HAP:   hospital-acquired pneumonia 
 
I 
ICIS: intensive care information system 
ICU:  intensive care unit 
IDSA:   Infectious Diseases Society of America 
INTEC:   Department of Information Technology of the Faculty of Engineering of Ghent University 
IQR: interquartile range 
IT:   information technology 
IWT:  Institute for the Promotion of Innovation through Science and Technology in Flanders 
 
L 
LEBA:  local ecology based algorithm 
LOS:  length of stay 
LVAD:  left ventricular assist device 
 
M 
MALDI-TOF: matrix assisted laser desorption ionization time-offlight 
MDR:   multidrug-resistant 
MICU:   medical intensive care unit 
MRSA:  methicillin-resistant Staphylococcus aureus 
 
N 
NFP:   non-fermenting pathogen 
NHSN:   National Healthcare Safety Network 
 




PaO2:  arterial oxygen tension 
PBS:   paper-based surveillance 
PCD:  percutaneous drainage 
PCR:  polymerase chain reaction 
PCT:  procalcitonin 
PIDS:  Pediatric Infectious Diseases Society 
 
R 
RCT:   randomized controlled trial 
RTI:   respiratory tract infection 
 
S 
SAPS:  simplified acute physiology score 
SC:   surveillance culture 
SCBA:  surveillance culture based algorithm 
SHEA:   Society for Healthcare Epidemiology of America 
SICU:   surgical intensive care unit 
SIRS:  systemic inflammatory response syndrome 
SOFA:   sequential organ failure assessment score 
SSC:  Surviving Sepsis Campaign 
SSI:  surgical site infections 
 
U 
UTI:  urinary tract infection 
 
V 
VAE:  ventilator-associated event 
VAP:  ventilator-associated pneumonia 
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Na het afwerken van mijn manuscripten, heeft finaliseren van deze doctoraatsthesis tussen mijn 
klinische taken en een druk gezinsleven door een jaar tijd gevraagd. Tijdens deze periode is het 
voor mij duidelijk geworden dat het schrijven van een doctoraat om meer draait dan wat hier in 
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Prof. Pieter Depuydt en Prof. Johan Decruyenaere zeer dankbaar dat ze me de eerste klinische 
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dit doctoraatsproject op te starten. Als promotor heeft hij me onophoudelijk verder opgeleid, 
begeleid en gemotiveerd. Op momenten dat ik overenthousiast was en mezelf voorbij liep, werd 
ik voorzichtig bijgestuurd en als ik het even moe was, kreeg ik een extra duwtje (wat op die 
ogenblikken niet steeds zo vrolijk door mij onthaald werd). Pieter is door de jaren heen een 
voorbeeld voor me geworden als arts, als onderzoeker en vooral als mens. 
Het heeft vele jaren geduurd vooraleer het niet meer onwennig aanvoelde om Prof. 
Decruyenaere als Johan aan te spreken. Als diensthoofd Intensieve Zorg op het ogenblik dat ik 
assistent in opleiding was, was Johan diegene die mij voorstelde om voluit voor een IZ traject te 
gaan. Ik ben dankbaar voor het vertrouwen dat me gegeven werd, alle steun over het verloop 
van de voorbije jaren en het feit dat zijn deur nu vlak naast de mijne vaak open staat voor advies. 
Bram Gadeyne heeft als informatica ingenieur samen met ons de nieuwe versies van de COSARA 
software vorm gegeven. Ik bewonder hem voor zijn inspanningen om zich in te werken in ons 
onderzoekdomein, zijn kunde om vele IT & statistiek- issues snel aan te pakken en zijn kalmte 
(samenwerken met artsen zoals ik, die te pas en te onpas vergaderingen moeten verlaten of 
herplannen, maar anderzijds zo snel mogelijk geholpen willen zijn als het IT –gewijs even fout 
loopt, is niet steeds evident). 
Prof. Geert Claeys benaderde onze projecten steeds vanuit een microbiologische invalshoek, wat 
interessante discussies opgeleverd heeft en ons onderzoek zeker ten goede gekomen is. Prof. 
Dominique Benoit was steeds bereikbaar voor inhoudelijke commentaar. Daarnaast wens ik 
zeker ook de leden van de examencommissie te bedanken die met een frisse kritische blik dit 
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